US20140221277A1 - Method For Elevating Prolactin In Mammals - Google Patents
Method For Elevating Prolactin In Mammals Download PDFInfo
- Publication number
- US20140221277A1 US20140221277A1 US14/087,142 US201314087142A US2014221277A1 US 20140221277 A1 US20140221277 A1 US 20140221277A1 US 201314087142 A US201314087142 A US 201314087142A US 2014221277 A1 US2014221277 A1 US 2014221277A1
- Authority
- US
- United States
- Prior art keywords
- phe
- xaa
- prolactin
- arg
- opioid receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010057464 Prolactin Proteins 0.000 title claims abstract description 154
- 229940097325 prolactin Drugs 0.000 title claims abstract description 154
- 238000000034 method Methods 0.000 title claims abstract description 102
- 241000124008 Mammalia Species 0.000 title claims abstract description 52
- 230000003028 elevating effect Effects 0.000 title claims abstract description 23
- 102000003946 Prolactin Human genes 0.000 title claims abstract 9
- 210000002966 serum Anatomy 0.000 claims abstract description 62
- 102000048260 kappa Opioid Receptors Human genes 0.000 claims abstract description 55
- 108020001588 κ-opioid receptors Proteins 0.000 claims abstract description 55
- 150000001875 compounds Chemical class 0.000 claims description 110
- -1 with A being H Chemical compound 0.000 claims description 69
- 239000002632 kappa opiate receptor agonist Substances 0.000 claims description 62
- 229940126470 kappa opioid receptor agonist Drugs 0.000 claims description 62
- 230000006651 lactation Effects 0.000 claims description 60
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 51
- 238000001990 intravenous administration Methods 0.000 claims description 46
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 33
- 230000027455 binding Effects 0.000 claims description 29
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 21
- 239000000651 prodrug Substances 0.000 claims description 21
- 229940002612 prodrug Drugs 0.000 claims description 21
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 20
- 230000008499 blood brain barrier function Effects 0.000 claims description 19
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 19
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims description 14
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 13
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 11
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims description 10
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 10
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 10
- 101150049660 DRD2 gene Proteins 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000002757 morpholinyl group Chemical group 0.000 claims description 10
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 8
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 6
- 229940121891 Dopamine receptor antagonist Drugs 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 6
- 239000003210 dopamine receptor blocking agent Substances 0.000 claims description 6
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 6
- FXHCFPUEIDRTMR-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;chloride Chemical compound Cl.C1=CC=C2CNC(C(=O)O)CC2=C1 FXHCFPUEIDRTMR-UHFFFAOYSA-N 0.000 claims description 6
- 239000002756 mu opiate receptor agonist Substances 0.000 claims description 6
- 229940126487 mu opioid receptor agonist Drugs 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 101800000989 Oxytocin Proteins 0.000 claims description 5
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 5
- 238000007918 intramuscular administration Methods 0.000 claims description 5
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 5
- 229960001723 oxytocin Drugs 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 230000035606 childbirth Effects 0.000 claims description 4
- 239000000094 lactation enhancer Substances 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 3
- 231100000469 sperm hypomotility Toxicity 0.000 claims 2
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 abstract description 17
- 239000000018 receptor agonist Substances 0.000 abstract description 17
- 230000000087 stabilizing effect Effects 0.000 abstract description 10
- 230000002829 reductive effect Effects 0.000 abstract description 6
- 150000001408 amides Chemical class 0.000 abstract description 4
- 102100024819 Prolactin Human genes 0.000 description 145
- 108700012194 D-phenylalanyl-D-phenylalanyl-D-norleucyl-N-(4-pyridinylmethyl)- D-argininamide Proteins 0.000 description 130
- DBOGGOVKHSCMNB-OMRVPHBLSA-N (2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-n-[(2r)-5-(diaminomethylideneamino)-1-oxo-1-(pyridin-4-ylmethylamino)pentan-2-yl]hexanamide Chemical compound C([C@H](C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC=1C=CN=CC=1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 DBOGGOVKHSCMNB-OMRVPHBLSA-N 0.000 description 129
- 238000001802 infusion Methods 0.000 description 120
- 239000003814 drug Substances 0.000 description 61
- 230000000694 effects Effects 0.000 description 56
- 229940079593 drug Drugs 0.000 description 53
- 239000000203 mixture Substances 0.000 description 37
- 239000008267 milk Substances 0.000 description 35
- 230000036470 plasma concentration Effects 0.000 description 35
- 235000013336 milk Nutrition 0.000 description 34
- 210000004080 milk Anatomy 0.000 description 34
- 210000003491 skin Anatomy 0.000 description 33
- 239000000902 placebo Substances 0.000 description 29
- 229940068196 placebo Drugs 0.000 description 29
- 230000001965 increasing effect Effects 0.000 description 25
- 241000282414 Homo sapiens Species 0.000 description 24
- 238000011282 treatment Methods 0.000 description 23
- 210000002700 urine Anatomy 0.000 description 21
- 238000004519 manufacturing process Methods 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 102000051367 mu Opioid Receptors Human genes 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 108020001612 μ-opioid receptors Proteins 0.000 description 18
- 210000003169 central nervous system Anatomy 0.000 description 17
- 238000009472 formulation Methods 0.000 description 17
- 230000037396 body weight Effects 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 206010021082 Hypoprolactinaemia Diseases 0.000 description 15
- 230000008774 maternal effect Effects 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 230000008030 elimination Effects 0.000 description 14
- 238000003379 elimination reaction Methods 0.000 description 14
- 239000003623 enhancer Substances 0.000 description 13
- 238000007619 statistical method Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 238000009826 distribution Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000003937 drug carrier Substances 0.000 description 11
- 235000013350 formula milk Nutrition 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 230000035515 penetration Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000012377 drug delivery Methods 0.000 description 10
- 230000035611 feeding Effects 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 235000020256 human milk Nutrition 0.000 description 10
- 210000004251 human milk Anatomy 0.000 description 10
- 230000000009 lactational effect Effects 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 230000002093 peripheral effect Effects 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 230000009885 systemic effect Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 210000000481 breast Anatomy 0.000 description 9
- 238000002565 electrocardiography Methods 0.000 description 9
- 230000003285 pharmacodynamic effect Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 208000004547 Hallucinations Diseases 0.000 description 8
- 208000004880 Polyuria Diseases 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 7
- 230000001747 exhibiting effect Effects 0.000 description 7
- 230000004907 flux Effects 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 210000004400 mucous membrane Anatomy 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 206010013954 Dysphoria Diseases 0.000 description 6
- 150000001204 N-oxides Chemical class 0.000 description 6
- 102000003840 Opioid Receptors Human genes 0.000 description 6
- 108090000137 Opioid Receptors Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000001647 drug administration Methods 0.000 description 6
- 238000005370 electroosmosis Methods 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 125000001624 naphthyl group Chemical group 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 230000002035 prolonged effect Effects 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000037317 transdermal delivery Effects 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 108010002519 Prolactin Receptors Proteins 0.000 description 5
- 102100029000 Prolactin receptor Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000003502 anti-nociceptive effect Effects 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 230000000474 nursing effect Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000002287 radioligand Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102400000050 Oxytocin Human genes 0.000 description 4
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000019504 cigarettes Nutrition 0.000 description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 108700023159 delta Opioid Receptors Proteins 0.000 description 4
- 102000048124 delta Opioid Receptors Human genes 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 210000005075 mammary gland Anatomy 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 239000003399 opiate peptide Substances 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000036325 urinary excretion Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 206010006240 Breast engorgement Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 208000028399 Critical Illness Diseases 0.000 description 3
- 125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010093625 Opioid Peptides Proteins 0.000 description 3
- 102000001490 Opioid Peptides Human genes 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000599 controlled substance Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000000955 neuroendocrine Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000036280 sedation Effects 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- UJOQOPBFLFQOJJ-HXUWFJFHSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-methylhexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](CCC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UJOQOPBFLFQOJJ-HXUWFJFHSA-N 0.000 description 2
- IFPQOXNWLSRZKX-GSVOUGTGSA-N (2r)-2-amino-4-(diaminomethylideneamino)butanoic acid Chemical compound OC(=O)[C@H](N)CCNC(N)=N IFPQOXNWLSRZKX-GSVOUGTGSA-N 0.000 description 2
- QUOGESRFPZDMMT-RXMQYKEDSA-N (2r)-2-amino-6-(diaminomethylideneamino)hexanoic acid Chemical group OC(=O)[C@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-RXMQYKEDSA-N 0.000 description 2
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 2
- HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 2
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical group NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- NYNKCGWJPNZJMI-UHFFFAOYSA-N Clebopride malate Chemical compound [O-]C(=O)C(O)CC(O)=O.COC1=CC(N)=C(Cl)C=C1C(=O)NC1CC[NH+](CC=2C=CC=CC=2)CC1 NYNKCGWJPNZJMI-UHFFFAOYSA-N 0.000 description 2
- 206010011469 Crying Diseases 0.000 description 2
- BWKMGYQJPOAASG-SECBINFHSA-N D-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CN[C@@H](C(=O)O)CC2=C1 BWKMGYQJPOAASG-SECBINFHSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-RXMQYKEDSA-N D-norleucine Chemical compound CCCC[C@@H](N)C(O)=O LRQKBLKVPFOOQJ-RXMQYKEDSA-N 0.000 description 2
- 102400000242 Dynorphin A(1-17) Human genes 0.000 description 2
- 108010065372 Dynorphins Proteins 0.000 description 2
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 208000007914 Labor Pain Diseases 0.000 description 2
- 208000035945 Labour pain Diseases 0.000 description 2
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 2
- 206010025327 Lymphopenia Diseases 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- GNJCUHZOSOYIEC-GAROZEBRSA-N Morphine-6-glucuronide Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)O)O[C@@H]1[C@]52CCN3C)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O GNJCUHZOSOYIEC-GAROZEBRSA-N 0.000 description 2
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010042576 Suppressed lactation Diseases 0.000 description 2
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229960001391 alfentanil Drugs 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 2
- 229960004193 dextropropoxyphene Drugs 0.000 description 2
- 239000008355 dextrose injection Substances 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 2
- 229960004192 diphenoxylate Drugs 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 2
- 229960001253 domperidone Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
- 229960000240 hydrocodone Drugs 0.000 description 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 2
- 229960001410 hydromorphone Drugs 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XBMIVRRWGCYBTQ-AVRDEDQJSA-N levacetylmethadol Chemical group C=1C=CC=CC=1C(C[C@H](C)N(C)C)([C@@H](OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-AVRDEDQJSA-N 0.000 description 2
- 229940087121 levomethadyl Drugs 0.000 description 2
- 229960003406 levorphanol Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 229960001571 loperamide Drugs 0.000 description 2
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 2
- 231100001023 lymphopenia Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000023247 mammary gland development Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229960001797 methadone Drugs 0.000 description 2
- 229960004503 metoclopramide Drugs 0.000 description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229960002085 oxycodone Drugs 0.000 description 2
- 229960005118 oxymorphone Drugs 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229960003111 prochlorperazine Drugs 0.000 description 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000025160 regulation of secretion Effects 0.000 description 2
- 230000000246 remedial effect Effects 0.000 description 2
- 229960003394 remifentanil Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 229960004739 sufentanil Drugs 0.000 description 2
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 2
- 229960004380 tramadol Drugs 0.000 description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
- 238000013271 transdermal drug delivery Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SHAPQBYCPZRQIP-RXMQYKEDSA-N (2r)-2-(thiophen-2-ylamino)propanoic acid Chemical compound OC(=O)[C@@H](C)NC1=CC=CS1 SHAPQBYCPZRQIP-RXMQYKEDSA-N 0.000 description 1
- NIGWMJHCCYYCSF-MRVPVSSYSA-N (2r)-2-amino-3-(4-chlorophenyl)propanoic acid Chemical compound OC(=O)[C@H](N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-MRVPVSSYSA-N 0.000 description 1
- XWHHYOYVRVGJJY-MRVPVSSYSA-N (2r)-2-amino-3-(4-fluorophenyl)propanoic acid Chemical compound OC(=O)[C@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-MRVPVSSYSA-N 0.000 description 1
- ARSWQPLPYROOBG-SSDOTTSWSA-N (2r)-2-azaniumyl-2,4-dimethylpentanoate Chemical compound CC(C)C[C@@](C)([NH3+])C([O-])=O ARSWQPLPYROOBG-SSDOTTSWSA-N 0.000 description 1
- NRCSJHVDTAAISV-MRVPVSSYSA-N (2r)-2-azaniumyl-3-(3,4-dichlorophenyl)propanoate Chemical compound [O-]C(=O)[C@H]([NH3+])CC1=CC=C(Cl)C(Cl)=C1 NRCSJHVDTAAISV-MRVPVSSYSA-N 0.000 description 1
- FCFVSQCEDOCNBL-MRVPVSSYSA-N (2r)-5-(diaminomethylideneamino)-2-(diethylamino)pentanoic acid Chemical compound CCN(CC)[C@@H](C(O)=O)CCCNC(N)=N FCFVSQCEDOCNBL-MRVPVSSYSA-N 0.000 description 1
- ZDNGHSXYPNGLMT-SSDOTTSWSA-N (2r)-5-amino-2-(propan-2-ylamino)pentanoic acid Chemical compound CC(C)N[C@@H](C(O)=O)CCCN ZDNGHSXYPNGLMT-SSDOTTSWSA-N 0.000 description 1
- BVYGCENHXMSEPS-SECBINFHSA-N (2r)-6-(diaminomethylideneamino)-2-(diethylamino)hexanoic acid Chemical compound CCN(CC)[C@@H](C(O)=O)CCCCNC(N)=N BVYGCENHXMSEPS-SECBINFHSA-N 0.000 description 1
- ZODMYTRQCNEOFM-MRVPVSSYSA-N (2r)-6-amino-2-(propan-2-ylamino)hexanoic acid Chemical compound CC(C)N[C@@H](C(O)=O)CCCCN ZODMYTRQCNEOFM-MRVPVSSYSA-N 0.000 description 1
- OVVIBUHLQIYUEU-IWIISZHXSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminometh Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 OVVIBUHLQIYUEU-IWIISZHXSA-N 0.000 description 1
- WRPLGMBDXVBPEG-VGXZEHLRSA-N (2s,3s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pen Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 WRPLGMBDXVBPEG-VGXZEHLRSA-N 0.000 description 1
- UFIVEPVSAGBUSI-REOHCLBHSA-N (S)-dihydroorotic acid Chemical compound OC(=O)[C@@H]1CC(=O)NC(=O)N1 UFIVEPVSAGBUSI-REOHCLBHSA-N 0.000 description 1
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 1
- DKMFBWQBDIGMHM-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-1-butanone Chemical compound C1CC(C)CCN1CCCC(=O)C1=CC=C(F)C=C1 DKMFBWQBDIGMHM-UHFFFAOYSA-N 0.000 description 1
- BTFMCMVEUCGQDX-UHFFFAOYSA-N 1-[10-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propyl]-2-phenothiazinyl]ethanone Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(CCO)CC1 BTFMCMVEUCGQDX-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- NYCRCTMDYITATC-MRVPVSSYSA-N 2-fluoro-D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1F NYCRCTMDYITATC-MRVPVSSYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical group CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- GUJRSXAPGDDABA-NSHDSACASA-N 3-bromo-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2,6-dimethoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC GUJRSXAPGDDABA-NSHDSACASA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- 208000019738 Abnormality of the breast Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010006242 Breast enlargement Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- UJMGRNFQPVLBKU-CXDXLJMYSA-P CC(=O)[O-].CC(=O)[O-].[H]N(C(=O)[C@H]([NH3+])CC1=CC=CC=C1)[C@H](CC1=CC=CC=C1)C(=O)N([H])[C@H](CC(C)C)C(=O)N([H])[C@H](CCC[NH3+])C(=O)N1CCOCC1 Chemical compound CC(=O)[O-].CC(=O)[O-].[H]N(C(=O)[C@H]([NH3+])CC1=CC=CC=C1)[C@H](CC1=CC=CC=C1)C(=O)N([H])[C@H](CC(C)C)C(=O)N([H])[C@H](CCC[NH3+])C(=O)N1CCOCC1 UJMGRNFQPVLBKU-CXDXLJMYSA-P 0.000 description 1
- 0 CC(=O)[O-].CC(=O)[O-].[H]N(CC1=CC=NC=C1)C(=O)[C@@H](CCCnc(n)[nH2+])N([H])C(=O)[C@@H](CCCC)N([H])C(=O)[C@@H](CC1=CC=CC=C1)N([H])C(=O)[C@H]([NH3+])CC1=CC=CC=C1 Chemical compound CC(=O)[O-].CC(=O)[O-].[H]N(CC1=CC=NC=C1)C(=O)[C@@H](CCCnc(n)[nH2+])N([H])C(=O)[C@@H](CCCC)N([H])C(=O)[C@@H](CC1=CC=CC=C1)N([H])C(=O)[C@H]([NH3+])CC1=CC=CC=C1 0.000 description 1
- FFOPCHBRQFNFPF-UHFFFAOYSA-N CC12=NC=C1S2 Chemical compound CC12=NC=C1S2 FFOPCHBRQFNFPF-UHFFFAOYSA-N 0.000 description 1
- JRLPEMVDPFPYPJ-UHFFFAOYSA-N CCC1=CC=C(C)C=C1 Chemical compound CCC1=CC=C(C)C=C1 JRLPEMVDPFPYPJ-UHFFFAOYSA-N 0.000 description 1
- RESJWIKYGZTYSK-UHFFFAOYSA-N CCC1=CC=C(CC(C(=O)O)C(=O)O)C=C1 Chemical compound CCC1=CC=C(CC(C(=O)O)C(=O)O)C=C1 RESJWIKYGZTYSK-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N CN1CCCCC1 Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 1
- 229930182819 D-leucine Natural products 0.000 description 1
- 229930182818 D-methionine Natural products 0.000 description 1
- 229930182832 D-phenylalanine Natural products 0.000 description 1
- 229930182827 D-tryptophan Natural products 0.000 description 1
- 229930195709 D-tyrosine Natural products 0.000 description 1
- 229930182831 D-valine Natural products 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
- 102400000239 Dynorphin A(1-13) Human genes 0.000 description 1
- 101800000028 Dynorphin A(1-17) Proteins 0.000 description 1
- 102400000240 Dynorphin A(1-8) Human genes 0.000 description 1
- 101800001278 Dynorphin A(1-8) Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 206010019070 Hallucination, auditory Diseases 0.000 description 1
- 206010019075 Hallucination, visual Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000895818 Homo sapiens Chorionic somatomammotropin hormone 1 Proteins 0.000 description 1
- 101000956228 Homo sapiens Chorionic somatomammotropin hormone 2 Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 125000001992 L-gamma-glutamyl group Chemical group N[C@@H](CCC(=O)*)C(=O)O 0.000 description 1
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 241000288904 Lemur Species 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 description 1
- 102000002710 Neurophysins Human genes 0.000 description 1
- 108010018674 Neurophysins Proteins 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 229940127450 Opioid Agonists Drugs 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 102000004576 Placental Lactogen Human genes 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 239000000381 Placental Lactogen Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 206010036595 Premature delivery Diseases 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000183290 Scleropages leichardti Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 description 1
- 229960000276 acetophenazine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003329 adenohypophysis hormone Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- NNAIYOXJNVGUOM-UHFFFAOYSA-N amperozide Chemical compound C1CN(C(=O)NCC)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 NNAIYOXJNVGUOM-UHFFFAOYSA-N 0.000 description 1
- 229950000388 amperozide Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003295 arcuate nucleus Anatomy 0.000 description 1
- 210000003818 area postrema Anatomy 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960001768 buspirone hydrochloride Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 229950009852 carfenazine Drugs 0.000 description 1
- TVPJGGZLZLUPOB-SPIKMXEPSA-N carphenazine maleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C12=CC(C(=O)CC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 TVPJGGZLZLUPOB-SPIKMXEPSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229960001552 chlorprothixene Drugs 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- HWDVTQAXQJQROO-UHFFFAOYSA-N cyclopropylazanide Chemical compound [NH-]C1CC1 HWDVTQAXQJQROO-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 108010074881 dynorphin (1-13) Proteins 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- DVGHHMFBFOTGLM-UHFFFAOYSA-L fluorogold Chemical compound F[Au][Au]F DVGHHMFBFOTGLM-UHFFFAOYSA-L 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 230000000942 galactokinetic effect Effects 0.000 description 1
- 230000001892 galactopoietic effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009532 heart rate measurement Methods 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000007946 hypodermic tablet Substances 0.000 description 1
- 239000002117 illicit drug Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000001983 lactogenic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001756 lactotroph Anatomy 0.000 description 1
- 230000001381 lactotroph Effects 0.000 description 1
- 229960004145 levosulpiride Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960000423 loxapine Drugs 0.000 description 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001294 luteotrophic effect Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960001861 melperone Drugs 0.000 description 1
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 1
- 229960000300 mesoridazine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960004938 molindone Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- MKQLBNJQQZRQJU-UHFFFAOYSA-N morpholin-4-amine Chemical compound NN1CCOCC1 MKQLBNJQQZRQJU-UHFFFAOYSA-N 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 210000002963 paraventricular hypothalamic nucleus Anatomy 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 description 1
- 229960002776 pipamperone Drugs 0.000 description 1
- 229960004265 piperacetazine Drugs 0.000 description 1
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108010074732 preproenkephalin Proteins 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 229960003448 remoxipride Drugs 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229960000652 sertindole Drugs 0.000 description 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012453 solvate Chemical class 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- XCTYLCDETUVOIP-UHFFFAOYSA-N thiethylperazine Chemical compound C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 XCTYLCDETUVOIP-UHFFFAOYSA-N 0.000 description 1
- 229960004869 thiethylperazine Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 229960005013 tiotixene Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 125000005490 tosylate group Chemical class 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 1
- 229960003904 triflupromazine Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- 239000008136 water-miscible vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1
- 229960004496 zotepine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Definitions
- the invention relates to the use of peripherally selective kappa opioid receptor agonists to elevate serum levels of prolactin for the benefit of a mammal in need of such elevation.
- Prolactin is a 198 amino acid polypeptide synthesized in pituitary lactotrophs, which constitute about 20 percent of adenohypophysial cells (for review, see Harrison's Principles of Internal Medicine, 16th Ed., p. 2084; also Freeman M E et al. Prolactin: Structure, function, and regulation of secretion. Physiol. Rev. 80: 1523 1631, 2000).
- Prolactin is also referred to in the art as Galactin, Lactogen, Lactoropin, LMTH, LTH, Luteomammotrophic Hormone, Luteotrophic Hormone, Luteotropin, and Mammotrophin, although these names are now obsolete.
- prolactin The best studied effects of prolactin are on the mammary gland, and include growth and development of the mammary gland (mammogenesis), synthesis of milk (lactogenesis), and maintenance of milk secretion (galactopoiesis).
- mammogenesis growth and development of the mammary gland
- lactogenesis synthesis of milk
- galactopoiesis maintenance of milk secretion
- the endocrine control of lactation involves multiple complex physiological mechanisms since mammogenesis, lactogenesis, galactopoiesis, and galactokinesis are all essential for proper lactation.
- Prolactin is the key hormone of lactation and is believed to be the single most important galactopoietic hormone.
- Normal adult serum prolactin levels are about 10 25 ng/ml in women and 10 20 ng/ml in men. Prolactin is secreted in an episodic manner with a distinct 24 hour pattern. Circulating prolactin levels are lowest at midday, and a modest increase occurs during the afternoon. Prolactin levels increase shortly after onset of sleep, peaking in the early morning. Serum prolactin levels rise substantially during pregnancy (150 200 ng/ml) and decline rapidly within two weeks of parturition. Breastfeeding will normally cause prolactin levels to remain elevated, due to suckling induced activation of neural reflexes that that induce prolactin release.
- Signs of insufficient lactation in a human infant include: (1) insufficient weight gain in an infant who is receiving food only by breast feeding, even if the infant appears content; (2) infant latching on poorly; (3) infant sucking inconsistently; (4) inconsistency of let down reflex, and (5) evidence of hunger, indicated by crying soon after feedings.
- Lactation failure in humans is a common clinical event with serious emotional sequelae. It has been considered to be a significant problem in 5 to 10% of all lactations. In many instances this leads to premature initiation of supplements or total weaning. This is considered to be an inferior child rearing practice and may be harmful to certain infants with an increased risk of gastritis and other disorders. Many affected women are severely emotionally distressed by their perceived inadequacy, thus affecting the parent child bond. Failure to thrive in infants is not uncommon if the mother refuses to supplement.
- a number of causes of reductions in prolactin levels that are associated with insufficient lactation were noted above. Certain of these causes are also associated with reduced prolactin levels in non lacting subjects, e.g., cigarette smoking (Fuxe K et al. Neuroendocrine actions of nicotine and of exposure to cigarette smoke: medical implications. Psychoneuroendocrinology 14: 1.9-41, 1989). Other causes of low prolactin levels (hypoprolactinemia) include the use of various therapeutic agents, such as L deprenyl for the treatment of migraine (Fanciullacci M et al. Dopamine involvement in the migraine attack. Funct Neurol. 15 Suppl 3:171-81, 2000).
- hypoprolactinemia of unknown origin has also been associated with poor sperm motility in adult men (Gonzales G F et al. Hypoprolactinemia as related to seminal quality and serum testosterone. Arch. Androl. 23:259-65, 1989), a finding that is supported by the observation that pharmacological suppression of prolactin release for several weeks in young men decreased subsequent hCG stimulated testosterone secretion (Oseko F et al. Effects of chronic bromocriptine induced hypoprolactinemia on plasma testosterone responses to human chorionic gonadotropin stimulation in normal men. Fertil. Steril. 55:355-357, 1991). Hypoprolactinemia could also contribute to age related changes in physiological functions.
- Serum prolactin concentrations tend to fall with age, e.g. in older men and estrogen unreplaced postmenopausal women (Maddox P et al. Bioactive and immunoactive prolactin levels after TRH stimulation in the sera of normal women. Horm. Metab. Res. 24:181-184, 1992; Maddox P et al. Basal prolactin and total lactogenic hormone levels by microbioassay and immunoassay in normal human sera. Acta Endocrinol . ( Copenh .) 125:621-627, 1991). Remarkably, a comparable quantitative reduction in prolactin secretion occurs in critically ill individuals (Van den Berghe G et al.
- hypoprolactinemia is also reported to be a risk factor for prolonged lymphopenia and apoptosis associated depletion of lymphoid organs in nosocomial sepsis related death in critically ill children (Felmet K A et al. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J. Immunol. 174:3765-72, 2005). The findings reviewed above indicate that prolactin deficiency may contribute to impaired testosterone dependent functioning and age related changes as well as vulnerability to illness.
- prolactin is important for maintenance of rapid eye movement sleep (REM sleep), which is essential for normal brain function.
- REM sleep rapid eye movement sleep
- investigators found that administration of prolactin to female rats significantly increased REM sleep (Zhang S Q et al. Effects of prolactin on sleep in cyclic rats. Psychiatry Clin. Neurosci. 53:101-3, 1999). Consistent with these findings, induction of experimental hypoprolactinemia in male rats was found to decrease REM sleep (Obál Jr F et al. Antiserum to prolactin decreases rapid eye movement sleep (REM sleep) in the male rat. Physiol. Behav. 52:1063-1068, 1992). These findings indicate that subjects experiencing insufficient REM sleep could benefit from elevations in prolactin.
- the invention provides methods for treating a subject suffering from insufficient or inadequate serum prolactin, such as functional hypoprolactinemia and the disorders disclosed herein and known in the art associated with insufficient or inadequate serum prolactin, as well as methods for treating a subject in need of elevated or stabilized levels of prolactin.
- a method employs a peripherally selective kappa opioid receptor agonist compound, optionally in a pharmaceutically acceptable vehicle for local, regional or systemic administration, said compound possessing prolactin elevating, increasing or stabilizing activity, optionally administered without causing a severe or a clinically significant side effect, such as CNS effects or diuretic effects.
- the invention features a method of treating functional hypoprolactinemia in a subject with a formulation of a peripherally selective kappa opioid receptor agonist, optionally suitable for incorporation into a controlled drug delivery device.
- a controlled drug delivery device is applied to the skin of a subject.
- a controlled drug delivery device is applied to the skin of a subject and optionally further utilizes iontophoresis to increase transdermal drug delivery.
- a formulation is a solid or liquid or gel.
- a formulation includes a liquid carrier.
- a therapeutically effective dose of a peripherally selective kappa opioid receptor agonist is selected to produce elevated, increased or stabilized serum prolactin levels without producing severe or significant diuresis and/or a CNS side effect.
- a peripherally selective kappa opioid receptor agonist produces pharmacologically insignificant or physiologically tolerable levels of said agonist in the plasma of an infant consuming the breast milk from or produced by a subject treated with said agonist.
- the peripherally selective kappa opioid receptor agonist is selected to avoid producing a severe or a clinically significant side effect in an infant consuming the breast milk from or produced by a subject treated with said agonist.
- the invention features methods of elevating, increasing or stabilizing plasma levels of prolactin to a subject in need of elevated, increased or stabilized prolactin.
- a method includes administration of a therapeutically effective dose of a peripherally selective kappa opioid receptor agonist to the subject.
- a method includes administration of a therapeutically effective dose of a peripherally selective kappa opioid receptor agonist to the subject, in combination with a prolactin elevating-increasing or stabilizing dose of a second compound selected from a D2 dopamine receptor antagonist, mu opioid receptor agonist, or prolactin.
- a subject is: a person, e.g., a human patient, in need of elevated prolactin levels.
- the subject can be: a person in need of stimulation of lactation or stabilization of lactation, e.g., a mother.
- the invention features methods for treatment and/or prevention of lactational failure, which can be diagnosed by various criteria, including:
- compositions that contain one or more compounds that exert prolactin elevating, increasing or stabilizing activity via kappa opiate receptors, but that do not exhibit a severe or significant side effect, such as a CNS or diuretic effect at effective dosages.
- compositions containing peripherally selective kappa opioid receptor agonists that do not, upon systemic administration, evoke severe or clinically significant diuresis or CNS effects, as defined herein, particularly at the prolactin elevating dosage.
- Compositions that contain a peripherally selective kappa opioid receptor agonist together with other prolactin elevating compounds are also provided.
- compounds intended for use in the compositions and methods herein possess prolactin elevating, increasing or stabilizing activity and reduced or tolerable CNS effects, as defined herein, because, without being bound by any theory, they do not substantially cross the blood brain barrier.
- a relative or complete absence of substantial crossing of the blood brain barrier lessens the occurrence of CNS systemic effects.
- Kappa opioid receptors agonists that readily cross the blood brain barrier could be effective as prolactin elevating agents, but permeability through the blood brain barrier can result in severe or intolerable side effects, such as dysphoria and hallucinations.
- Peripherally selective kappa opioid receptor agonists include kappa opioid receptor agonists that do not substantially cross the blood brain barrier as assessed by assays described herein or known in the art.
- the peripherally selective kappa opioid receptor agonists for use in the methods and compositions provided herein also include any compound that by virtue of its interaction, either directly or indirectly, with peripheral kappa opioid receptor receptors ameliorates failure of lactation, or elevates, increases or stabilizes levels of serum prolactin, without exhibiting medically severe or significant CNS effects, such as dysphoria and hallucinations, at effective doses.
- peripherally selective when used in reference to a “kappa opioid receptor agonist” refers to a chemical compound having a reduced ability to cross (traverse) the blood-brain barrier, or that exhibits little or substantially no crossing of the blood-brain barrier when not administered to the CNS (brain and spinal cord).
- a peripherally selective kappa opioid receptor agonist typically exhibits fewer or less severe (minor or tolerable) side effects in the CNS, such as dysphoria, hallucinations, or sedation.
- Various measures of the ability of a compound to cross (traverse) the blood-brain barrier are known in the art and can be used to measure the amount or rate (kinetics) of blood-brain barrier crossing (traversal).
- One non-limiting example is to compare the ability of a compound to elicit peripheral effects versus the ability of the compound to elicit central effects following treatment with a particular compound (e.g., kappa opioid receptor agonist).
- Peripheral effects can be measured using the mouse writhing test (WT) and central effects, due to action of kappa opioid receptors located in the brain and spinal cord, can be measured using the mouse tail-flick test (TF).
- WT mouse writhing test
- TF mouse tail-flick test
- mice writhing test (WT) test employs conscious male ICR mice (available from Harlan) weighing about 20 to 30 grams. Mice are fasted for about 12 to 16 hours prior to the test and writhing is induced by intraperitoneal administration of dilute acetic acid (10 ml of 0.6% aqueous acetic acid/kg body weight). Writhing is scored during the 15 minutes following acetic acid administration.
- Compounds are typically tested at 3 to 4 increasing doses, given by intravenous route, and at a unique pretreatment time (e.g., ⁇ 5 minutes before acetic acid injection). This step is used to determine the potency (WT-ED 50 ) as well as a submaximal effective dose (about 80-90% antinociception).
- a submaximal effective dose for each specific compound is administered at various pretreatment times (e.g., ⁇ 5 minutes, ⁇ 60 minutes, ⁇ 120 minutes and ⁇ 180 minutes) prior to the administration of the acetic acid in order to determine the duration of action.
- mice a control group of mice are used which are administered only the vehicle without the compound.
- the number of writhes are counted over a15-minute period, starting from the time of acetic acid injection, and bioactivity, i.e. antinociception, is expressed as a percentage, and is calculated as follows:
- the writhing test In addition to using the writhing test to determine duration of antinociceptive activity, it is also used to measure the in vivo biopotency (short term) of the peptide. This value is represented as WT-ED 50 in milligrams per kg of body weight, a measure of the dosage necessary to reduce the number of writhes in the mouse being tested by 50% (as compared to a control mouse) over a period of 15 minutes.
- the tail-flick test is an assay of acute somatic pain, designed to evaluate potency and duration of action of centrally acting analgesics (described, for example, in Vanderah, et al., J. Pharm. Exper. Therapeutics, 262:190 (1992)).
- Nociception induced by tail-dip into hot water (52° C.) results in a rapid tail withdrawal, or a “tail-flick.”
- Centrally acting compounds are expected to increase, in a dose-related manner, the latency for tail withdrawal.
- BPI Brain Penetration Index
- WT ⁇ ED 50 mouse writhing test
- TF ⁇ ED 50 mouse tail-flick test
- BPI values lower than 5 indicate significant or substantial brain penetration, and, therefore, a compound that is likely to substantially cross the blood-brain barrier, which can result in severe side effects (e.g., dysphoria, hallucinations and sedation) when used clinically.
- compounds useful in the invention have BPI values typically greater than 5, or more, for example, BPI values of 10, 15, 20, 25, 30, 40, 45, 50, 60, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, or more.
- Peripherally selective kappa opioid receptor agonists of the invention can be peptides, such as those containing D-amino acids instead of L-amino acids, and which optionally can have little to no sequence homology with known mammalian endogenous opioid peptides, e.g., the enkephalins, endorphins, and dynorphins.
- a peripherally selective kappa opioid receptor agonist can comprise a tetrapeptide D-amino acid sequence.
- Peptides that are encompassed by the criteria of the invention are any of the known mammalian endogenous opioid peptides, e.g., as identified in Akil et al (1984), such as dynorphin A(1-17), including naturally occurring, processed forms of these peptides, e.g., dynorphin A(1-13) and dynorphin A (1-8).
- the invention relates to the use of peripherally selective kappa opioid receptor agonists alone or in conjunction with lactational enhancers, elevators, or stabilizers for the treatment of lactation failure, or inadequate or insufficient lactation in a subject.
- the invention also relates to the use of peripherally selective kappa opioid agonists, alone or in conjunction with lactational enhancers elevators, or stabilizers for the manufacture of a medicament in treatment of lactation failure or inadequate or insufficient lactation in a subject.
- Lactational enhancers, elevators, or stabilizers can be chosen from among D2 dopamine receptor antagonists, mu opioid receptor agonists, prolactin, or oxytocin, for example.
- the invention further relates to a method for the treatment of lactation failure, or inadequate or insufficient lactation in a subject, characterized in that a peripherally selective kappa opioid receptor agonist, alone or in conjunction with a lactational enhancer, elevator, or stabilizer is administered to a female subject.
- Non-limiting administration methods include subcutaneous, intravenous, intramuscular, nasal, oral or transdermal administration.
- the invention moreover relates to a composition
- a composition comprising peripherally selective kappa opioid receptor agonist in conjunction with a lactational enhancer, elevators, or stabilizers, optionally including a pharmaceutically acceptable carrier.
- lactation failure is here meant both when a female has no or insufficient amount of milk or is at risk for none or insufficient amount of milk.
- Lactation can be promoted and, therefore, lactation failure, or inadequate or insufficient lactation in a subject, methods are provided in the following situations:
- Certain embodiments of the invention involve peptides, optionally tetrapeptides containing four D-isomer amino acid residues, which bind to kappa opioid receptor receptors, which do not substantially cross the blood brain barrier and enter the brain, which exhibit high affinity for the kappa opioid receptor versus the mu opioid receptor, which have high potency and efficacy, and can exhibit a relative long duration of action in vivo.
- Mammals are defined herein as all animals, including humans, primates, and ungulates, for which the females of the species have mammary glands and produce milk.
- a “dairy animal” refers to a milk producing animal.
- the dairy animal produces large volumes of milk and has a long period of lactation, e.g., cows or goats.
- compositions which comprise a therapeutically effective amount of peripherally selective kappa opioid receptor agonist, formulated together with one or more pharmaceutically acceptable carrier(s).
- formulation refers to a composition in solid, e.g., powder, or liquid form, which includes a peripherally selective kappa opioid receptor agonist.
- formulations can provide therapeutic benefits. These formulations may contain a preservative to prevent growth of microorganisms.
- terapéuticaally effective amount is meant a tolerable (e.g., does not produce a severe side effect, which can be relatively, substantially, or completely nontoxic) amount of an active agent to provide the desired therapeutic effect.
- transdermal drug delivery is meant administration of a drug to the skin surface of an individual so that the drug passes through the skin tissue and into the individual's blood stream, thereby providing a systemic effect.
- transdermal is intended to include “transmucosal” drug administration, i.e., administration of a drug to the mucosal (e.g., sublingual, buccal, vaginal, rectal) surface of an individual so that the drug passes through the mucosal tissue and into the individual's blood stream.
- body surface is used to refer to skin or mucosal tissue.
- predetermined area of skin or mucosal tissue which refers to the area of skin or mucosal tissue through which a drug enhancer formulation is delivered, is intended a defined area of intact unbroken living skin or mucosal tissue. That area will usually be in the range of about 5 cm 2 to about 200 cm 2 , more usually in the range of about 5 cm 2 to about 100 cm 2 , typically in the range of about 20 cm 2 to about 60 cm 2 . However, it will be appreciated by those skilled in the art of drug delivery that the area of skin or mucosal tissue through which drug is administered may vary significantly, depending on patch configuration, dose, and the like.
- “Penetration enhancement” or “permeation enhancement” as used herein relates to an increase in the permeability of the skin or mucosal tissue to a selected pharmacologically active agent, i.e., so that the rate at which the agent permeates therethrough (i.e., the “flux” of the agent through the body surface) is increased relative to the rate that would be obtained in the absence of permeation enhancement.
- the enhanced permeation effected through the use of such enhancers can be observed by measuring the rate of diffusion of drug through animal or human skin using, for example a Franz diffusion apparatus as known in the art and as employed in the Examples herein.
- an “effective amount” or “an effective permeation enhancing amount” of a permeation enhancer refers to a nontoxic, nondamaging but sufficient amount of the enhancer composition to provide the desired increase in skin permeability and, correspondingly, the desired depth of penetration, rate of administration, and amount of drug delivered.
- peptides A genus of peptides has been discovered which exhibit high selectivity for the kappa opioid receptor and relative long duration of in vivo action and which can exhibit reduced or substantially little if any significant brain penetration.
- These peptides include sequences in which a sequence of four D-isomer amino acids having a C-terminus is either a mono or disubstituted amide. These compounds have the following general formula:
- Xaa 1 is (A)D-Phe, (C alpha Me)D-Phe, D-Tyr, D-Tic or D-Ala(cyclopentyl or thienyl), with A being H, NO 2 , F, Cl or CH 3 ;
- Xaa 2 is (A′)D-Phe, D-1Nal, D-2Nal, D-Tyr or D-Trp, with A′ being A or 3,4Cl 2 ;
- Xaa 3 is D-Nle, (B)D-Leu, D-Hle, D-Met, D-Val, D-Phe or D-Ala(cyclopentyl) with B being H or C alpha Me;
- Xaa 4 is D-Arg, D-Har, D-nArg, D-Lys, D-Lys(Ipr), D-Arg(Et 2 ), D-Har(Et 2 ), D-Amf(G), D-Dbu, (B)D-
- the invention also provides a method of treating a mammal in need of elevated prolactin by increasing levels of serum prolactin of said mammal, comprising administering to said mammal an amount of a peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof effective to treat the mammal.
- the method increases or stabilizes levels of serum prolactin to greater than 25, 50, 75, 100, 125, 150, 175, or 200 ng/ml serum in the mammal.
- the peripherally selective kappa opioid receptor agonist or salt thereof or prodrug thereof effective to treat the mammal is a peptide, or ionizes or is metabolized to form a peptide.
- the peptide can comprise a pentapeptide or tetrapeptide, which can include a sequence of four D-isomer amino acids having a C-terminus that is either a mono- or di-substituted amide.
- the peptide has a binding affinity for the kappa opioid receptor that is greater than its binding affinity for non-kappa opioid receptors.
- the peptide has a binding affinity for the kappa opioid receptor at least 1,000 times greater than its binding affinity for the mu opioid receptor.
- the peptide has a binding affinity for the kappa opioid receptor at least 1,000 times greater than its binding affinity for the mu opioid receptor and in addition has an ED 50 for elevating prolactin of about 0.5 mg/kg or less.
- Particular compounds useful in the methods of the present invention include the compound having the formula:
- H-D-Phe-D-Phe-D-Nle-D-Arg-NH-4-picolyl or a picolyl N-oxide thereof, optionally excluding or including an acetate counterion.
- Another particular compound useful in the methods of the present invention is the compound having the formula:
- H-D-Phe-D-Phe-D-Leu-D-Orn-Morpholinyl optionally excluding or including an acetate counterion.
- FIG. 1 is a graph showing the Arithmetic Mean Changes from Baseline (Pre dose) in Serum Prolactin Concentrations Following a 1 hour IV Infusion of CR665 at various dosages in Male Subjects (Part A).
- FIG. 2 is a graph showing the Arithmetic Mean Changes from Baseline (Pre dose) in Serum Prolactin Concentrations Following a 1 hour IV Infusion of CR665 in Female Subjects (Part A).
- FIG. 3 is a graph showing the Arithmetic Mean Changes from Baseline (Pre dose) in Serum Prolactin Concentrations Following a 5 minute IV. Infusion of CR665 in Male Subjects (Part B).
- FIG. 4 is a graph showing the Geometric Mean Plasma Concentrations of CR665 Following a 1 hour IV Infusion of CR665 in Male Subjects (Part A) (Linear Scale).
- FIG. 5 is a graph showing the Geometric Mean Plasma Concentrations of CR665 Following a 1 hour IV Infusion of CR665 in Male Subjects (Part A) (Semi logarithmic Scale).
- FIG. 6 is a graph showing the Geometric Mean AUC0 ⁇ for CR665 Versus Dose Level Following a 1 hour IV Infusion of CR665 in Male Subjects (Part A).
- FIG. 7 is a graph showing the Geometric Mean Plasma Concentrations of CR665 Following a 1 hour IV Infusion of 0.24 mg/kg CR665 in Female Subjects (Part A) (Linear Scale).
- FIG. 8 is a graph showing the Geometric Mean Plasma Concentrations of CR665 Following a 1 hour IV Infusion of 0.24 mg/kg CR665 in Female Subjects (Part A) (Semi logarithmic Scale).
- FIG. 9 is a graph showing the Arithmetic Mean ( ⁇ SD) Plasma Concentrations of CR665 Following a 1-hour IV Infusion of 0.24 mg/kg CR665 in Male and Female Subjects (Part A) (Linear Scale).
- FIG. 10 is a graph showing the Geometric Mean Plasma. Concentrations of CR665 Following a 5-minute IV Infusion of CR665 in Male and Female Subjects (Part B) (Linear Scale).
- FIG. 11 is a graph showing the Geometric Mean Plasma Concentrations of CR665 Following a 5-minute IV Infusion of CR665 in Male and Female Subjects (Part B) (Semi logarithmic Scale).
- FIG. 12 is a graph showing the Geometric Mean AUC (0 to infinity) for CR665 Versus Dose Level Following a 5-minute IV infusion of CR665 in Male Subjects (Part B).
- FIG. 13 is a graph showing the Relationship Between AUC0 12 h of Changes from Baseline in Serum Prolactin and AUC (0 to infinity) of CR665 over the 0.015 to 0.36 mg/kg Dose Range in Male Subjects (Part A).
- FIG. 14 is a graph showing the Relationship Between Cmaxof Changes from Baseline in Serum Prolactin and Cmaxof CR665 over the 0.015 to 0.36 mg/kg Dose. Range in Male Subjects (Part A).
- the invention provides methods, compositions, or dosage forms that employ and/or contain compounds, such as peptides, that are selective for kappa opioid receptor and not only exhibit a strong affinity for the kappa opioid receptor but exhibit, optionally, long duration of in vivo prolactin elevating activity in the absence of a severe or significant side effect, such as CNS side effects or diuresis.
- compounds such as peptides
- Exemplary kappa selective opioid, receptor compounds have a Ki against a mammalian kappa opioid receptor, such as a human kappa opioid receptor, of less than 1000 nM, or less than 100 nMor less than 10 nM, or less than 1 nM, optionally having a selectivity for kappa opioid receptors over other mammalian opioid receptor subtypes greater than 100, or greater than 1,000 or greater than 10,000 times greater affinity, measurable in vitro by the ratio of their 1050 or Ki values against the mammalian, e.g., human mu and delta opioid receptors, respectively.
- Kappa opioid receptor agonists can exhibit both a lack of significant brain penetration and a prolonged duration of in vivo activity.
- compounds also include those that exhibit no significant brain penetration while preserving substantial activity for measurable or detectable period of time, for example, at least about one hour, at least about two hours, for three hours or longer (e.g., 4, 5, 6, 12, 24, 48 hours or days, or longer).
- the method of the invention can be practiced using a peripherally selective kappa opioid receptor agonist, which when administered peripherally, is effective to increase or stabilize levels of prolactin without substantially crossing the blood-brain barrier of the subject.
- the amount of the peripherally selective kappa opioid receptor agonist administered is an amount effective to increase or stabilize levels of prolactin without causing a severe side effect in the subject.
- the amount of the peripherally selective kappa opioid receptor agonist administered is an amount effective to increase or stabilize levels of prolactin with minor or tolerable side effects in the subject.
- Side effects can include a neuropsychiatric side effect (such as but not limited to dysphoria or hallucinations), diuresis or sedation.
- the administered dose of the peripherally selective kappa opioid receptor agonist is between about 1 microgram/kg of body weight to about 100 milligrams/kg of body weight of said mammal per hour, or per day, or per week or per month.
- the prolactin levels can be elevated to greater than 10, 15, 20, 25, 50, 75, 100, 125, 150, 175, or 200 ng/rnl serum above the baseline level of serum prolactin.
- the method of the invention for treating insufficient or inadequate lactation in a mammal includes administering, separately or in combination an amount of a peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof, and an amount of prolactin effective to treat insufficient or inadequate lactation in the mammal.
- the invention provides a method for treating insufficient or inadequate lactation.
- the method includes administering an amount of a peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof, to a mammal, separately or in combination, with (1) another prolactin-elevating agent, (2) prolactin, or (3) a non-drug therapy, the method effective to treat insufficient or inadequate lactation in the mammal.
- the invention provides a method for treating insufficient or inadequate lactation in a mammal.
- the method includes administering separately or in combination 1) a peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof, and; 2) another prolactin-elevating agent, said administration in an amount effective for treating insufficient or inadequate lactation in the mammal.
- the invention provides a method of for treating a mammal exhibiting insufficient or inadequate milk production or at risk of insufficient or inadequate milk production.
- the method includes administering to said mammal an amount of a peripherally selective kappa opioid receptor agonist or salt thereof or prodrug thereof effective to treat the mammal.
- the peripherally selective kappa opioid receptor agonist or salt thereof or prodrug thereof can include a peptide, or can ionize or metabolize to form a peptide.
- the peptide can include a tetrapeptide or a pentapeptide.
- the prolactin-elevating agent useful in the methods of the present invention can be administered with a mu opioid receptor agonist selected from the group consisting of (i) morphine, (ii) hydromorphone, (iii) oxymorphone, (iv) levorphanol, (v) methadone, (vi) codeine, (vii) hydrocodone, (viii) oxycodone, (ix) morphine 6 glucuronide, (x) tramadol, (xi) meperidine, (xii) diphenoxylate, (xiii) loperamide, (xiv) fentanyl, (xv) sufentanil, (xvi) alfentanil, (xvii) remifentanil, (xviii) levomethadyl and (xviv) propoxyphene.
- a mu opioid receptor agonist selected from the group consisting of (i) morphine, (ii) hydromorphone, (iii)
- the prolactin-elevating agent can be a peptide having a binding affinity for the peripheral kappa opioid receptor that is greater than its binding affinity for non-peripheral kappa opioid receptor.
- the peptide can have a binding affinity for the peripheral kappa opioid receptor that is 10 times greater, 100 times greater, 1,000 times greater, or more than its binding affinity for a non-peripheral kappa opioid receptor.
- the peptide can have a binding affinity for the kappa opioid receptor which is at least 1,000 times greater than its binding affinity for the mu opioid receptor.
- the peptide has a binding affinity for the kappa opioid receptor which is at least 1,000 times greater than its binding affinity for the mu opioid receptor and an ED 50 for elevating prolactin of about 0.5 mg/kg or less.
- the invention provides a method of treating a mammal in need of elevated or stabilized prolactin levels, wherein the method includes administering to said mammal an amount of a peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof, in conjunction with an amount of an additional prolactin elevating compound, effective to treat the mammal.
- the additional prolactin elevating compound can include a D2 dopamine receptor antagonist or mu opioid receptor agonist.
- the D2 dopamine receptor agonist is selected from the group consisting of (i) domperidone, (ii) metoclopramide, (iii) levosulpiride, (iv) sulpiride, (v) thiethylperazine, (vi) ziprasidone, (vii) zotepine, (viii) clozapine, (ix) chlorpromazine, (x) acetophenazine, (xi) carphenazine (xii) chlorprothixene, (xiii) fluphenazine, (xiv) loxapine, (xv) mesoridazine, (xvi) molindone, (xvii) perphenazine, (xviii) pimozide, (xviv) piperacetazine, (xx) prochlorperazine, (xxi) thioridazine, (xxii) thiothixen
- the mu opioid receptor agonist is selected from the group consisting of (i) morphine, (ii) hydromorphone, (iii) oxymorphone, (iv) levorphanol, (v) methadone, (vi) codeine, (vii) hydrocodone, (viii) oxycodone, (ix) morphine-6-glucuronide, (x) tramadol, (xi) meperidine, (xii) diphenoxylate, (xiii) loperamide, (xiv) fentanyl, (xv) sufentanil, (xvi) alfentanil, (xvii) remifentanil, (xviii) levomethadyl, and (xviv) propoxyphene.
- prolactin elevating activity refers to the pharmacological activity of a compound If it causes an elevation in circulating plasma or serum levels of prolactin in a subject.
- a “prolactin increasing activity” refers to a compound that causes a measurable or detectable, transient or longer term increase in circulating plasma or serum levels of prolactin in a subject.
- a “prolactin stabilizing activity” refers to a compound that causes a measurable or detectable, transient or longer term, stabilization in circulating plasma or serum levels of prolactin in a subject, e.g., prevents or inhibits a reduction in prolactin levels, maintains a particular level of prolactin for a measurable period of time, prevents or inhibits a reduction in prolactin levels below a certain amount (e.g., below 200, 175, 150, 125, 100, 75, 50, 25 ng/ml serum), etc.
- a certain amount e.g., below 200, 175, 150, 125, 100, 75, 50, 25 ng/ml serum
- “functional hypoprolactinemia” refers to a condition in which a subject has insufficient or inadequate levels of circulating prolactin required to initiate, maintain or enhance a physiological function, e.g. lactation.
- the level of circulating prolactin required for a given physiological function will vary, as is knownin the art, depending upon the function and the gender and physiological or pathophysiological status of the subject. Thus, for example, a normal pre pregnancy baseline level of circulating prolactin would be insufficient to sustain lactation after delivery. Under these circumstances, the failure of lactation in a post pregnant female with this level of prolactin would be characterized as a functional hypoprolactinemia, even though the circulating level of prolactin would be normal for a non lactating female.
- CNS side effect refers to a clinically significant side effect of a compound in which the symptoms are psychiatric or neurological, e.g., visual or auditory hallucinations, delusions, impaired intellectual functioning, or impaired control of voluntary movements.
- subject is intended to include human and non human mammals.
- Subjects include a person, e.g., a patient, in need of elevated, increased or stabilized levels of prolactin, e.g., a person in need of stimulation of lactation, e.g., a female (mother).
- prolactin e.g., a person in need of stimulation of lactation, e.g., a female (mother).
- mamammals includes humans and all non human mammals, such as non human primates, ungulates and ruminants.
- an “effective amount” or “sufficient amount” refers to an amount of a compound as described herein that may be therapeutically effective to inhibit, prevent or treat a symptom of a particular disease, disorder, condition, or side effect.
- diseases, disorders, conditions, and side effects include those conditions associated with insufficient, or inadequate circulating levels of prolactin, wherein the treatment comprises elevating, increasing or stabilizing circulating levels of prolactin by contacting cells, tissues or receptors with compounds as set forth herein.
- an “effective amount”, when used in connection with lactational insufficiency or inadequacy for example, refers to an amount of a compound required for treatment and/or prevention of this condition.
- an “effective amount”, when used in connection with functional hypoprolactinemia, refers to the treatment and/or prevention of one or more symptoms, diseases, disorders, and conditions associated with circulating levels of prolactin that are undesirably low, for example, to optimally sustain a physiological function.
- “pharmaceutically acceptable” refers to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without severe toxicity, irritation, allergic response, or other complications commensurate with a reasonable benefit/risk ratio.
- a peripherally selective kappa opioid receptor agonist of the invention refers, in certain embodiments, to the concurrent administration to a patient of a peripherally selective kappa opioid receptor agonist of the invention and either or both of prolactin and a compound with prolactin elevating, increasing or stabilizing activity but lacking peripherally selective kappa opioid receptor agonist activity, e.g., a D2 dopamine receptor antagonist, e.g., domperidone.
- each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide a desired therapeutic effect.
- a “D2 dopamine receptor antagonist” refers to compounds with a binding affinity (K D or K i ) for a mammalian D2 dopamine receptor of less than 10 micromolar, regardless of binding affinity for other receptors. Where there is ambiguity or an absence of useful information regarding whether the binding affinity of a compound for a mammalian D2 dopamine receptor meets this definition, data from in vitro or in vivo functional studies, as are commonly employed by those with skill in the art, can be used to determine whether a compound is a functional antagonist of a mammalian D2 dopamine receptor.
- “mu opioid receptor agonist” refers to compounds with a binding affinity (K D or K i ) for a mammalian mu opioid receptor of less than 10 micromolar, regardless of binding affinity for other receptors. Where there is ambiguity or an absence of useful information regarding whether the binding affinity of a compound for a mammalian mu opioid receptor meets this definition, data from in vitro or in vivo functional studies, as are commonly employed by those with skill in the art, can be used to determine whether a compound is a functional agonist of a mammalian mu opioid receptor.
- dosage unit refers to a physically discrete unit suited as unitary dosages for a particular individual or condition to be treated. Each unit may contain a predetermined quantity of active compound(s) calculated to produce the desired therapeutic effect(s), optionally in association with a pharmaceutical carrier.
- the specification for the dosage unit forms may be dictated by (a) the unique characteristics of the active compound(s) and the particular therapeutic effect(s) to be achieved, and (b) the limitations inherent in the art of compounding such active compound(s).
- pharmaceutically acceptable salts refer to derivatives of compounds wherein the parent compound is modified by making acid or base salts thereof.
- examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid sals of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts include the conventional non toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non toxic inorganic or organic acids.
- such conventional non toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2 acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
- inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
- organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic,
- physiologically acceptable salts are prepared by methods known in the art, e.g., by dissolving the free amine bases with an excess of the acid in aqueous alcohol, or neutralizing a free carboxylic acid with an alkali metal base such as a hydroxide, or with an amine.
- Certain acidic or basic compounds of the present invention may exist as zwitterions. All forms of the compounds, including free acid, free base and zwitterions, are contemplated to be within the scope of the present invention. It is well known in the art that compounds containing both amino and carboxyl groups often exist in equilibrium with their zwitterionic forms. Thus, any of the compounds described herein throughout that contain, for example, both amino and carboxyl groups, also include reference to their corresponding zwitterions.
- a peripherally selective kappa opioid receptor agonist of the invention can be incorporated into a pharmaceutical composition to ameliorate functional hypoprolactinemia in a subject, e.g., a subject presenting with a deficiency, inadequacy or insufficiency in lactation associated with insufficient or inadequate plasma levels of prolactin.
- the compositions should contain an effective amount of a peripherally selective kappa opioid receptor agonist, in a pharmaceutically acceptable carrier.
- the pharmaceutical carrier can be any compatible, non toxic substance suitable to deliver the peripherally selective kappa opioid receptor agonist to the subject.
- Sterile water, alcohol, fats, waxes, and inert solids may be used as the carrier.
- Pharmaceutically acceptable adjuvants, buffering agents, dispersing agents, and the like, may also be incorporated into the pharmaceutical compositions.
- concentration of peripherally selective kappa opioid receptor agonist or other active agent in the pharmaceutical composition can vary widely, i.e., from less than about 0.01% by weight, usually being at least about 1% weight to as much as 50% by weight or more.
- an active ingredient can be administered in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions.
- Active component(s) can be encapsulated in gelatin capsules together with inactive ingredients and powdered carriers, such as glucose, lactose, sucrose, mannitol, starch, cellulose or cellulose derivatives, magnesium stearate, stearic acid, sodium saccharin, talcum, magnesium carbonate and the like.
- inactive ingredients examples include red iron oxide, silica gel, sodium lauryl sulfate, titanium dioxide, edible white ink and the like.
- Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
- Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
- peptides of the invention can be released from a capsule after passing through the harsh proteolytic environment of the stomach.
- Methods for enhancing peptide stability and absorption after oral administration are well known in the art (e.g., Mahato R I. Emerging trends in oral delivery of peptide and protein drugs. Critical Reviews in Therapeutic Drug Carrier Systems. 20:153-214, 2003).
- oral delivery of compounds of the invention can be optimized through the use of remote controlled capsules as disclosed by Wilding and Prior in Critical Reviews in Therapeutic Drug Carrier Systems 20:405-431 (2003).
- the peripherally selective kappa opioid receptor agonists can be formulated as aerosols.
- aerosol includes any gas-borne suspended phase of the compounds of the instant invention which is capable of being inhaled into the bronchioles or nasal passages.
- aerosol includes a gas-borne suspension of droplets of the compounds of the instant invention, as may be produced in a metered dose inhaler or nebulizer, or in a mist sprayer.
- Aerosol also includes a dry powder composition of a compound of the instant invention suspended in air or other carrier gas, which may be delivered by insufflation from an inhaler device, for example.
- Parenteral administration of the formulations of the present invention includes intravenous, subcutaneous, intramuscular and transdermal administrations.
- Preparations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile emulsions.
- the solutions may be either aqueous or nonaqueous, and thereby formulated for delivery by injection, infusion, or using implantable pumps.
- useful formulations of the invention include microcapsule preparations with controlled release properties (R. Pwar et al. Protein and peptide parenteral controlled delivery. Expert Opin Biol Ther.
- liposomes 4(8):1203-12, 2004 or encapsulation in liposomes, with an exemplary form being polyethylene coated liposomes, which are known in the art to have an extended circulation time in the vasculature (e.g.Koppal, T. “Drug delivery technologies are right on target”, Drug Discov. Dev. 6, 49-50, 2003).
- Preparations for transdermal delivery are incorporated into a device suitable for said delivery, said device utilizing, e.g., iontophoresis (Kalia Y N et al. Iontophoretic drug delivery. Adv Drug Deliv Rev. 56:619-58, 2004) or a dermis penetrating surface (Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev. 56:581-7, 2004), such as are known in the art to be useful for improving the transdermal delivery of drugs.
- An electrotransport device and methods of operating same are disclosed in U.S. Pat. No. 6,718,201.
- Electroosmosis has also been referred to as electrohydrokinesis, electro convection, and electrically induced osmosis.
- electroosmosis of a compound into a tissue results from the migration of solvent in which the compound is contained, as a result of the application of electromotive force to the therapeutic species reservoir, i.e., solvent flow induced by electromigration of other ionic species.
- electromotive force i.e., solvent flow induced by electromigration of other ionic species.
- certain modifications or alterations of the skin may occur such as the formation of transiently existing pores in the skin, also referred to as “electroporation.” Any electrically assisted transport of species enhanced by modifications or alterations to the body surface (e.g., formation of pores in the skin) are also included in the term “electrotransport” as used herein.
- Electrotransport refers to (1) the delivery of charged agents by electromigration, (2) the delivery of uncharged agents by the process of electroosmosis, (3) the delivery of charged or uncharged agents by electroporation, (4) the delivery of charged agents by the combined processes of electromigration and electroosmosis, and/or (5) the delivery of a mixture of charged and uncharged agents by the combined processes of electromigration and electroosmosis.
- Electrotransport devices generally employ two electrodes, both of which are positioned in close electrical contact with some portion of the skin of the body.
- One electrode is the electrode from which the therapeutic agent is delivered into the body.
- the other electrode called the counter or return electrode, serves to close the electrical circuit through the body.
- the circuit is completed by connection of the electrodes to a source of electrical energy, e.g., a battery, and usually to circuitry capable of controlling current passing through the device.
- either the anode or cathode may be the active or donor electrode.
- the positive electrode the anode
- the negative electrode the cathode
- Electrotransport devices additionally require a reservoir or source of the therapeutic agent that is to be delivered into the body.
- Such drug reservoirs are connected to the anode or the cathode of the electrotransport device to provide a fixed or renewable source of one or more desired species or agents.
- Each electrode assembly is comprised of an electrically conductive electrode in ion-transmitting relation with an ionically conductive liquid reservoir which in use is placed in contact with the patient's skin.
- Gel reservoirs such as those described in Webster (U.S. Pat. No. 4,383,529) are one form of reservoir since hydrated gels are easier to handle and manufacture than liquid-filled containers.
- Water is one liquid solvent that can be used in such reservoirs, in part because the salts of the peptide compounds of the invention are water soluble and in part because water is non-irritating to the skin, thereby enabling prolonged contact between the hydrogel reservoir and the skin.
- reservoirs and sources include a pouch as described in U.S. Pat. No. 4,250,878, a pre-formed gel body as disclosed in U.S. Pat. No. 4,382,529, and a glass or plastic container holding a liquid solution of the drug, as disclosed in the figures of U.S. Pat. No. 4,722,726.
- compounds e.g., peptides
- the invention can be formulated with flux enhancers such as ionic surfactants (e.g., U.S. Pat. No. 4,722,726) or cosolvents other than water (e.g., European Patent Application 278,473).
- flux enhancers such as ionic surfactants (e.g., U.S. Pat. No. 4,722,726) or cosolvents other than water (e.g., European Patent Application 278,473).
- the outer layer i.e., the stratum corneum
- the stratum corneum can be mechanically disrupted prior to electrotransport delivery therethrough (e.g., U.S. Pat. No. 5,250,023).
- Peripherally selective kappa opioid receptor agonists that are well suited for electrotransport can be selected, by measuring their electrotransport flux through the body surface (e.g., the skin or mucosa), e.g., as compared to a standardized test peptide with known electrotransport flux characteristics, e.g. thyrotropin releasing hormone (R. Burnette et al. J. Pham. Sci. (1986) 75:738) or vasopressin (Nair et al., Pharmacol Res. 48:175-82, 2003).
- Transdermal electrotransport flux can be determined using a number of in vivo or in vitro methods well known in the art.
- In vitro methods include clamping a piece of skin of an appropriate mammal (e.g., human cadaver skin) between the donor and receptor compartments of an electrotransport flux cell, with the stratum corneum side of the skin piece facing the donor compartment.
- a liquid solution or gel containing the drug to be delivered is placed in contact with the stratum corneum, and electric current is applied to electrodes, one electrode in each compartment.
- the transdermal flux is calculated by sampling the amount of drug in the receptor compartment.
- Two successful models used to optimize transdermal electrotransport drug delivery are the isolated pig skin flap model (Heit M C et al. Transdermal iontophoretic peptide delivery: in vitro and in vivo studies with luteinizing hormone releasing hormone. J. Pharm. Sci.
- Compounds of the invention for transdermal iontophoretic delivery can have one, or typically, two charged nitrogens, to facilitate their delivery.
- the scope of the present invention also includes methods of treating a mammal in need of elevated prolactin wherein the peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof is administered transdermally, for instance and without limitation, by an electrotransport device.
- the electrotransport device can, in some embodiments, deliver the peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof through a body surface.
- Transdermal delivery devices employ high velocity delivery under pressure to achieve skin penetration without the use of a needle.
- Transdermal delivery can be improved, as is known in the art, by the use of chemical enhancers, sometimes referred to in the art as “permeation enhancers”, i.e., compounds that are administered along with the drug (or in some cases used to pretreat the skin, prior to drug administration) in order to increase the permeability of the stratum corneum, and thereby provide for enhanced penetration of the drug through the skin.
- Chemical penetration enhancers are compounds that are innocuous and serve merely to facilitate diffusion of the drug through the stratum corneum, whether by passive diffusion or an energy driven process such as electrotransport. See, for example, Meidan V M et al. Enhanced iontophoretic delivery of buspirone hydrochloride across human skin using chemical enhancers. Int. J. Pharm. 264:73-83, 2003.
- Pharmaceutically acceptable carriers used in parenteral preparations include aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances.
- aqueous vehicles examples include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection.
- Nonaqueous parenteral vehicles include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut oil.
- Antimicrobial agents in bacteriostatic or fungistatic concentrations must be added to parenteral preparations packaged in multiple dose containers which include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride.
- Isotonic agents include sodium chloride and dextrose. Buffers include phosphate and citrate. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. Suspending and dispersing agents include sodium carboxymethylcelluose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Emulsifying agents include Polysorbate 80 (Tween 80). A sequestering or chelating agent of metal ions includes EDTA. Pharmaceutical carriers also include ethyl alcohol, polyethylene glycol and propylene glycol for water miscible vehicles and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.
- a therapeutically effective amount of a peripherally selective kappa opioid receptor agonist is at least about 0.01% w/w up to about 50% w/w or more, or more than 0.1% w/w of the active compound.
- the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time, or as a controlled release formulation.
- controlled release formulation encompasses formulations that allow the continuous delivery of a peripherally selective kappa opioid receptor agonist to a subject over a period of time, for example, several days to weeks. Such formulations may administered subcutaneously or intramuscularly and allow for the continual steady state release of a predetermined amount of compound in the subject over time.
- the controlled release formulation of peripherally selective kappa opioid receptor agonist may be, for example, a formulation of drug containing polymeric microcapsules, such as those described in U.S. Pat. Nos. 4,677,191 and 4,728,721, incorporated herein by reference.
- concentration of the pharmaceutically active compound is adjusted so that administration provides an effective amount to produce a desired effect.
- the exact dose depends on the age, weight and condition of the patient or animal, as is known in the art.
- specific dosage regimens can be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations.
- concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed invention.
- the unit dose parenteral preparations include packaging in an ampoule or a syringe with a needle.
- intravenous infusion of a sterile aqueous buffered solution containing an active compound is an effective mode of administration.
- Another embodiment is a sterile aqueous or oily solution or suspension containing an active material injected as necessary to produce the desired pharmacological effect.
- compositions and methods of the invention can be delivered or administered intravenously, transdermally, intranasally, subcutaneously, intramuscularly, or orally.
- Compositions can be administered for prophylactic treatment of individuals suffering from, or at risk of a disease or a disorder, e.g., a female experiencing insufficient or inadequate lactation.
- a pharmaceutical composition is typically administered to a subject suffering from a disease or disorder, e.g., a lactational deficiency, in an amount sufficient to inhibit, prevent, or ameliorate the disease or disorder. An amount adequate to accomplish this is defined as a “therapeutically effective dose.”
- peripherally selective kappa opioid receptor agonist administered to subjects stimulates release of the anterior pituitary hormone prolactin.
- the compound is typically administered in an amount sufficient to stimulate secretion of prolactin, or stabilize or prevent or inhibit reductions or decreases in prolactin, without causing a severe side effect, such as CNS side effects or diuresis.
- a useful dose range of a peripherally selective kappa opioid receptor agonist can be determined by one of skill in the art through routine testing.
- a dose depends, in part, upon physical characteristics of the patient to be treated, e.g., body weight, as well as the route of administration, e.g., intravenous injection or transdermal delivery, and the bioavailability and plasma clearance of the compound by that route of administration, as well as the kappa opioid receptor affinity of the compound.
- One method of approximating an effective dose is to titrate the dose to achieve a plasma concentration of drug that exceeds the affinity constant (Kd or Ki) of the drug for the kappa opioid receptor, e.g., as determined by a conventional radioreceptor assay as is routinely employed in the art.
- One method is to titrate the dose to effect, e.g., to employ a dose that is found to effectively elevate prolactin levels, as measured by an immunoassay selective for prolactin.
- a dose that is found to effectively elevate prolactin levels as measured by an immunoassay selective for prolactin.
- Serum prolactin concentrations can be assessed by any of several, validated methods as are known in the art, e.g., a prolactin-specific immunoassay, e.g., the IMx prolactin assay (Abbott Laboratories, Abbott Park, Ill.), a microparticle enzyme immunoassay used in conjunction with an Abbott IMx Automated Immunoassay Analyzer.
- a prolactin-specific immunoassay e.g., the IMx prolactin assay (Abbott Laboratories, Abbott Park, Ill.)
- a microparticle enzyme immunoassay used in conjunction with an Abbott IMx Automated Immunoassay Analyzer.
- an additional method of dose titration is to employ a prolactin-elevating dose that effectively increases the amount of milk that can be expressed, for example, to between about 500 to 1000 ml per day for a nursing human mother, with the level of milk expression selected according to the needs
- the needs of the nursing infant can be assessed by methods known to those with skill in the art, and which can include evidence for adequate lactation: (1) infant is satisfied after breast feeding, (2) infant gains weight appropriately in relation to age/length, (3) breast engorgement and/or leaking occurs if infant feeding is missed, and (4) milk is secreted in volumes above 500 ml/day.
- the volume of milk ingested by infants is commonly estimated as 150 ml/kg/day.
- Methods of the invention therefore include those that minimize transfer of a compound or compounds of the invention into breast milk that is fed to an offspring, such as an infant.
- the transfer of drugs into breast milk is most commonly described quantitatively using the milk to plasma (M/P) concentration ratio. The accuracy of this value is improved if it is based on the area under the concentration time curves (AUC), of the drug in maternal milk and plasma.
- the infant daily dose can be estimated with the following equation:
- M/P milk to plasma ratio
- the average maternal serum concentration refers to AUC after maternal ingestion of a single dose of drug or at steady state during, chronic maternal dosing (Bennett 1988, 1996).
- the AUC is either the AUC from time zero to infinity after maternal ingestion of a single dose of drug or the AUC within a dosing interval at steady state during chronic maternal dosing.
- the volume of milk ingested by infants is commonly estimated as 150 ml/kg/day.
- the infant dose (mg/kg) can then be expressed as a percentage of the maternal dose (mg/kg).
- Compounds of the invention can result in an infant dose of less than 10% of the maternal dose, or less than 1% or less than 0.1% of the maternal dose. Since compounds of the invention include peptides, they can be formulated, e.g., with polymeric microspheres, to protect them from degradation and enhance absorption in the gastrointestinal tract (e.g., Mahato R I. Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. 20:153 214, 2003).
- Microsphere-encapsulated peptides for example typically do not survive the maternal gastrointestinal environment and release free peptide into the circulation, such that peptides would be orally bioavailable to the offspring through breast milk in significant amounts, which can be readily confirmed by drug assay of infant plasma and/or urine.
- the utility of the present invention is not limited to promoting, elevating, increasing or stabilizing lactation in human and non human mammals.
- the prolactin receptor is indeed found in the mammary gland and the ovary, two of the best characterized sites of prolactin actions in mammals, the receptor is also found in areas of the brain that are outside the blood brain barrier, and are therefore accessible to circulating prolactin (Freeman M E et al. Prolactin: Structure, function, and regulation of secretion. Physiol. Rev. 80:1523-1631, 2000).
- the prolactin receptor (and/or the mRNA encoding the prolactin receptor) is found in the choroid plexus the area postrema, and the mediobasal hypothalamus.
- Prolactin receptors are also present in a wide range of peripheral tissues, including the pituitary gland, heart, lung, thymus, spleen, liver, pancreas, kidney, adrenal gland, uterus; skeletal muscle, and skin. Accordingly, it is contemplated that peripherally selective kappa opioid receptor agonists, as described herein, will be useful in preventing, ameliorating or modulating conditions associated with these regions of the brain and periphery, as well.
- elevated circulating prolactin caused by a compound of the instant invention, would have access to the mediobasal hypothalamus, a region outside the blood-brain barrier that includes the anterior periventricular area, paraventricular nucleus, and arcuate nucleus (e.g., Merchenthaler I. Neurons with access to the general circulation in the central nervous system of the rat: a retrograde tracing study with fluoro gold. Neuroscience 44:655-62; 1991).
- hypothalamic nuclei are critical for neuroendocrine regulation, and contain prolactin receptors, which would thereby be therapeutically affected, e.g., in neuroendocrine related disorders, by elevations in circulating prolactin caused by a compound of the instant invention.
- a variety of assays may be employed to test whether the compounds of the invention exhibit high affinity and selectivity for the kappa opioid receptor, long duration of in vivo bioactivity, lack of CNS side effects, and prolactin elevating activity.
- Receptor assays are known in the art and kappa opioid receptors from several species have been cloned, as have'mu and delta opioid receptors.
- Kappa opioid receptors as well as mu and delta opioid receptors are classical, seven transmembrane spanning, G-protein coupled receptors.
- a mammalian form of the opioid receptor is used for screening; typically, the species source of the receptors is the same as the species for which the compound of the invention is being assessed, e.g., human placental tissue as a source of kappa opioid receptors (Porthe G et al. Kappa opiate binding sites in human placenta. Biochem. Biophys. Res. Commun. 101:1-6, 1981) for screening if the contemplated use of the screened compounds is for treatment of a human subject.
- the species source of the receptors is the same as the species for which the compound of the invention is being assessed, e.g., human placental tissue as a source of kappa opioid receptors (Porthe G et al. Kappa opiate binding sites in human placenta. Biochem. Biophys. Res. Commun. 101:1-6, 1981) for screening if the contemplated use of the screened compounds is for treatment of a human subject.
- Binding affinity refers to the strength of interaction between ligand and receptor.
- the compounds of the invention can be evaluated using competition binding studies. These studies can be performed using cloned kappa and mu opioid receptors expressed in stable transfected cell lines or naturally occurring opioid receptors from a receptor-enriched tissue source, as noted above. In these studies, the test compounds (unlabeled or cold ligand) are used at increasing concentrations to displace the specific binding of a radiolabeled ligand that has high affinity and selectivity for the receptor studied. Tritiated U-69,593 and DAMGO can be used as ligands in kappa and mu opioid receptor studies, respectively. Both ligands are commercially available (NEN-Dupont).
- DAMGO is an acronym for [D-Ala 2 , MePhe 4 , Gly-ol 5 ]-enkephalin.
- the affinity of the radioligands is defined by the concentration of radioligand that results in half-maximal specific binding (K D ) in saturation studies.
- the affinity of the test compound (unlabeled or cold ligand) is determined in competition binding studies by calculating the inhibitory constant (KO according to the following formula:
- K i IC 50 /[1+( F/K D )]
- the calculated K i for the test compound is a good approximation of its dissociation constant K D , which represents the concentration of ligand necessary to occupy one-half (50%) of the binding sites.
- K D dissociation constant
- a low K i value in the nanomolar and subnanomolar range is considered to identify a high affinity ligand in the opioid field.
- Exemplary analogs have a K i for kappa opioid receptor of about 10 nanomolar (nM) or less, and typical analogs have a K i of about 1 nM or less.
- High affinity compounds (1) enable the use of relatively low doses of drug, which minimizes the likelihood of side effects due to low affinity interactions, and (2) potentially reduce the cost of manufacturing a dose since a correspondingly smaller amount of a higher affinity compound would be required to produce the desired therapeutic effect, assuming equal absorption, distribution, metabolism, and excretion.
- binding assays employing kappa opioid receptors and mu opioid receptors are straightforward to perform and can be readily carried out with large numbers of compounds to determine whether such compounds are kappa opioid receptor selective and have high affinity.
- Such binding assays can be carried out in a variety of ways as well known to one of skill in the art, and one detailed example of an assay of this general type is set forth in Young E A et al. [ 3 H]Dynorphin A binding and kappa selectivity of prodynorphin peptides in rat, guinea pig and monkey brain. Eur. J. Pharmacol. 121:355-65, 1986.
- D-Nle D-norleucine
- D-Hle D-homoleucine
- D-Har represents D-homoarginine
- D-nArg represents D-norarginine which is one carbon shorter than D-Arg.
- D-NaI is meant the D-isomer of alanine which is substituted by naphthyl on the n-carbon.
- D-2Nal is employed, i.e. the attachment to naphthalene is at the 2-position on the ring structure; however, D-1Nal may also be used.
- the abbreviations D-Cpa and D-Fpa are used to represent, respectively, chloro-D-Phe and fluoro-D-Phe, with D-4 Cpa, D-2Fpa, D-3Fpa and D-4Fpa being typical.
- D-Npa means nitro-D-Phe
- D-Mpa is used to represent methyl D-Phe.
- D-3,4 Cpa means 3,4-dichloro-D-Phe.
- D-Acp represents D-Ala(cyclopentyl).
- D-Orn represents D-ornithine, and D-Dbu represents alpha, gamma-diamino butyric acid.
- CML represents C alpha methyl Leu, and CMP and CMO represent C alpha Me Phe and C allpha Me Orn.
- D-4Amf is meant D-4(NH 2 CH 2 )Phe, and by D-Gmf is meant Amf(amidino) which represents D-Phe where the 4-position is substituted with CH 2 NHC(NH)NH 2 . Amd represents amidino, and the symbol D-Amf(Amd) is also used.
- D-Tic D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
- Thi represents the thienyl group, which is typically linked at its 2-position to alanine, although 3-thienyl is an equivalent.
- Ily and Ior are respectively meant isopropyl Lys and isopropyl Orn where the side chain amino group is alkylated with isopropyl.
- lower alkyl is meant C 1 to C 6 , for example, C 1 -C 4 but including cyclopropyl and cyclobutyl.
- Me, Et, Pr, Tpr, Bu, Pn and Bzl are used to represent methyl, ethyl, propyl, isopropyl, butyl, pentyl and benzyl.
- Cyp is meant cyclopropyl, and by Cyb is meant cyclobutyl.
- the linkage is typically to one end of an alkyl chain, the linkage may be elsewhere in the chain, e.g. 3-pentyl which may also be referred to as ethylpropyl.
- 4Nbz and 4Abz represent 4-nitrobenzyl and 4-aminobenzyl.
- 2-, 3- and 4-picolyl (Pic) are meant methylpyridine groups with the attachment being via a methylene in the 2-, 3- or 4-position.
- Mor is meant morpholinyl
- Tmo thiomorpholinyl
- Ahx is used to represent 4-aminocyclohexyl
- hEt is used to represent hydroxyethyl, i.e. —CH 2 CH 2 OH.
- Aeb is used to represent 4-(2-amino-2-carboxyethyl)benzyl, i.e.
- Pip is meant piperidinyl, and by 4-HyP and OxP are meant 4-hydroxypiperidinyl and 4-oxo-piperidinyl.
- Ppz is meant piperazinyl.
- Ecp represents 4-ethylcarbamoylpiperazinyl; quaternary ammonium moieties, such as 4-dimethyl piperazinyl (Dmp) or other di-lower alkyl substitutions, may also be used.
- Substituted benzyl is typically 4-aminobenzyl, i.e.
- 2-Tzl 2-thiazolyl, i.e.
- Dor is meant ⁇ -omithinyl where the side chain amino group of L-ornithine is connected by an amide bond to the C-terminus.
- D-Phe or substituted D-Phe is an example at the 1-position.
- the phenyl ring may be substituted at the 2-, 3- and/or 4-positions, and commonly substitutions by chlorine or fluorine at the 2 or 4-position are particular examples.
- the alpha-carbon atom may also be methylated.
- Other equivalent residues which resemble D-Phe may also be used, and these include D-Ala(cyclopentyl), D-Ala(thienyl), D-Tyr and D-Tic.
- the 2-position residue can also be D-Phe or substituted D-Phe with such substitutions including a substituent on the 4-position carbon of the phenyl ring or the 3- and 4-positions.
- D-alanine substituted by naphthyl can be used, as well as D-Trp and D-Tyr.
- the 3-position can be occupied by a residue such as D-Nle, D-Leu, D-CML, D-Hle, D-Met or D-Val; however, D-Ala(cyclopentyl) or D-Phe may also be used.
- D-Arg and D-Har which may be substituted with diethyl, are examples for the 4-position; however, D-nArg and other equivalent residues may be used, such as D-Lys or D-Orn (either of which can have its omega-amino group alkylated as by isopropyl or have its ⁇ -carbon group methylated).
- D-Dbu, D-4Amf which is typically substituted with amidino
- D-His may also be used.
- the invention provides a method of treating a mammal exhibiting insufficient or inadequate milk production or at risk of insufficient or inadequate milk production; wherein the method includes administering to the mammal an amount of a peripherally selective kappa opioid receptor agonist or salt thereof or prodrug thereof effective to treat the mammal, the peripherally selective kappa opioid receptor agonist or salt thereof or prodrug thereof being a peptide, or ionizes or is metabolized to form a peptide having the formula:
- Xaa 1 is (A)D-Phe, (C alpha Me)D-Phe, D-Tyr, D-Tic or D-Ala(cyclopentyl or thienyl), with A being H, NO 2 , F, Cl or CH 3 ;
- Xaa 2 is (A′)D-Phe, D-1Nal, D-2Nal, D-Tyr or D-Trp, with A′ being A or 3,4Cl 2 ;
- Xaa 3 is D-Nle, (B)D-Leu, D-Hle, D-Met, D-Val, D-Phe or D-Ala(cyclopentyl) with B being H or C alpha Me;
- Xaa 4 is D-Arg, D-Har, D-nArg, D-Lys, D-Lys(Ipr), D-Arg(Et 2 ), D-Har(Et 2 ), D-Amf(G), D-Dbu, (B)D-
- Xaa 2 is D-Phe
- Xaa 3 is D-Nle
- Xaa 4 is D-Arg.
- Q is NHR 1 and R 1 is ethyl, propyl, butyl, cyclopropyl or cyclobutyl.
- Q is morpholinyl or thiomorpholinyl; or Q is NHR 1 and R 1 is 4-picolyl.
- Xaa l is D-Ala(2-thienyl); alternatively, Xaa 1 is D-4FPhe and Xaa 2 is D-4ClPhe.
- Xaa 3 is D-Nle or D-Leu and Xaa 4 is D-Orn or D-Amf(Amd).
- Xaa 2 is D-Phe
- Xaa 3 is D-Leu or D-CML
- Xaa 4 is D-Orn.
- the invention further provides a method of treating a mammal exhibiting insufficient or inadequate milk production or at risk of insufficient or inadequate milk production; wherein the method includes administering to the mammal an amount of a peripherally selective kappa opioid receptor agonist or salt thereof or prodrug thereof effective to treat the mammal, the peripherally selective kappa opioid receptor agonist or salt thereof or prodrug thereof being a peptide, or ionizes or is metabolized to form a peptide having the formula:
- Xaa 1 is D-Phe (unsubstituted or substituted by C alpha , Me, 2F, 4F or 4Cl) or D-Ala(cyclopentyl or thienyl);
- Xaa 2 is (A′)D-Phe, D-1Nal, D-2Nal or D-Trp, with A′ being H, 4F, 4Cl, 4NO 2 or 3,4Cl 2 ;
- Xaa 3 is D-Nle, D-Leu, D-CML, D-Met or D-Acp;
- Xaa 4 is D-Arg, D-Arg(Et 2 ), D-Lys, D-Ily, D-Har, D-Har(Et 2 ), D-nArg, D-Orn, D-Ior, D-Dbu, D-Amf, and D-Amf(Amd); and
- Q is NR 1 R 2 , Mor, Tmo, Pip, 4-Hyp, OxP or
- Xaa 2 is D-Phe
- Xaa 3 is D-Nle
- Xaa 4 is D-Arg.
- Q is NHR 1 and R 1 is ethyl, propyl, butyl, cyclopropyl or cyclobutyl.
- Q can be morpholinyl or thiomorpholinyl.
- Q is NHR 1 and R 1 is 4-picolyl.
- Q is NR 1 , R 2 and R 1 is ethyl and R 2 is ethyl.
- Xaa 1 is D-Phe or D-Ala(2-thienyl) and Xaa 2 is D-4ClPhe.
- Xaa 3 is D-Nle or D-Leu and Q is morpholinyl.
- Xaa 1 is D-Phe, D-4Fpa, D-2Fpa, D-Acp or D-Ala(2Thi);
- Xaa 2 is (A)D-Phe, D-1Nal, D-2Nal or D-Trp, with A being 4F or 4Cl;
- Xaa 3 is D-Nle, D-Met or D-Leu;
- Xaa 4 is D-Arg, D-Har, D-nArg, D-Lys, D-Orn or D-Amf(Amd); and Q NHR 1 , Mor, Tmo, Pip or Ppz, with R 1 being Et, Pr or 4Pic.
- the peptide has the formula: H-D-Phe-D-Phe-D-Nle-D-Arg-NHEt, H-D-Phe-D-Phe-D-Nle-D-Arg-morpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NH-4-picolyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NHPr, H-D-Phe-D-Phe-D-Nle-D-Arg-thiomorpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-Net 2 , H-D-Phe-D-Phe-D-Nle-D-Arg-NHMe, H-D-Phe-D-Phe-D-Leu-D-Orn-morpholinyl, H-D-Phe-D-D-Nle-D-Arg-NHhEt, H-D-Phe
- Mammals exhibiting insufficient or inadequate milk production or at risk of insufficient or inadequate milk production can be treated by a method according to the present invention; the method includes administering to the mammal an amount of a peripherally selective kappa opioid receptor agonist or salt thereof or prodrug thereof effective to treat the mammal, wherein the administration includes intravenous, subcutaneous, intramuscular, intranasal, oral, or transdermal administration, such as for instance by an electrotransport device.
- the electrotransport device delivers the peripherally selective kappa opioid receptor agonist through a body surface.
- the method includes: (a) providing a first electrode; (b) providing a second electrode; (c) providing a power source electrically connected to said first and said second electrodes; (d) providing at least one donor reservoir having the peripherally selective kappa opioid receptor agonist, wherein said donor reservoir is associated with said first or second electrode; and (e) delivering a therapeutically effective amount of said peripherally selective kappa opioid receptor agonist through said body surface.
- the peripherally selective kappa opioid receptor agonist can administered by any of these methods between about 1 microgram/kg of body weight to about 100 milligrams/kg of body weight of said mammal per hour, day, week or month. These methods of the invention delivering the peripherally selective kappa opioid receptor agonist administered can increase prolactin to levels greater than 10, 15, 20, 25, 50, 75, 100, 125, 150, 175, or 200 ng/ml serum above the baseline level of serum prolactin.
- Suitable primates include an ape, gorilla, monkey, macaque, chimpanzee, lemur or orangutan.
- Suitable ungulates include a cow, pig, sheep, goat or horse.
- the invention further provides a method of treating a mammal exhibiting an insufficient or inadequate amount of milk production or at risk of exhibiting an insufficient or inadequate amount of milk production, wherein the method includes administering to the subject prior to or after childbirth an amount of a peripherally selective kappa opioid receptor agonist in conjunction with a lactation enhancer, such as for instance, oxitocin or a stabilizer effective to treat the mammal.
- a lactation enhancer such as for instance, oxitocin or a stabilizer effective to treat the mammal.
- the oxytocin can be administered within one or more hours, days, or weeks following childbirth.
- the lactation enhancer or stabilizer is administered within one or more hours, days, or weeks following childbirth.
- CR665 D-phenylalanyl-D-phenylalanyl-D-norleucyl-N-(4-pyridinylmethyl)-D-argininamide, acetate salt, herein designated as CR665, was assessed in healthy male and surgically sterile female human subjects following 1-hour or 5-minute infusions.
- CR665 also referenced in the literature as FE 200665, is a peripherally selective kappa opioid receptor agonist; see U.S. Pat. No. 5,965,701; also Riviere P. J.-M. et al.
- Novel D-amino acid tetrapeptides demonstrate unprecedented k-opioid receptor selectivity and antinociception.
- This clinical study was conducted as a double blind, placebo controlled, ascending single intravenous (IV) dose, sequential group study.
- the results reported herein were obtained with 54 male and female human subjects in fifteen groups as shown in Table X below.
- This study was double blind and placebo controlled in order to avoid bias in the collection and evaluation of data during its conduct. Placebo was chosen as the control treatment to assess whether any observed effects were treatment related or simply reflected the study conditions.
- subjects received CR665 or placebo.
- Doses were administered as a single constant rate IV infusion over 1 hour (part A) or 5 minutes (part B) on the morning of Day 1.
- Doses were administered in an escalating manner following satisfactory review of the safety data and pharmacokinetic data from the lower dose levels. There was a minimum of 6 days between dose escalations to allow sufficient time for an adequate safety review.
- Treatments infusion Part Group Population Treatment duration A A1 Males 0.015 mg/kg/placebo 1 hour A2 Males 0.03 mg/kg/placebo 1 hour A3 Males 0.06 mg/kg/placebo 1 hour A4 Males 0.12 mg/kg/placebo 1 hour A5 Males 0.24 mg/kg/placebo 1 hour A6 Males 0.48 mg/kg/placebo 1 hour A7 Males 0.36 mg/kg/placebo 1 hour A8 Males 0.48 mg/kg/placebo 1 hour A9 Females 0.24 mg/kg/placebo 1 hour A10 Females 0.42 mg/kg/placebo 1 hour A12 Males 0.42 mg/kg/placebo 1 hour B B1 Males 0.03 mg/kg/placebo 5 minutes B2 Females 0.06 mg/kg/placebo 5 minutes B3 Males 0.06 mg/kg/placebo 5 minutes B4 Males 0.09 mg/kg/placebo 5 minutes
- CR665 was prepared according to Good Manufacturing Practice (GMP) standards and provided as bulk supply in 2 mL glass vials, each containing CR665 solution (1.1 mL at a concentration of 10 mg/mL [free base] in isotonic 0.04 M acetate buffer, pH 4.5). Placebo solution (isotonic 0.04°M acetate buffer, pH 4.5) for IV administration, of identical appearance, i.e., a clear, colorless, solution, was also prepared. The TV dose solutions were stored at 2° C. to 8° C.
- GMP Good Manufacturing Practice
- the individual intravenous dose for each subject was prepared from bulk supplies (2 mL vials containing 1.1 mL of CR665 or placebo solution).
- an appropriate volume of CR665 solution (10 mg/mL) or placebo solution was withdrawn from one or more vials using a syringe, and injected into a 60 mL Plastipak polypropylene syringe (Beckton Dickinson S.A., Spain) containing an appropriate volume of sterile NaCl buffer.
- the final volume prepared was 40 mL, of which 30 mL was infused.
- the dose calculation was as follows:
- Table 2 provides some example dilutions, based on a 70 kg body weight.
- the dose was administered via a cannula inserted into a suitable vein of the forearm in the non dominant arm of the subject.
- the dose was infused over a 1 hour period in the morning between 07:00 and 10:30, using an IMED Gemini PC I infusion pump operating at a constant rate of 0.5 ml/min (30 mL/h).
- a total of 30 mL of dosing solution (from 40 mL in the syringe) was administered, and the subjects remained supine throughout the infusion.
- Subjects were also encouraged to spontaneously report adverse events occurring at any other time during the study. Any adverse events and remedial action required were to be recorded for each subject. The nature, time of onset, duration and severity were documented, together with the Project Physician's opinion of the relationship to drug administration.
- the condition of the dosing cannula site for each subject was monitored for erythema, pruritus and swelling at the following times: Pre dose, 0.5, 1, 2 and 24 hours after the start of the infusion. Subjects were also encouraged to spontaneously report adverse events relating to the infusion site at any other time during the study. Any adverse events and observations relating to the infusion site and remedial action required were to be recorded for each subject. The nature, time of onset, duration, and severity were to be documented, together with the Project Physician's opinion of the relationship to drug administration.
- Supine and standing blood pressure, supine pulse rate and oral body temperature were measured in duplicate at the following times: Day 1; Pre dose, 15 minutes (Part B only), 30 minutes, 55 minutes, 1.5, 2, 2.5, 3, 4, 8, 12, 24 and 48 hours after the start of the infusion (up to 24 hours only for Groups A1 to A4); and at Follow up visit. Supine vital signs only were measured during the infusion period. Pre dose blood pressure and pulse rate were measured in triplicate at approximately 2 minute intervals. The median value was used as the baseline value in the data analysis. All subsequent measurements were performed singly, but repeated in duplicate if outside the relevant clinical reference ranges. If repeated, the median of the three values were used in the data analysis.
- Blood pressure and pulse rate were measured using automated Critikon DinamapTM PRO400 monitors. Subjects were required to be supine for at least 5 minutes before blood pressure and pulse rate measurements. Standing blood pressure and pulse rate were then measured singly after the subject had been sitting for approximately 1 minute and then standing for approximately 2 minutes. Oral body temperature was measured singly using an Omron digital thermometer. To assess drug effects on cardiovascular function, a 12 lead resting ECG with a 10 second rhythm strip was recorded on a Marquette MAC5000 ECG machine at the following times, after the subject has been supine for at least 5 minutes: Day 1; Pre dose, 50 minutes, 2, 4, 8, 24 and 48 hours after the start of the infusion (up to 24 hours only for Groups A1 to A4); and at the follow up visit.
- the ECG machine computed the PR, QT and QTc intervals, QRS duration, and heart rate.
- the QT interval was corrected for heart rate (QTc) using Bazett's formula.
- continuous cardiac Holter monitoring of each subject using Reynolds Tracker II Bolter monitors, was performed from 1 hour prior to until 4 hours after the start of the infusion. Blood and urine samples were collected, after at least a 6 hour fast, for clinical laboratory evaluations at the following times during the study: Pre dose and 24 hours after the start of the infusion; and at the follow up visit.
- Plasma samples (2.5 mL) were collected for evaluation of serum prolactin at the following times: Pre dose (in triplicate, with at least a 15 minute interval between each of the triplicate pre dose samples), 15 minutes, 30 minutes, 45 minutes, 1 hour (immediately prior to the end of infusion), 1 hour 5 minutes, 1 hour 10 minutes, 1 hour 15 minutes, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 hours after the start of the infusion (18 samples).
- Plasma and urine samples for the analysis of CR665 and N oxide metabolite were prepared by solid phase extraction.
- the centrifuged eluates were quantified by liquid chromatography with tandem mass spectrometric detection (LC MS/MS).
- the lower limit of quantification was 1 ng/mL.
- urine was pooled over the following time intervals: 24 to 0 hours and 0 to 24 hours after the start of the infusion. A 10 mL aliquot was removed from the each pooled collection for determination of urinary creatinine.
- blood samples (1 ⁇ 3 mL) were taken from the contralateral forearm vein(s) at the following times: Pre-dose, 15 minutes, 30 minutes, 45 minutes, 1 hour (immediately prior to the end of infusion), 1 hour 5 minutes, 1 hour 10 minutes, 1 hour 15 minutes, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours after the start of the infusion).
- An indwelling cannula (Venflon®; BOC Ohmeda AB, Sweden) was used for all blood collection pre-dose and up to at least 12 hours after the start of the infusion. Otherwise, samples were collected using venipuncture.
- Plasma samples were collected into pre-chilled 3 mL K 3 EDTA VacutainerTM tubes (Becton Dickinson UK, Ltd., Oxford) and, after mixing, were placed in a cool box containing crushed ice/water. The samples were centrifuged, within 30 minutes of collection, at 1500 g for 10 minutes at approximately 4° C. For each sample, the separated plasma was transferred into two 5 mL suitably labeled polypropylene, tubes, and stored immediately at approximately ⁇ 20° C. Plasma samples were analyzed for CR665 using liquid chromatography with tandem mass spectrometric detection.
- Urine was collected into standard weight polyethylene containers over the following time intervals: Pre dose ( ⁇ 24 to 0), 0 to 4, 4 to 8, 8 to 12, 12 to 24 and 24 to 48 hours after the start of the infusion. During each collection period, the containers were stored in a refrigerator at 2 to 8° C. The weight (g) of each collection was recorded prior to removal of two sub samples (each approximately 4 mL) into suitably labeled polypropylene containers, which were stored within 2 hours of collection, at approximately ⁇ 20° C. Additional aliquots (1 ⁇ 100 mL per collection period) were stored for possible future analyses. Any remaining urine from post close collection intervals was pooled with the rest of the urine collected during the 0 to 24 hour collection period, for analysis of creatinine clearance. A nominal value for specific gravity of 1.018 was used to calculate urine volume.
- Pharmacokinetic parameters were determined from the plasma and urine concentrations of CR665 and the N-oxide metabolite using non compartmental procedures. The pharmacokinetic parameters determined are presented in Table 4 below.
- Dose and body weight normalized values were determined for AUC 0-t , AUC 0- ⁇ , C inf and C max .
- Body weight normalized values [norm] were determined for V a , V ss , CL and CL R .
- the pharmacokinetic analysis was conducted using model independent methods as implemented in WinNonlin software, based on plasma concentrations of CR665 from those subjects who have received CR665 and have evaluable plasma concentration-time profiles.
- Vz/F Dose/ ⁇ z *AUC iff
- Mean values for AUC 0-12 h increased up to 0.36 mg/kg, and thereafter were generally similar over the 0.36 to 0.48 mg/kg dose range. Following maximum concentrations of prolactin, there was a dose-related decrease to baseline levels. Mean values had fallen to close to baseline values by 8 hours at the 0.36, 0.42 and 0.48 mg/kg dose levels.
- Part A Pharmacokinetics of CR665 After a One Hour Intravenous Infusion
- FIGS. 4 and 5 The plasma concentrations of CR665 following a 1 hour infusion in male subjects are shown in FIGS. 4 and 5 .
- Plasma concentrations of CR665 were generally similar at 45 minutes and 1 hour after the start of the infusion for individual subjects at each dose level.
- the mean apparent elimination half life was relatively constant in the 0.015 to 0.06: mg/kg dose range, at about 0.7 hours, but became longer across the 0.12 to 0.48 mg/kg dose range, varying from 1.4 to 1.9 hours, with a trend toward longer half life values at higher doses.
- the apparent elimination half life ranged from 1.2 to 3.0 hours. This apparent increase in half life at higher dose levels is consistent with plasma concentrations of CR665 being quantifiable for a longer period of time at the higher dose levels, revealing more of true terminal elimination phase. As a result, statistical analysis showed that the elimination half life for CR665 was dose dependent over the entire dose range.
- FIG. 6 illustrates the dose-proportional increase in AUC 0- ⁇ for CR665 over the dose range of 0.015 to 0.48 mg/kg.
- the dose proportionality of the increase in AUC was found to be almost perfectly linear, as shown in FIG. 6 , with an R 2 value of 0.98, meaning that, for this data set, 98% of the variation in systemic exposure to CR665 is due to variation in the administered dose of CR665.
- R 2 value 0.98
- FIGS. 7 and 8 Geometric mean plasma concentrations of CR665 following a 1-hour infusion of 0.24 mg CR665 in female subjects are summarized in FIGS. 7 and 8 .
- Arithmetic mean plasma concentrations of CR665 following a 1-hour infusion of 0.24 mg/kg CR665 in male and female subjects are summarized in FIG. 9 .
- the fraction of the dose excreted in the urine as unchanged drug was low in female subjects, and similar to that seen for male subjects.
- Part B Extrapolation of Part A PK Data to Design Brief IV Infusions of CR665
- Plasma concentrations of CR665 following a 5-minute infusion in male and female subjects are shown in FIGS. 10 and 11 .
- FIG. 12 illustrates the dose-proportional increase in AUC 0- ⁇ for CR665 over the dose range of 0.03 to 0.09 mg/kg in male subjects.
- mean values for AUC 0- ⁇ , AUC 0- ⁇ (norm), C max and C max (norm) were generally similar in male and female subjects following a 5-minute infusion.
- Mean values for MRT int , CL, V z and V ss were similar across the 0.03 to 0.09 mg/kg dose range in male subjects, which was confirmed by statistical analysis. Mean values for each parameter were also similar for male and female subjects at the 0.06 mg/kg dose level.
- the fraction of the dose excreted in the urine as unchanged drug was low for all dose levels, with approximately 3.5% being eliminated up to 24 hours post-dose.
- the fraction of unchanged drug excreted in the urine was also low in female subjects (3.8%), and similar to male subjects.
- Geometric least Ratio of squares means geometric least 5-minute 1-hour squares means 90% CI for the 95% CI for the Parameter infusion infusion 5-minute:1-hour ratio ratio
- Geometric least Ratio of squares means geometric least 5-minute 1-hour squares means 90% CI for the 95% CI for the Parameter infusion infusion 5-minute:1-hour ratio ratio
- AUC 0-t 2013 1936 1.04 0.918 to 1.18 0.893 to 1.21 (norm)
- AUC 0- ⁇ 2044 1943 1.05 0.928 to 1.19 0.903 to 1.23 (norm)
- C max 8716 1655 5.27 4.17 to 6.66 3.96 to 7.01 (norm) t 1/2 0.946 1.05 0.901 0.606 to 1.34 0.554 to 1.47 (h)
- CL 544 573 0.950 0.837 to 1.08 0.813 to 1.11 (mL/min)
- Part A there was a direct linear correlation between serum concentrations of prolactin (based on AUC 0-12h and C max ) and the plasma concentration of CR665 (based on AUC 0- ⁇ and C max ) over the 0.015 to 0.36 mg/kg dose range following a 1-hour infusion in male subjects, with correlation coefficients of 0.667 and 0.565 for AUC and C max values, respectively.
- the AUC 0-12 h and C max values for serum prolactin appeared to plateau at higher AUC 0- ⁇ and C max values for CR665 associated with dose levels of 0.36 to 0.48 mg/kg, indicating that the maximum increase in serum prolactin had been achieved by 0.36 mg/kg CR665 administered as a 1-hour infusion.
- the plasma concentration of CR665 may better reflect the concentration of CR665 in the pharmacodynamically relevant compartment (i.e., high affinity kappa opioid receptors), and thereby yield the significant linear relationship shown in FIGS. 13 and 14 .
- AUC 0- ⁇ and C max increased in a dose-proportional manner over the entire dose range.
- the between-subject variability in the pharmacokinetics of CR665 was low in male subjects.
- CR665 In female subjects, maximum plasma concentrations of CR665 occurred at the end of the 1-hour infusion period following a 0.24 mg/kg dose, which was similar to male subjects.
- the disposition of CR665 was also similar between genders, with a mean terminal elimination half-life of 1.2 hours in female subjects. Furthermore, similar between-subject variability was observed in male and female subjects.
- the duration of infusion had no effect on the overall systemic exposure to CR665, with AUC 0- ⁇ being similar following the 1-hour and 5-minute infusions in both male and female subjects.
- maximum plasma concentrations of CR665 were notably higher following the 5-minute infusion compared to the 1-hour infusion, being approximately 4.5-fold higher in male subjects and 5.3-fold higher in female subjects.
- the difference in C max was expected because of the higher rate of infusion used for the 5-minute infusion (360 mL/hour) compared to the 1-hour infusion (30 mL/hour).
- the disposition kinetics of CR665 was similar for the 1-hour and 5-minute infusion, and low between-subject variability was observed for both infusion times.
- the apparent volume of distribution at steady state (V ss ) of CR665 in male subjects ranged from 19 to 23 L over the 0.12 to 0.48 mg/kg dose range, which is similar to the volume of extracellular fluid, and is consistent for a peptide with limited ability to penetrate lipid-containing membranes.
- V ss steady state
- the volume of distribution is a quantitative measure of the extent of distribution of drug outside the vasculature; it is the apparent volume which would contain the entire amount of drug in the body at the same concentration it is present in the blood.
- a compound with a low volume of distribution will have physical characteristics that impede transport across biological membranes.
- a polar compound with a low apparent volume of distribution such as CR665
Abstract
Methods for elevating and stabilizing prolactin levels in a mammal including methods of treating disorders and conditions associated with reduced serum levels of prolactin are provided. Also provided are methods of using certain synthetic tetrapeptide amides which are peripherally selective kappa opioid receptor agonists to elevate or stabilize serum prolactin levels.
Description
- This application claims priority to and incorporates by reference herein U.S. Provisional Application Ser. No. 60/808,677 filed May 26, 2006 and entitled “METHOD FOR ELEVATING PROLACTIN IN MAMMALS.”
- 1. Field of the Invention
- The invention relates to the use of peripherally selective kappa opioid receptor agonists to elevate serum levels of prolactin for the benefit of a mammal in need of such elevation.
- 2. Background
- Prolactin is a 198 amino acid polypeptide synthesized in pituitary lactotrophs, which constitute about 20 percent of adenohypophysial cells (for review, see Harrison's Principles of Internal Medicine, 16th Ed., p. 2084; also Freeman M E et al. Prolactin: Structure, function, and regulation of secretion. Physiol. Rev. 80: 1523 1631, 2000). Prolactin is also referred to in the art as Galactin, Lactogen, Lactoropin, LMTH, LTH, Luteomammotrophic Hormone, Luteotrophic Hormone, Luteotropin, and Mammotrophin, although these names are now obsolete. The best studied effects of prolactin are on the mammary gland, and include growth and development of the mammary gland (mammogenesis), synthesis of milk (lactogenesis), and maintenance of milk secretion (galactopoiesis). The endocrine control of lactation involves multiple complex physiological mechanisms since mammogenesis, lactogenesis, galactopoiesis, and galactokinesis are all essential for proper lactation. Prolactin is the key hormone of lactation and is believed to be the single most important galactopoietic hormone. Oxytocin, serotonin, opioid peptides, histamine, substance P, and other physiological substances modulate prolactin release by means of an autocrine/paracrine mechanism at the level of the hypothalamus, whereas estrogen and progesterone hormones can act at the hypothalamic and adenohypophysial levels. Human placental lactogen and growth factors play an essential role in successful lactation during pregnancy, with oxytocin functioning as a key galactokinetic hormone.
- Normal adult serum prolactin levels are about 10 25 ng/ml in women and 10 20 ng/ml in men. Prolactin is secreted in an episodic manner with a distinct 24 hour pattern. Circulating prolactin levels are lowest at midday, and a modest increase occurs during the afternoon. Prolactin levels increase shortly after onset of sleep, peaking in the early morning. Serum prolactin levels rise substantially during pregnancy (150 200 ng/ml) and decline rapidly within two weeks of parturition. Breastfeeding will normally cause prolactin levels to remain elevated, due to suckling induced activation of neural reflexes that that induce prolactin release. However, inadequate activation of prolactin release will interfere with breastfeeding, with a variety of potentially deleterious psychological and physiological consequences, e.g., a failure of mother infant bonding and a failure to transmit maternal protective antibodies to the infant (American Academy of Pediatrics, Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 115: 496 506, 2005). According to the American Academy of Pediatrics, in this most current version of their guidance on breastfeeding, “Extensive research using improved epidemiologic methods and modern laboratory techniques documents diverse and compelling advantages for infants, mothers, families, and society from breastfeeding and use of human milk for infant feeding. These advantages include health, nutritional, immunologic, developmental, psychologic, social, economic, and environmental benefits.” Because of the well documented benefits of breastfeeding, insufficient lactation is now viewed as an important medical problem.
- There are numerous risk factors for insufficient lactation, including:
- (i) restarting lactation after termination, e.g., to care for a sick infant (Thompson N Relactation in a newborn intensive care setting. J. Hum. Lact. 12: 233-235, 1996)
- (ii) physical abnormality of the breast (Neifert M R et al. Lactation failure due to insufficient glandular development of the breast. Pediatrics 76:823-828, 1985)
- (iii) absence of breast enlargement during pregnancy (Moon J et al. Breast engorgement: contributing variables and variables amenable to nursing intervention. J. Obstet. Gynecol. Neonatal Nurs. 18: 309-315, 1989).
- (iv) history of breast surgery (Widdice L The effects of breast reduction and breast augmentation surgery on lactation: An annotated bibliography. J. Hum. Lact. 9:161-163, 1993).
- (v) first time delivery of infant (Dewey K G et al. Risk factors for suboptimal infant breastfeeding behavior, delayed onset of lactation, and excess neonatal weight loss. Pediatrics 112:607-619, 2003).
- (vi) premature delivery of infant (Ehrenkranz R A et al. Metoclopramide effect on faltering milk production by mothers of premature infants. Pediatrics; 78:614 20, 1986; Feher S D K et al. Increasing breast milk production for premature infants with a relaxation/imagery audiotape. Pediatrics 83:57-60, 1989)
- (vii) delivery of more than one infant (Leonard, L. Breastfeeding higher order multiples: Enhancing support during the postpartum hospitalization period. J. Hum. Lact. 18:386-392, 2002).
- (viii) adoption of infant (Cheales Siebenaler, N. Induced lactation in an adoptive mother. J. Hum. Lact. 15:41-43, 1999).
- (ix) retention of placental fragments (Neifert, M R et al. Failure of lactogenesis associated with placental retention. Am. J. Obstet. Gynecol. 140:477-478, 1981)
- (x) use of hormonal birth control (Tankeyoon M et al. Effects of hormonal contraceptives on milk volume and infant growth. WHO Special Programme of Research, Development and Research Training in Human Reproduction Task force on oral contraceptives. Contraception 30:505-22, 1984)
- (xi) use of certain OTC decongestants (Aljazaf K et al. Pseudoephedrine: effects on milk production in women and estimation of infant exposure via breastmilk. Br. J. Clin. Pharmacol. 56:18-24, 2003)
- (xii) cigarette smoking (Andersen A N et al: Suppressed prolactin but normal neurophysin levels in cigarette smoking breast feeding women. Clin. Endocrinol. (Oxf.) 17:363-8, 1982.
- (xiii) prepregnant overweight and obesity (Hilson J A et al. High prepregnant body mass index is associated with poor lactation outcomes among white, rural women independent of psychosocial and demographic correlates. J. Hum. Lact. 20:18-29, 2004; Rasmussen K M et al. Prepregnant overweight and obesity diminish the prolactin response to suckling in the first week postpartum. Pediatrics 113:465-71, 2004).
- (xiv) Cesarean delivery (Chapman D J et al. Identification of risk factors for delayed onset of lactation. J. Am. Diet. Assoc. 99:450-454, 1999)
- (xv) insulin dependent maternal diabetes (Neubauer, S H et al. Delayed lactogenesis in women with insulin dependent diabetes mellitus. Am. J. Nutr. 58:54-60, 1993)
- (xvi) medications to treat labor pain (Riordan J et al. The effect of labor pain relief medication on neonatal suckling and breastfeeding duration. J. Hum. Lact. 16:7-12, 2000; Ransjo Arvidson A B et al. Maternal analgesia during labor disturbs newborn behavior: effects on breastfeeding, temperature, and crying. Birth 28:5-12; 2001).
- (xvii) stress (Chen D C et al. Stress during labor and delivery and early lactation performance. Am. J. Clin. Nutr. 68:335-344, 1998; Dewey K. Maternal and fetal stress are associated with impaired lactogenesis in humans. J. Nutr. 131:3012 S-3015S, 2001)
- Signs of insufficient lactation in a human infant include: (1) insufficient weight gain in an infant who is receiving food only by breast feeding, even if the infant appears content; (2) infant latching on poorly; (3) infant sucking inconsistently; (4) inconsistency of let down reflex, and (5) evidence of hunger, indicated by crying soon after feedings.
- Lactation failure in humans is a common clinical event with serious emotional sequelae. It has been considered to be a significant problem in 5 to 10% of all lactations. In many instances this leads to premature initiation of supplements or total weaning. This is considered to be an inferior child rearing practice and may be harmful to certain infants with an increased risk of gastritis and other disorders. Many affected women are severely emotionally distressed by their perceived inadequacy, thus affecting the parent child bond. Failure to thrive in infants is not uncommon if the mother refuses to supplement.
- There has therefore been a long need for a medicament that can promote human lactation, e.g., when there is insufficient lactation after the birth of the child. For animal breeders, the inability of their livestock, e.g., mares, to produce and secrete milk after giving birth can be a significant problem. Should the breeding animals not lactate properly, the offspring must then be bottle fed, which is time consuming, labor intensive, and costly; thus, there is a need for a medicament to safely and effectively promote breeding animal lactation. For commercial milk producing animals like cows and goats, there is an economic need to safely and effectively increase their milk production above a normal level.
- A number of causes of reductions in prolactin levels that are associated with insufficient lactation were noted above. Certain of these causes are also associated with reduced prolactin levels in non lacting subjects, e.g., cigarette smoking (Fuxe K et al. Neuroendocrine actions of nicotine and of exposure to cigarette smoke: medical implications. Psychoneuroendocrinology 14: 1.9-41, 1989). Other causes of low prolactin levels (hypoprolactinemia) include the use of various therapeutic agents, such as L deprenyl for the treatment of migraine (Fanciullacci M et al. Dopamine involvement in the migraine attack. Funct Neurol. 15 Suppl 3:171-81, 2000). Hypoprolactinemia of unknown origin has also been associated with poor sperm motility in adult men (Gonzales G F et al. Hypoprolactinemia as related to seminal quality and serum testosterone. Arch. Androl. 23:259-65, 1989), a finding that is supported by the observation that pharmacological suppression of prolactin release for several weeks in young men decreased subsequent hCG stimulated testosterone secretion (Oseko F et al. Effects of chronic bromocriptine induced hypoprolactinemia on plasma testosterone responses to human chorionic gonadotropin stimulation in normal men. Fertil. Steril. 55:355-357, 1991). Hypoprolactinemia could also contribute to age related changes in physiological functions. Serum prolactin concentrations tend to fall with age, e.g. in older men and estrogen unreplaced postmenopausal women (Maddox P et al. Bioactive and immunoactive prolactin levels after TRH stimulation in the sera of normal women. Horm. Metab. Res. 24:181-184, 1992; Maddox P et al. Basal prolactin and total lactogenic hormone levels by microbioassay and immunoassay in normal human sera. Acta Endocrinol. (Copenh.) 125:621-627, 1991). Remarkably, a comparable quantitative reduction in prolactin secretion occurs in critically ill individuals (Van den Berghe G et al. Thyrotropin and prolactin release in prolonged critical illness—dynamics of spontaneous secretion and effects of growth hormone secretagogues. Clin. Endocrinol. (Oxf.) 47:599-612, 1998) as well as in patients with poorly controlled type I diabetes mellitus (Iranmanesh A et al. Attenuated pulsatile release of prolactin in men with insulin dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 71:73-78, 1990). Hypoprolactinemia is also reported to be a risk factor for prolonged lymphopenia and apoptosis associated depletion of lymphoid organs in nosocomial sepsis related death in critically ill children (Felmet K A et al. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J. Immunol. 174:3765-72, 2005). The findings reviewed above indicate that prolactin deficiency may contribute to impaired testosterone dependent functioning and age related changes as well as vulnerability to illness.
- In addition to the apparent roles of prolactin discussed above, there is evidence that prolactin is important for maintenance of rapid eye movement sleep (REM sleep), which is essential for normal brain function. After observing that pregnancy associated sleep enhancement is correlated with the daily surges of prolactin, investigators found that administration of prolactin to female rats significantly increased REM sleep (Zhang S Q et al. Effects of prolactin on sleep in cyclic rats. Psychiatry Clin. Neurosci. 53:101-3, 1999). Consistent with these findings, induction of experimental hypoprolactinemia in male rats was found to decrease REM sleep (Obál Jr F et al. Antiserum to prolactin decreases rapid eye movement sleep (REM sleep) in the male rat. Physiol. Behav. 52:1063-1068, 1992). These findings indicate that subjects experiencing insufficient REM sleep could benefit from elevations in prolactin.
- Based on the findings reviewed above, there is a need for a medicament that can safely and effectively elevate prolactin level in a variety of subjects with functional hypoprolactinemia, particularly including females experiencing insufficient lactation, but also males experiencing insufficient testosterone related functions, and both females and males who are suffering from the effects of severe illness, including type I diabetes, or who are suffering the effects of insufficient REM sleep, e.g., due to insomnia.
- The citation of any reference herein should not be construed as an admission that such reference is available as “Prior Art” to the instant application.
- In general, the invention provides methods for treating a subject suffering from insufficient or inadequate serum prolactin, such as functional hypoprolactinemia and the disorders disclosed herein and known in the art associated with insufficient or inadequate serum prolactin, as well as methods for treating a subject in need of elevated or stabilized levels of prolactin. In one embodiment, a method employs a peripherally selective kappa opioid receptor agonist compound, optionally in a pharmaceutically acceptable vehicle for local, regional or systemic administration, said compound possessing prolactin elevating, increasing or stabilizing activity, optionally administered without causing a severe or a clinically significant side effect, such as CNS effects or diuretic effects.
- In another embodiment, the invention features a method of treating functional hypoprolactinemia in a subject with a formulation of a peripherally selective kappa opioid receptor agonist, optionally suitable for incorporation into a controlled drug delivery device. In a particular aspect, a controlled drug delivery device is applied to the skin of a subject. In certain embodiments, a controlled drug delivery device is applied to the skin of a subject and optionally further utilizes iontophoresis to increase transdermal drug delivery.
- In certain embodiments, a formulation is a solid or liquid or gel.
- In certain embodiments, a formulation includes a liquid carrier.
- In certain embodiments, a therapeutically effective dose of a peripherally selective kappa opioid receptor agonist is selected to produce elevated, increased or stabilized serum prolactin levels without producing severe or significant diuresis and/or a CNS side effect.
- In certain embodiments, a peripherally selective kappa opioid receptor agonist produces pharmacologically insignificant or physiologically tolerable levels of said agonist in the plasma of an infant consuming the breast milk from or produced by a subject treated with said agonist.
- In certain embodiments, the peripherally selective kappa opioid receptor agonist is selected to avoid producing a severe or a clinically significant side effect in an infant consuming the breast milk from or produced by a subject treated with said agonist.
- In certain aspects, the invention features methods of elevating, increasing or stabilizing plasma levels of prolactin to a subject in need of elevated, increased or stabilized prolactin. In one embodiment, a method includes administration of a therapeutically effective dose of a peripherally selective kappa opioid receptor agonist to the subject. In another embodiment, a method includes administration of a therapeutically effective dose of a peripherally selective kappa opioid receptor agonist to the subject, in combination with a prolactin elevating-increasing or stabilizing dose of a second compound selected from a D2 dopamine receptor antagonist, mu opioid receptor agonist, or prolactin.
- In various embodiments a subject is: a person, e.g., a human patient, in need of elevated prolactin levels. E.g., the subject can be: a person in need of stimulation of lactation or stabilization of lactation, e.g., a mother.
- The invention features methods for treatment and/or prevention of lactational failure, which can be diagnosed by various criteria, including:
- a) baby is dissatisfied and irritable after breast feeding;
- b) poor infant weight gain in relation to age/length;
- c) lack of breast engorgement/leaking if feeding is missed;
- d) baby is satisfied by supplemental feeding following breast feeding;
- e) milk secretion of less than 500 ml/day.
- These methods involve systemic administration of compositions that contain one or more compounds that exert prolactin elevating, increasing or stabilizing activity via kappa opiate receptors, but that do not exhibit a severe or significant side effect, such as a CNS or diuretic effect at effective dosages.
- In various embodiments, methods use compositions containing peripherally selective kappa opioid receptor agonists that do not, upon systemic administration, evoke severe or clinically significant diuresis or CNS effects, as defined herein, particularly at the prolactin elevating dosage. Compositions that contain a peripherally selective kappa opioid receptor agonist together with other prolactin elevating compounds are also provided.
- Typically, compounds intended for use in the compositions and methods herein possess prolactin elevating, increasing or stabilizing activity and reduced or tolerable CNS effects, as defined herein, because, without being bound by any theory, they do not substantially cross the blood brain barrier. A relative or complete absence of substantial crossing of the blood brain barrier lessens the occurrence of CNS systemic effects. Kappa opioid receptors agonists that readily cross the blood brain barrier could be effective as prolactin elevating agents, but permeability through the blood brain barrier can result in severe or intolerable side effects, such as dysphoria and hallucinations.
- Peripherally selective kappa opioid receptor agonists include kappa opioid receptor agonists that do not substantially cross the blood brain barrier as assessed by assays described herein or known in the art. The peripherally selective kappa opioid receptor agonists for use in the methods and compositions provided herein also include any compound that by virtue of its interaction, either directly or indirectly, with peripheral kappa opioid receptor receptors ameliorates failure of lactation, or elevates, increases or stabilizes levels of serum prolactin, without exhibiting medically severe or significant CNS effects, such as dysphoria and hallucinations, at effective doses.
- As used herein, the term “peripherally selective,” when used in reference to a “kappa opioid receptor agonist” refers to a chemical compound having a reduced ability to cross (traverse) the blood-brain barrier, or that exhibits little or substantially no crossing of the blood-brain barrier when not administered to the CNS (brain and spinal cord). As a consequence of a reduced ability or inability to cross (traverse) the blood-brain barrier, a peripherally selective kappa opioid receptor agonist typically exhibits fewer or less severe (minor or tolerable) side effects in the CNS, such as dysphoria, hallucinations, or sedation.
- Various measures of the ability of a compound to cross (traverse) the blood-brain barrier are known in the art and can be used to measure the amount or rate (kinetics) of blood-brain barrier crossing (traversal). One non-limiting example is to compare the ability of a compound to elicit peripheral effects versus the ability of the compound to elicit central effects following treatment with a particular compound (e.g., kappa opioid receptor agonist). Peripheral effects can be measured using the mouse writhing test (WT) and central effects, due to action of kappa opioid receptors located in the brain and spinal cord, can be measured using the mouse tail-flick test (TF).
- In brief, the mouse writhing test (WT) test (described in Bentley et al., Br. J. Phamac., 73:325 (1981)) employs conscious male ICR mice (available from Harlan) weighing about 20 to 30 grams. Mice are fasted for about 12 to 16 hours prior to the test and writhing is induced by intraperitoneal administration of dilute acetic acid (10 ml of 0.6% aqueous acetic acid/kg body weight). Writhing is scored during the 15 minutes following acetic acid administration. Compounds (e.g., kappa opioid receptor agonists) are typically tested at 3 to 4 increasing doses, given by intravenous route, and at a unique pretreatment time (e.g., −5 minutes before acetic acid injection). This step is used to determine the potency (WT-ED50) as well as a submaximal effective dose (about 80-90% antinociception). In a second step, a submaximal effective dose for each specific compound is administered at various pretreatment times (e.g., −5 minutes, −60 minutes, −120 minutes and −180 minutes) prior to the administration of the acetic acid in order to determine the duration of action. Throughout the test, a control group of mice are used which are administered only the vehicle without the compound. The number of writhes are counted over a15-minute period, starting from the time of acetic acid injection, and bioactivity, i.e. antinociception, is expressed as a percentage, and is calculated as follows:
-
100×(writhes in control group-writhes in treated group)/writhes in control group - Because each submaximal dose likely varies so as not to be directly comparable, results are normalized mathematically, to provide comparable values. Values higher than 100% indicate greater antinociception than at the beginning of the study. Compounds effective at reducing writhing by at least about 25% at a time of 1 hour are considered to have long duration of in vivo action.
- In addition to using the writhing test to determine duration of antinociceptive activity, it is also used to measure the in vivo biopotency (short term) of the peptide. This value is represented as WT-ED50 in milligrams per kg of body weight, a measure of the dosage necessary to reduce the number of writhes in the mouse being tested by 50% (as compared to a control mouse) over a period of 15 minutes.
- The tail-flick test (TF) is an assay of acute somatic pain, designed to evaluate potency and duration of action of centrally acting analgesics (described, for example, in Vanderah, et al., J. Pharm. Exper. Therapeutics, 262:190 (1992)). Nociception induced by tail-dip into hot water (52° C.) results in a rapid tail withdrawal, or a “tail-flick.” Centrally acting compounds are expected to increase, in a dose-related manner, the latency for tail withdrawal.
- “Brain Penetration Index” (BPI) can be used to provide a numerical representation of whether a compound functions centrally or peripherally. BPI is defined as: BPI=TF−ED50/WT−ED50; where the ED50 values are the doses that produce half maximal effect in the mouse writhing test (WT−ED50) and the mouse tail-flick test (TF−ED50), respectively, when administered intravenously. A high BPI value reflects low brain penetration and, therefore, a compound that is less likely to substantially cross the blood-brain barrier or produce severe CNS side effects. BPI values lower than 5 indicate significant or substantial brain penetration, and, therefore, a compound that is likely to substantially cross the blood-brain barrier, which can result in severe side effects (e.g., dysphoria, hallucinations and sedation) when used clinically. Accordingly, compounds useful in the invention have BPI values typically greater than 5, or more, for example, BPI values of 10, 15, 20, 25, 30, 40, 45, 50, 60, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, or more.
- Particular non-limiting compounds of the invention are disclosed in U.S. Pat. No. 5,965,701, are sequences of four D-isomer amino acid residues having a C-terminus which is a mono or di-substituted amide. Representative compounds, which have an affinity for the kappa opioid receptor at least 1,000 times their affinity for the mu opioid receptor and an ED50 of not greater than about 0.5 mg/kg, include H-D-Phe-D-Phe-D-Nle-D-Arg-NHEt, H-D-Phe-D-Phe-D-Nle-D-Arg-morpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NH-4-picolyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NHPr, H-D-Phe-D-Phe-D-Nle-D-Arg-thiomorpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NEt2, H-D-Phe-D-Phe-D-Nle-D-Arg-NHMe, H-D-Phe-D-Phe-D-Leu-D-Orn-morpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NHhEt, H-D-Phe-D-Phe-D-Nle-D-Arg-NH-cyclopropyl, H-D-Ala(2Thi)-D-4 Cpa-D-Leu-D-Arg-morpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-piperidinyl, H-D-Phe-D-Phe-D-Leu-D-Orn-NHEt, H-D-Phe-D-Phe-D-Leu-D-Lys-morpholinyl, and H-D-Phe-D-Phe-D-Nle-D-Arg-piperazinyl.
- Peripherally selective kappa opioid receptor agonists of the invention can be peptides, such as those containing D-amino acids instead of L-amino acids, and which optionally can have little to no sequence homology with known mammalian endogenous opioid peptides, e.g., the enkephalins, endorphins, and dynorphins. A peripherally selective kappa opioid receptor agonist can comprise a tetrapeptide D-amino acid sequence. Peptides that are encompassed by the criteria of the invention are any of the known mammalian endogenous opioid peptides, e.g., as identified in Akil et al (1984), such as dynorphin A(1-17), including naturally occurring, processed forms of these peptides, e.g., dynorphin A(1-13) and dynorphin A (1-8).
- The invention, among other things, relates to the use of peripherally selective kappa opioid receptor agonists alone or in conjunction with lactational enhancers, elevators, or stabilizers for the treatment of lactation failure, or inadequate or insufficient lactation in a subject.
- The invention also relates to the use of peripherally selective kappa opioid agonists, alone or in conjunction with lactational enhancers elevators, or stabilizers for the manufacture of a medicament in treatment of lactation failure or inadequate or insufficient lactation in a subject.
- Lactational enhancers, elevators, or stabilizers can be chosen from among D2 dopamine receptor antagonists, mu opioid receptor agonists, prolactin, or oxytocin, for example.
- The invention further relates to a method for the treatment of lactation failure, or inadequate or insufficient lactation in a subject, characterized in that a peripherally selective kappa opioid receptor agonist, alone or in conjunction with a lactational enhancer, elevator, or stabilizer is administered to a female subject. Non-limiting administration methods include subcutaneous, intravenous, intramuscular, nasal, oral or transdermal administration.
- The invention moreover relates to a composition comprising peripherally selective kappa opioid receptor agonist in conjunction with a lactational enhancer, elevators, or stabilizers, optionally including a pharmaceutically acceptable carrier. These and other compositions set forth herein can be used in methods for the treatment of lactation failure, or inadequate or insufficient lactation in a subject, in accordance with the invention, as well as a method for the manufacture of these compositions.
- By lactation failure is here meant both when a female has no or insufficient amount of milk or is at risk for none or insufficient amount of milk.
- Lactation can be promoted and, therefore, lactation failure, or inadequate or insufficient lactation in a subject, methods are provided in the following situations:
- i) Normalize lactation volumes in women with lactational failure;
- ii) Maintain/enhance, increase lactation in females of premature babies who are being cared for in a neonatal unit;
- iii) Enhance lactational performance in females with twins and triplets;
- iv) Promote and prolong (frequency or duration) lactation in females with offspring at risk of developing lactose intolerance or other milk allergies if formula milk was used;
- v) Promote/prolong lactation in females where adverse hygiene conditions would make the use of formula undesirable;
- vi) Enhance, increase or stabilize lactation in females where suckling frequency is diminished during part of the day, e.g. working mothers;
- vii) To treat females prophylactically if they are at risk for having an insufficient or inadequate amount of milk production.
- Certain embodiments of the invention involve peptides, optionally tetrapeptides containing four D-isomer amino acid residues, which bind to kappa opioid receptor receptors, which do not substantially cross the blood brain barrier and enter the brain, which exhibit high affinity for the kappa opioid receptor versus the mu opioid receptor, which have high potency and efficacy, and can exhibit a relative long duration of action in vivo.
- It is an object herein to provide peripherally selective kappa opioid receptor agonists for systemic application that have tolerable, minimal or few if any CNS or diuretic effects at dosages that are sufficient to elevate, increase or stabilize prolactin and thereby produce a benefit, such as increased lactation or prevent significant reductions, or decreases in lactation, in a subject in need thereof.
- Mammals are defined herein as all animals, including humans, primates, and ungulates, for which the females of the species have mammary glands and produce milk.
- As used herein, a “dairy animal” refers to a milk producing animal. In certain embodiments, the dairy animal produces large volumes of milk and has a long period of lactation, e.g., cows or goats.
- The term “pharmaceutically acceptable composition” refers to compositions which comprise a therapeutically effective amount of peripherally selective kappa opioid receptor agonist, formulated together with one or more pharmaceutically acceptable carrier(s).
- As used herein, the term “formulation” refers to a composition in solid, e.g., powder, or liquid form, which includes a peripherally selective kappa opioid receptor agonist. Formulations can provide therapeutic benefits. These formulations may contain a preservative to prevent growth of microorganisms.
- By “therapeutically effective” amount is meant a tolerable (e.g., does not produce a severe side effect, which can be relatively, substantially, or completely nontoxic) amount of an active agent to provide the desired therapeutic effect.
- By “transdermal” drug delivery is meant administration of a drug to the skin surface of an individual so that the drug passes through the skin tissue and into the individual's blood stream, thereby providing a systemic effect. The term “transdermal” is intended to include “transmucosal” drug administration, i.e., administration of a drug to the mucosal (e.g., sublingual, buccal, vaginal, rectal) surface of an individual so that the drug passes through the mucosal tissue and into the individual's blood stream.
- The term “body surface” is used to refer to skin or mucosal tissue.
- By “predetermined area” of skin or mucosal tissue, which refers to the area of skin or mucosal tissue through which a drug enhancer formulation is delivered, is intended a defined area of intact unbroken living skin or mucosal tissue. That area will usually be in the range of about 5 cm2 to about 200 cm2, more usually in the range of about 5 cm2 to about 100 cm2, typically in the range of about 20 cm2 to about 60 cm2. However, it will be appreciated by those skilled in the art of drug delivery that the area of skin or mucosal tissue through which drug is administered may vary significantly, depending on patch configuration, dose, and the like.
- “Penetration enhancement” or “permeation enhancement” as used herein relates to an increase in the permeability of the skin or mucosal tissue to a selected pharmacologically active agent, i.e., so that the rate at which the agent permeates therethrough (i.e., the “flux” of the agent through the body surface) is increased relative to the rate that would be obtained in the absence of permeation enhancement. The enhanced permeation effected through the use of such enhancers can be observed by measuring the rate of diffusion of drug through animal or human skin using, for example a Franz diffusion apparatus as known in the art and as employed in the Examples herein.
- An “effective amount” or “an effective permeation enhancing amount” of a permeation enhancer refers to a nontoxic, nondamaging but sufficient amount of the enhancer composition to provide the desired increase in skin permeability and, correspondingly, the desired depth of penetration, rate of administration, and amount of drug delivered.
- A genus of peptides has been discovered which exhibit high selectivity for the kappa opioid receptor and relative long duration of in vivo action and which can exhibit reduced or substantially little if any significant brain penetration. These peptides include sequences in which a sequence of four D-isomer amino acids having a C-terminus is either a mono or disubstituted amide. These compounds have the following general formula:
-
H Xaa1-Xaa2-Xaa3-Xaa4-substituted amide - wherein Xaa1 is (A)D-Phe, (Calpha Me)D-Phe, D-Tyr, D-Tic or D-Ala(cyclopentyl or thienyl), with A being H, NO2, F, Cl or CH3; Xaa2 is (A′)D-Phe, D-1Nal, D-2Nal, D-Tyr or D-Trp, with A′ being A or 3,4Cl2; Xaa3 is D-Nle, (B)D-Leu, D-Hle, D-Met, D-Val, D-Phe or D-Ala(cyclopentyl) with B being H or Calpha Me; Xaa4 is D-Arg, D-Har, D-nArg, D-Lys, D-Lys(Ipr), D-Arg(Et2), D-Har(Et2), D-Amf(G), D-Dbu, (B)D-Orn or D-Orn(Ipr), and with G being H or amidino. Non-limiting amides include ethylamide, morpholinylamide, 4-picolylamide, piperazineamide, propyl amide, cyclopropylamide and diethylamide.
- The invention also provides a method of treating a mammal in need of elevated prolactin by increasing levels of serum prolactin of said mammal, comprising administering to said mammal an amount of a peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof effective to treat the mammal. In certain embodiments, the method increases or stabilizes levels of serum prolactin to greater than 25, 50, 75, 100, 125, 150, 175, or 200 ng/ml serum in the mammal. In other embodiments the method the peripherally selective kappa opioid receptor agonist or salt thereof or prodrug thereof effective to treat the mammal is a peptide, or ionizes or is metabolized to form a peptide. The peptide can comprise a pentapeptide or tetrapeptide, which can include a sequence of four D-isomer amino acids having a C-terminus that is either a mono- or di-substituted amide. In certain embodiments the peptide has a binding affinity for the kappa opioid receptor that is greater than its binding affinity for non-kappa opioid receptors. In particular embodiments the peptide has a binding affinity for the kappa opioid receptor at least 1,000 times greater than its binding affinity for the mu opioid receptor. In some of these particular embodiments the peptide has a binding affinity for the kappa opioid receptor at least 1,000 times greater than its binding affinity for the mu opioid receptor and in addition has an ED50 for elevating prolactin of about 0.5 mg/kg or less.
- Particular compounds useful in the methods of the present invention include the compound having the formula:
- H-D-Phe-D-Phe-D-Nle-D-Arg-NH-4-picolyl, or a picolyl N-oxide thereof, optionally excluding or including an acetate counterion.
- Another particular compound useful in the methods of the present invention is the compound having the formula:
- H-D-Phe-D-Phe-D-Leu-D-Orn-Morpholinyl, optionally excluding or including an acetate counterion.
-
FIG. 1 is a graph showing the Arithmetic Mean Changes from Baseline (Pre dose) in Serum Prolactin Concentrations Following a 1 hour IV Infusion of CR665 at various dosages in Male Subjects (Part A). -
FIG. 2 is a graph showing the Arithmetic Mean Changes from Baseline (Pre dose) in Serum Prolactin Concentrations Following a 1 hour IV Infusion of CR665 in Female Subjects (Part A). -
FIG. 3 is a graph showing the Arithmetic Mean Changes from Baseline (Pre dose) in Serum Prolactin Concentrations Following a 5 minute IV. Infusion of CR665 in Male Subjects (Part B). -
FIG. 4 is a graph showing the Geometric Mean Plasma Concentrations of CR665 Following a 1 hour IV Infusion of CR665 in Male Subjects (Part A) (Linear Scale). -
FIG. 5 is a graph showing the Geometric Mean Plasma Concentrations of CR665 Following a 1 hour IV Infusion of CR665 in Male Subjects (Part A) (Semi logarithmic Scale). -
FIG. 6 is a graph showing the Geometric Mean AUC0 □ for CR665 Versus Dose Level Following a 1 hour IV Infusion of CR665 in Male Subjects (Part A). -
FIG. 7 is a graph showing the Geometric Mean Plasma Concentrations of CR665 Following a 1 hour IV Infusion of 0.24 mg/kg CR665 in Female Subjects (Part A) (Linear Scale). -
FIG. 8 is a graph showing the Geometric Mean Plasma Concentrations of CR665 Following a 1 hour IV Infusion of 0.24 mg/kg CR665 in Female Subjects (Part A) (Semi logarithmic Scale). -
FIG. 9 is a graph showing the Arithmetic Mean (±SD) Plasma Concentrations of CR665 Following a 1-hour IV Infusion of 0.24 mg/kg CR665 in Male and Female Subjects (Part A) (Linear Scale). -
FIG. 10 is a graph showing the Geometric Mean Plasma. Concentrations of CR665 Following a 5-minute IV Infusion of CR665 in Male and Female Subjects (Part B) (Linear Scale). -
FIG. 11 is a graph showing the Geometric Mean Plasma Concentrations of CR665 Following a 5-minute IV Infusion of CR665 in Male and Female Subjects (Part B) (Semi logarithmic Scale). -
FIG. 12 is a graph showing the Geometric Mean AUC(0 to infinity) for CR665 Versus Dose Level Following a 5-minute IV infusion of CR665 in Male Subjects (Part B). -
FIG. 13 is a graph showing the Relationship Between AUC0 12 h of Changes from Baseline in Serum Prolactin and AUC(0 to infinity) of CR665 over the 0.015 to 0.36 mg/kg Dose Range in Male Subjects (Part A). -
FIG. 14 is a graph showing the Relationship Between Cmaxof Changes from Baseline in Serum Prolactin and Cmaxof CR665 over the 0.015 to 0.36 mg/kg Dose. Range in Male Subjects (Part A). - The nomenclature used to define the peptides is specified by Schroder & Lubke, The Peptides, Academic Press, 1965, wherein, in accordance with conventional representation, the N-terminus appears to the left and the C-terminus to the right. Where an amino acid residue has isomeric forms, it is the L-isomer form of the amino acid that is being represented herein unless otherwise indicated.
- The invention provides methods, compositions, or dosage forms that employ and/or contain compounds, such as peptides, that are selective for kappa opioid receptor and not only exhibit a strong affinity for the kappa opioid receptor but exhibit, optionally, long duration of in vivo prolactin elevating activity in the absence of a severe or significant side effect, such as CNS side effects or diuresis. Exemplary kappa selective opioid, receptor compounds (e.g., agonists) have a Ki against a mammalian kappa opioid receptor, such as a human kappa opioid receptor, of less than 1000 nM, or less than 100 nMor less than 10 nM, or less than 1 nM, optionally having a selectivity for kappa opioid receptors over other mammalian opioid receptor subtypes greater than 100, or greater than 1,000 or greater than 10,000 times greater affinity, measurable in vitro by the ratio of their 1050 or Ki values against the mammalian, e.g., human mu and delta opioid receptors, respectively. Kappa opioid receptor agonists can exhibit both a lack of significant brain penetration and a prolonged duration of in vivo activity. Therefore, in addition to the above mentioned kappa opioid receptor affinity and selectivity, compounds also include those that exhibit no significant brain penetration while preserving substantial activity for measurable or detectable period of time, for example, at least about one hour, at least about two hours, for three hours or longer (e.g., 4, 5, 6, 12, 24, 48 hours or days, or longer).
- In certain embodiments, the method of the invention can be practiced using a peripherally selective kappa opioid receptor agonist, which when administered peripherally, is effective to increase or stabilize levels of prolactin without substantially crossing the blood-brain barrier of the subject. In other embodiments, the amount of the peripherally selective kappa opioid receptor agonist administered is an amount effective to increase or stabilize levels of prolactin without causing a severe side effect in the subject. Alternatively, the amount of the peripherally selective kappa opioid receptor agonist administered is an amount effective to increase or stabilize levels of prolactin with minor or tolerable side effects in the subject. Side effects can include a neuropsychiatric side effect (such as but not limited to dysphoria or hallucinations), diuresis or sedation.
- In some embodiments, according to the method of the invention for elevating levels of serum prolactin in a mammal, the administered dose of the peripherally selective kappa opioid receptor agonist is between about 1 microgram/kg of body weight to about 100 milligrams/kg of body weight of said mammal per hour, or per day, or per week or per month. The prolactin levels can be elevated to greater than 10, 15, 20, 25, 50, 75, 100, 125, 150, 175, or 200 ng/rnl serum above the baseline level of serum prolactin.
- In some embodiments, the method of the invention for treating insufficient or inadequate lactation in a mammal, includes administering, separately or in combination an amount of a peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof, and an amount of prolactin effective to treat insufficient or inadequate lactation in the mammal. In other embodiments, the invention provides a method for treating insufficient or inadequate lactation. The method includes administering an amount of a peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof, to a mammal, separately or in combination, with (1) another prolactin-elevating agent, (2) prolactin, or (3) a non-drug therapy, the method effective to treat insufficient or inadequate lactation in the mammal. In still other embodiments, the invention provides a method for treating insufficient or inadequate lactation in a mammal. The method includes administering separately or in combination 1) a peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof, and; 2) another prolactin-elevating agent, said administration in an amount effective for treating insufficient or inadequate lactation in the mammal.
- In other embodiments, the invention provides a method of for treating a mammal exhibiting insufficient or inadequate milk production or at risk of insufficient or inadequate milk production. The method includes administering to said mammal an amount of a peripherally selective kappa opioid receptor agonist or salt thereof or prodrug thereof effective to treat the mammal. The peripherally selective kappa opioid receptor agonist or salt thereof or prodrug thereof can include a peptide, or can ionize or metabolize to form a peptide. The peptide can include a tetrapeptide or a pentapeptide.
- In particular embodiments, the prolactin-elevating agent useful in the methods of the present invention can be administered with a mu opioid receptor agonist selected from the group consisting of (i) morphine, (ii) hydromorphone, (iii) oxymorphone, (iv) levorphanol, (v) methadone, (vi) codeine, (vii) hydrocodone, (viii) oxycodone, (ix)
morphine 6 glucuronide, (x) tramadol, (xi) meperidine, (xii) diphenoxylate, (xiii) loperamide, (xiv) fentanyl, (xv) sufentanil, (xvi) alfentanil, (xvii) remifentanil, (xviii) levomethadyl and (xviv) propoxyphene. - In certain embodiments of the method, the prolactin-elevating agent can be a peptide having a binding affinity for the peripheral kappa opioid receptor that is greater than its binding affinity for non-peripheral kappa opioid receptor. Alternatively, the peptide can have a binding affinity for the peripheral kappa opioid receptor that is 10 times greater, 100 times greater, 1,000 times greater, or more than its binding affinity for a non-peripheral kappa opioid receptor. For instance the peptide can have a binding affinity for the kappa opioid receptor which is at least 1,000 times greater than its binding affinity for the mu opioid receptor. In certain embodiments, the peptide has a binding affinity for the kappa opioid receptor which is at least 1,000 times greater than its binding affinity for the mu opioid receptor and an ED50 for elevating prolactin of about 0.5 mg/kg or less.
- In a particular embodiment, the invention provides a method of treating a mammal in need of elevated or stabilized prolactin levels, wherein the method includes administering to said mammal an amount of a peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof, in conjunction with an amount of an additional prolactin elevating compound, effective to treat the mammal. The additional prolactin elevating compound can include a D2 dopamine receptor antagonist or mu opioid receptor agonist.
- In one embodiment, the D2 dopamine receptor agonist is selected from the group consisting of (i) domperidone, (ii) metoclopramide, (iii) levosulpiride, (iv) sulpiride, (v) thiethylperazine, (vi) ziprasidone, (vii) zotepine, (viii) clozapine, (ix) chlorpromazine, (x) acetophenazine, (xi) carphenazine (xii) chlorprothixene, (xiii) fluphenazine, (xiv) loxapine, (xv) mesoridazine, (xvi) molindone, (xvii) perphenazine, (xviii) pimozide, (xviv) piperacetazine, (xx) prochlorperazine, (xxi) thioridazine, (xxii) thiothixene, (xxiii) trifluoperazine, (xxiv) triflupromazine, (xxv) pipamperone, (xxvi) amperozide, (xxvii) quetiapine, (xxviii) melperone, (xxix) remoxipride, (xxx) haloperidol, (xxxi) rispiridone, (xxxii) olanzepine, (xxxiii) sertindole, and (xxxiv) prochlorperazine.
- In another embodiment the mu opioid receptor agonist is selected from the group consisting of (i) morphine, (ii) hydromorphone, (iii) oxymorphone, (iv) levorphanol, (v) methadone, (vi) codeine, (vii) hydrocodone, (viii) oxycodone, (ix) morphine-6-glucuronide, (x) tramadol, (xi) meperidine, (xii) diphenoxylate, (xiii) loperamide, (xiv) fentanyl, (xv) sufentanil, (xvi) alfentanil, (xvii) remifentanil, (xviii) levomethadyl, and (xviv) propoxyphene.
- As used herein, “prolactin elevating activity” refers to the pharmacological activity of a compound If it causes an elevation in circulating plasma or serum levels of prolactin in a subject. A “prolactin increasing activity” refers to a compound that causes a measurable or detectable, transient or longer term increase in circulating plasma or serum levels of prolactin in a subject. A “prolactin stabilizing activity” refers to a compound that causes a measurable or detectable, transient or longer term, stabilization in circulating plasma or serum levels of prolactin in a subject, e.g., prevents or inhibits a reduction in prolactin levels, maintains a particular level of prolactin for a measurable period of time, prevents or inhibits a reduction in prolactin levels below a certain amount (e.g., below 200, 175, 150, 125, 100, 75, 50, 25 ng/ml serum), etc.
- As used herein, “functional hypoprolactinemia” refers to a condition in which a subject has insufficient or inadequate levels of circulating prolactin required to initiate, maintain or enhance a physiological function, e.g. lactation. The level of circulating prolactin required for a given physiological function will vary, as is knownin the art, depending upon the function and the gender and physiological or pathophysiological status of the subject. Thus, for example, a normal pre pregnancy baseline level of circulating prolactin would be insufficient to sustain lactation after delivery. Under these circumstances, the failure of lactation in a post pregnant female with this level of prolactin would be characterized as a functional hypoprolactinemia, even though the circulating level of prolactin would be normal for a non lactating female.
- As used herein, “CNS side effect” refers to a clinically significant side effect of a compound in which the symptoms are psychiatric or neurological, e.g., visual or auditory hallucinations, delusions, impaired intellectual functioning, or impaired control of voluntary movements.
- As used herein, the term “subject” is intended to include human and non human mammals. Subjects include a person, e.g., a patient, in need of elevated, increased or stabilized levels of prolactin, e.g., a person in need of stimulation of lactation, e.g., a female (mother). The term “mammals” includes humans and all non human mammals, such as non human primates, ungulates and ruminants.
- As used herein, “effective amount” or “sufficient amount” refers to an amount of a compound as described herein that may be therapeutically effective to inhibit, prevent or treat a symptom of a particular disease, disorder, condition, or side effect. Such diseases, disorders, conditions, and side effects include those conditions associated with insufficient, or inadequate circulating levels of prolactin, wherein the treatment comprises elevating, increasing or stabilizing circulating levels of prolactin by contacting cells, tissues or receptors with compounds as set forth herein. Thus, for example, an “effective amount”, when used in connection with lactational insufficiency or inadequacy, for example, refers to an amount of a compound required for treatment and/or prevention of this condition. An “effective amount”, when used in connection with functional hypoprolactinemia, refers to the treatment and/or prevention of one or more symptoms, diseases, disorders, and conditions associated with circulating levels of prolactin that are undesirably low, for example, to optimally sustain a physiological function.
- As used herein, “pharmaceutically acceptable” refers to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without severe toxicity, irritation, allergic response, or other complications commensurate with a reasonable benefit/risk ratio.
- As used herein, “in combination with”, “combination therapy” and “combination products” refer, in certain embodiments, to the concurrent administration to a patient of a peripherally selective kappa opioid receptor agonist of the invention and either or both of prolactin and a compound with prolactin elevating, increasing or stabilizing activity but lacking peripherally selective kappa opioid receptor agonist activity, e.g., a D2 dopamine receptor antagonist, e.g., domperidone. When administered in combination, each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide a desired therapeutic effect.
- As used herein, a “D2 dopamine receptor antagonist” refers to compounds with a binding affinity (KD or Ki) for a mammalian D2 dopamine receptor of less than 10 micromolar, regardless of binding affinity for other receptors. Where there is ambiguity or an absence of useful information regarding whether the binding affinity of a compound for a mammalian D2 dopamine receptor meets this definition, data from in vitro or in vivo functional studies, as are commonly employed by those with skill in the art, can be used to determine whether a compound is a functional antagonist of a mammalian D2 dopamine receptor.
- As used herein, “mu opioid receptor agonist” refers to compounds with a binding affinity (KD or Ki) for a mammalian mu opioid receptor of less than 10 micromolar, regardless of binding affinity for other receptors. Where there is ambiguity or an absence of useful information regarding whether the binding affinity of a compound for a mammalian mu opioid receptor meets this definition, data from in vitro or in vivo functional studies, as are commonly employed by those with skill in the art, can be used to determine whether a compound is a functional agonist of a mammalian mu opioid receptor.
- As used herein, “dosage unit” refers to a physically discrete unit suited as unitary dosages for a particular individual or condition to be treated. Each unit may contain a predetermined quantity of active compound(s) calculated to produce the desired therapeutic effect(s), optionally in association with a pharmaceutical carrier. The specification for the dosage unit forms may be dictated by (a) the unique characteristics of the active compound(s) and the particular therapeutic effect(s) to be achieved, and (b) the limitations inherent in the art of compounding such active compound(s).
- As used herein, “pharmaceutically acceptable salts” refer to derivatives of compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid sals of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non toxic inorganic or organic acids. For example, such conventional non toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2 acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like. These physiologically acceptable salts are prepared by methods known in the art, e.g., by dissolving the free amine bases with an excess of the acid in aqueous alcohol, or neutralizing a free carboxylic acid with an alkali metal base such as a hydroxide, or with an amine.
- Compounds described herein, can be used or prepared in alternate forms. For example, many amino containing compounds can be used or prepared as an acid addition salt. Often such salts improve isolation and handling properties of the compound. For example, depending on the reagents, reaction conditions and the like, compounds as described herein can be used or prepared, for example, as their hydrochloride or tosylate salts. Isomorphic crystalline forms, all chiral and racemic forms, N-oxide, hydrates, solvates, and acid salt hydrates, are also contemplated to be within the scope of the present invention.
- Certain acidic or basic compounds of the present invention may exist as zwitterions. All forms of the compounds, including free acid, free base and zwitterions, are contemplated to be within the scope of the present invention. It is well known in the art that compounds containing both amino and carboxyl groups often exist in equilibrium with their zwitterionic forms. Thus, any of the compounds described herein throughout that contain, for example, both amino and carboxyl groups, also include reference to their corresponding zwitterions.
- A peripherally selective kappa opioid receptor agonist of the invention can be incorporated into a pharmaceutical composition to ameliorate functional hypoprolactinemia in a subject, e.g., a subject presenting with a deficiency, inadequacy or insufficiency in lactation associated with insufficient or inadequate plasma levels of prolactin. The compositions should contain an effective amount of a peripherally selective kappa opioid receptor agonist, in a pharmaceutically acceptable carrier.
- The pharmaceutical carrier can be any compatible, non toxic substance suitable to deliver the peripherally selective kappa opioid receptor agonist to the subject. Sterile water, alcohol, fats, waxes, and inert solids may be used as the carrier. Pharmaceutically acceptable adjuvants, buffering agents, dispersing agents, and the like, may also be incorporated into the pharmaceutical compositions. The concentration of peripherally selective kappa opioid receptor agonist or other active agent in the pharmaceutical composition can vary widely, i.e., from less than about 0.01% by weight, usually being at least about 1% weight to as much as 50% by weight or more.
- For oral administration, an active ingredient can be administered in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. Active component(s) can be encapsulated in gelatin capsules together with inactive ingredients and powdered carriers, such as glucose, lactose, sucrose, mannitol, starch, cellulose or cellulose derivatives, magnesium stearate, stearic acid, sodium saccharin, talcum, magnesium carbonate and the like. Examples of additional inactive ingredients that may be added to provide desirable color, taste, stability, buffering capacity, dispersion or other known desirable features are red iron oxide, silica gel, sodium lauryl sulfate, titanium dioxide, edible white ink and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. To facilitate drug stability and absorption, peptides of the invention can be released from a capsule after passing through the harsh proteolytic environment of the stomach. Methods for enhancing peptide stability and absorption after oral administration are well known in the art (e.g., Mahato R I. Emerging trends in oral delivery of peptide and protein drugs. Critical Reviews in Therapeutic Drug Carrier Systems. 20:153-214, 2003). In addition, oral delivery of compounds of the invention can be optimized through the use of remote controlled capsules as disclosed by Wilding and Prior in Critical Reviews in Therapeutic Drug Carrier Systems 20:405-431 (2003).
- For nasal administration, the peripherally selective kappa opioid receptor agonists can be formulated as aerosols. The term “aerosol” includes any gas-borne suspended phase of the compounds of the instant invention which is capable of being inhaled into the bronchioles or nasal passages. Specifically, aerosol includes a gas-borne suspension of droplets of the compounds of the instant invention, as may be produced in a metered dose inhaler or nebulizer, or in a mist sprayer. Aerosol also includes a dry powder composition of a compound of the instant invention suspended in air or other carrier gas, which may be delivered by insufflation from an inhaler device, for example. See Ganderton & Jones, Drug Delivery to the Respiratory Tract, Ellis Horwood (1987); Gonda (1990) Critical Reviews in Therapeutic Drug Carrier Systems 6:273-313; and Raeburn et al. (1992) J. Pharmacol. Toxicol. Methods 27:143-159.
- Parenteral administration of the formulations of the present invention includes intravenous, subcutaneous, intramuscular and transdermal administrations.
- Preparations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile emulsions. The solutions may be either aqueous or nonaqueous, and thereby formulated for delivery by injection, infusion, or using implantable pumps. For intravenous, subcutaneous, and intramuscular administration, useful formulations of the invention include microcapsule preparations with controlled release properties (R. Pwar et al. Protein and peptide parenteral controlled delivery. Expert Opin Biol Ther. 4(8):1203-12, 2004) or encapsulation in liposomes, with an exemplary form being polyethylene coated liposomes, which are known in the art to have an extended circulation time in the vasculature (e.g.Koppal, T. “Drug delivery technologies are right on target”, Drug Discov. Dev. 6, 49-50, 2003).
- Preparations for transdermal delivery are incorporated into a device suitable for said delivery, said device utilizing, e.g., iontophoresis (Kalia Y N et al. Iontophoretic drug delivery. Adv Drug Deliv Rev. 56:619-58, 2004) or a dermis penetrating surface (Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev. 56:581-7, 2004), such as are known in the art to be useful for improving the transdermal delivery of drugs. An electrotransport device and methods of operating same are disclosed in U.S. Pat. No. 6,718,201. Methods for the use of iontophoresis to promote transdermal delivery of peptides are disclosed in U.S. Pat. No. 6,313,092 and U.S. Pat. No. 6,743,432. Herein the terms “electrotransport”, “iontophoresis”, and “iontophoretic” are used to refer to the delivery through a body surface (e.g., skin or mucosa) of one or more pharmaceutically active compounds by means of an applied electromotive force to an agent containing reservoir. The compound may be delivered by electromigration, electroporation, electroosmosis or any combination thereof. Electroosmosis has also been referred to as electrohydrokinesis, electro convection, and electrically induced osmosis. In general, electroosmosis of a compound into a tissue results from the migration of solvent in which the compound is contained, as a result of the application of electromotive force to the therapeutic species reservoir, i.e., solvent flow induced by electromigration of other ionic species. During the electrotransport process, certain modifications or alterations of the skin may occur such as the formation of transiently existing pores in the skin, also referred to as “electroporation.” Any electrically assisted transport of species enhanced by modifications or alterations to the body surface (e.g., formation of pores in the skin) are also included in the term “electrotransport” as used herein. Thus, as used herein, applied to the compounds of the instant invention, the terms “electrotransport”, “iontophoresis” and “iontophoretic” refer to (1) the delivery of charged agents by electromigration, (2) the delivery of uncharged agents by the process of electroosmosis, (3) the delivery of charged or uncharged agents by electroporation, (4) the delivery of charged agents by the combined processes of electromigration and electroosmosis, and/or (5) the delivery of a mixture of charged and uncharged agents by the combined processes of electromigration and electroosmosis. Electrotransport devices generally employ two electrodes, both of which are positioned in close electrical contact with some portion of the skin of the body. One electrode, called the active or donor electrode, is the electrode from which the therapeutic agent is delivered into the body. The other electrode, called the counter or return electrode, serves to close the electrical circuit through the body. In conjunction with the patient's skin, the circuit is completed by connection of the electrodes to a source of electrical energy, e.g., a battery, and usually to circuitry capable of controlling current passing through the device.
- Depending upon the electrical charge of the compound to be delivered transdermally, either the anode or cathode may be the active or donor electrode. Thus, if the compound to be transported is positively charged, e.g., the compound exemplified in Example 1 herein, then the positive electrode (the anode) will be the active electrode and the negative electrode (the cathode) will serve as the counter electrode, completing the circuit. However, if the compound to be delivered is negatively charged, then the cathodic electrode will be the active electrode and the anodic electrode will be the counter electrode. Electrotransport devices additionally require a reservoir or source of the therapeutic agent that is to be delivered into the body. Such drug reservoirs are connected to the anode or the cathode of the electrotransport device to provide a fixed or renewable source of one or more desired species or agents. Each electrode assembly is comprised of an electrically conductive electrode in ion-transmitting relation with an ionically conductive liquid reservoir which in use is placed in contact with the patient's skin. Gel reservoirs such as those described in Webster (U.S. Pat. No. 4,383,529) are one form of reservoir since hydrated gels are easier to handle and manufacture than liquid-filled containers. Water is one liquid solvent that can be used in such reservoirs, in part because the salts of the peptide compounds of the invention are water soluble and in part because water is non-irritating to the skin, thereby enabling prolonged contact between the hydrogel reservoir and the skin. Examples of reservoirs and sources include a pouch as described in U.S. Pat. No. 4,250,878, a pre-formed gel body as disclosed in U.S. Pat. No. 4,382,529, and a glass or plastic container holding a liquid solution of the drug, as disclosed in the figures of U.S. Pat. No. 4,722,726. For electrotransport, compounds (e.g., peptides) the invention can be formulated with flux enhancers such as ionic surfactants (e.g., U.S. Pat. No. 4,722,726) or cosolvents other than water (e.g., European Patent Application 278,473). Alternatively the outer layer (i.e., the stratum corneum) of the skin can be mechanically disrupted prior to electrotransport delivery therethrough (e.g., U.S. Pat. No. 5,250,023).
- Peripherally selective kappa opioid receptor agonists that are well suited for electrotransport can be selected, by measuring their electrotransport flux through the body surface (e.g., the skin or mucosa), e.g., as compared to a standardized test peptide with known electrotransport flux characteristics, e.g. thyrotropin releasing hormone (R. Burnette et al. J. Pham. Sci. (1986) 75:738) or vasopressin (Nair et al., Pharmacol Res. 48:175-82, 2003). Transdermal electrotransport flux can be determined using a number of in vivo or in vitro methods well known in the art. In vitro methods include clamping a piece of skin of an appropriate mammal (e.g., human cadaver skin) between the donor and receptor compartments of an electrotransport flux cell, with the stratum corneum side of the skin piece facing the donor compartment. A liquid solution or gel containing the drug to be delivered is placed in contact with the stratum corneum, and electric current is applied to electrodes, one electrode in each compartment. The transdermal flux is calculated by sampling the amount of drug in the receptor compartment. Two successful models used to optimize transdermal electrotransport drug delivery are the isolated pig skin flap model (Heit M C et al. Transdermal iontophoretic peptide delivery: in vitro and in vivo studies with luteinizing hormone releasing hormone. J. Pharm. Sci. 82:240 3, 1993), and the use of isolated hairless skin from hairless rodents or guinea pigs, for example. See Hadzija B W et al. Effect of freezing on iontophoretic transport through hairless rat skin. J. Pharm. Pharmacol. 44, 387 390, 1992. Compounds of the invention for transdermal iontophoretic delivery can have one, or typically, two charged nitrogens, to facilitate their delivery.
- The scope of the present invention also includes methods of treating a mammal in need of elevated prolactin wherein the peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof is administered transdermally, for instance and without limitation, by an electrotransport device. The electrotransport device can, in some embodiments, deliver the peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof through a body surface.
- Other useful transdermal delivery devices employ high velocity delivery under pressure to achieve skin penetration without the use of a needle. Transdermal delivery can be improved, as is known in the art, by the use of chemical enhancers, sometimes referred to in the art as “permeation enhancers”, i.e., compounds that are administered along with the drug (or in some cases used to pretreat the skin, prior to drug administration) in order to increase the permeability of the stratum corneum, and thereby provide for enhanced penetration of the drug through the skin. Chemical penetration enhancers are compounds that are innocuous and serve merely to facilitate diffusion of the drug through the stratum corneum, whether by passive diffusion or an energy driven process such as electrotransport. See, for example, Meidan V M et al. Enhanced iontophoretic delivery of buspirone hydrochloride across human skin using chemical enhancers. Int. J. Pharm. 264:73-83, 2003.
- Pharmaceutically acceptable carriers used in parenteral preparations include aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances.
- Examples of aqueous vehicles include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection. Nonaqueous parenteral vehicles include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut oil. Antimicrobial agents in bacteriostatic or fungistatic concentrations must be added to parenteral preparations packaged in multiple dose containers which include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride. Isotonic agents include sodium chloride and dextrose. Buffers include phosphate and citrate. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. Suspending and dispersing agents include sodium carboxymethylcelluose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Emulsifying agents include Polysorbate 80 (Tween 80). A sequestering or chelating agent of metal ions includes EDTA. Pharmaceutical carriers also include ethyl alcohol, polyethylene glycol and propylene glycol for water miscible vehicles and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.
- Typically a therapeutically effective amount of a peripherally selective kappa opioid receptor agonist is at least about 0.01% w/w up to about 50% w/w or more, or more than 0.1% w/w of the active compound. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time, or as a controlled release formulation. The term “controlled release formulation” encompasses formulations that allow the continuous delivery of a peripherally selective kappa opioid receptor agonist to a subject over a period of time, for example, several days to weeks. Such formulations may administered subcutaneously or intramuscularly and allow for the continual steady state release of a predetermined amount of compound in the subject over time. The controlled release formulation of peripherally selective kappa opioid receptor agonist may be, for example, a formulation of drug containing polymeric microcapsules, such as those described in U.S. Pat. Nos. 4,677,191 and 4,728,721, incorporated herein by reference. The concentration of the pharmaceutically active compound is adjusted so that administration provides an effective amount to produce a desired effect. The exact dose depends on the age, weight and condition of the patient or animal, as is known in the art. For any particular subject, specific dosage regimens can be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations. Thus, the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed invention.
- The unit dose parenteral preparations include packaging in an ampoule or a syringe with a needle.
- All preparations for parenteral administration are typically sterile, as is known and practiced in the art.
- Illustratively, intravenous infusion of a sterile aqueous buffered solution containing an active compound is an effective mode of administration. Another embodiment is a sterile aqueous or oily solution or suspension containing an active material injected as necessary to produce the desired pharmacological effect.
- Compositions and methods of the invention can be delivered or administered intravenously, transdermally, intranasally, subcutaneously, intramuscularly, or orally. Compositions can be administered for prophylactic treatment of individuals suffering from, or at risk of a disease or a disorder, e.g., a female experiencing insufficient or inadequate lactation. For therapeutic applications, a pharmaceutical composition is typically administered to a subject suffering from a disease or disorder, e.g., a lactational deficiency, in an amount sufficient to inhibit, prevent, or ameliorate the disease or disorder. An amount adequate to accomplish this is defined as a “therapeutically effective dose.”
- Although not wishing to be bound by any theory, it is believed that peripherally selective kappa opioid receptor agonist administered to subjects stimulates release of the anterior pituitary hormone prolactin. The compound is typically administered in an amount sufficient to stimulate secretion of prolactin, or stabilize or prevent or inhibit reductions or decreases in prolactin, without causing a severe side effect, such as CNS side effects or diuresis. A useful dose range of a peripherally selective kappa opioid receptor agonist can be determined by one of skill in the art through routine testing. One skilled in the art recognizes that a dose depends, in part, upon physical characteristics of the patient to be treated, e.g., body weight, as well as the route of administration, e.g., intravenous injection or transdermal delivery, and the bioavailability and plasma clearance of the compound by that route of administration, as well as the kappa opioid receptor affinity of the compound. One method of approximating an effective dose is to titrate the dose to achieve a plasma concentration of drug that exceeds the affinity constant (Kd or Ki) of the drug for the kappa opioid receptor, e.g., as determined by a conventional radioreceptor assay as is routinely employed in the art. One method is to titrate the dose to effect, e.g., to employ a dose that is found to effectively elevate prolactin levels, as measured by an immunoassay selective for prolactin. In this case, although only two samples of blood, before and after drug administration, are necessary to compare the basal prolactin level with the stimulated prolactin level, it is typical to measure the stimulated hormonal levels at timed intervals so that the dosing interval can be adjusted to maintain a persistently elevated prolactin level. Serum prolactin concentrations can be assessed by any of several, validated methods as are known in the art, e.g., a prolactin-specific immunoassay, e.g., the IMx prolactin assay (Abbott Laboratories, Abbott Park, Ill.), a microparticle enzyme immunoassay used in conjunction with an Abbott IMx Automated Immunoassay Analyzer. When the desired therapeutic effect is to increase lactation, an additional method of dose titration is to employ a prolactin-elevating dose that effectively increases the amount of milk that can be expressed, for example, to between about 500 to 1000 ml per day for a nursing human mother, with the level of milk expression selected according to the needs of the nursing infant. The needs of the nursing infant can be assessed by methods known to those with skill in the art, and which can include evidence for adequate lactation: (1) infant is satisfied after breast feeding, (2) infant gains weight appropriately in relation to age/length, (3) breast engorgement and/or leaking occurs if infant feeding is missed, and (4) milk is secreted in volumes above 500 ml/day. The volume of milk ingested by infants is commonly estimated as 150 ml/kg/day.
- The American Academy of Pediatrics has placed an emphasis on increasing breastfeeding in the United States, and has noted that most drugs likely to be prescribed to the nursing mother should have no effect on milk supply or on infant well being (American Academy of Pediatrics, Committee on Drugs. The Transfer of Drugs and Other Chemicals Into Human Milk. Pediatrics 108:776-789, 2001). Methods of the invention therefore include those that minimize transfer of a compound or compounds of the invention into breast milk that is fed to an offspring, such as an infant. The transfer of drugs into breast milk is most commonly described quantitatively using the milk to plasma (M/P) concentration ratio. The accuracy of this value is improved if it is based on the area under the concentration time curves (AUC), of the drug in maternal milk and plasma.
- The infant daily dose can be estimated with the following equation:
-
Estimated Daily Infant Dosage (mg/kg/day)=M/P×average maternal serum concentration×150 mL/kg/day - In this case M/P (milk to plasma ratio) is the ratio of AUCmilk to AUCplasma The average maternal serum concentration refers to AUC after maternal ingestion of a single dose of drug or at steady state during, chronic maternal dosing (Bennett 1988, 1996). When using this approach to estimate daily infant dosage, the AUC is either the AUC from time zero to infinity after maternal ingestion of a single dose of drug or the AUC within a dosing interval at steady state during chronic maternal dosing. The volume of milk ingested by infants is commonly estimated as 150 ml/kg/day. The infant dose (mg/kg) can then be expressed as a percentage of the maternal dose (mg/kg). Compounds of the invention can result in an infant dose of less than 10% of the maternal dose, or less than 1% or less than 0.1% of the maternal dose. Since compounds of the invention include peptides, they can be formulated, e.g., with polymeric microspheres, to protect them from degradation and enhance absorption in the gastrointestinal tract (e.g., Mahato R I. Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. 20:153 214, 2003). Microsphere-encapsulated peptides, for example typically do not survive the maternal gastrointestinal environment and release free peptide into the circulation, such that peptides would be orally bioavailable to the offspring through breast milk in significant amounts, which can be readily confirmed by drug assay of infant plasma and/or urine.
- The utility of the present invention is not limited to promoting, elevating, increasing or stabilizing lactation in human and non human mammals. Although the prolactin receptor is indeed found in the mammary gland and the ovary, two of the best characterized sites of prolactin actions in mammals, the receptor is also found in areas of the brain that are outside the blood brain barrier, and are therefore accessible to circulating prolactin (Freeman M E et al. Prolactin: Structure, function, and regulation of secretion. Physiol. Rev. 80:1523-1631, 2000). In particular, the prolactin receptor (and/or the mRNA encoding the prolactin receptor) is found in the choroid plexus the area postrema, and the mediobasal hypothalamus. Prolactin receptors are also present in a wide range of peripheral tissues, including the pituitary gland, heart, lung, thymus, spleen, liver, pancreas, kidney, adrenal gland, uterus; skeletal muscle, and skin. Accordingly, it is contemplated that peripherally selective kappa opioid receptor agonists, as described herein, will be useful in preventing, ameliorating or modulating conditions associated with these regions of the brain and periphery, as well. Thus, for example, elevated circulating prolactin, caused by a compound of the instant invention, would have access to the mediobasal hypothalamus, a region outside the blood-brain barrier that includes the anterior periventricular area, paraventricular nucleus, and arcuate nucleus (e.g., Merchenthaler I. Neurons with access to the general circulation in the central nervous system of the rat: a retrograde tracing study with fluoro gold. Neuroscience 44:655-62; 1991). These hypothalamic nuclei are critical for neuroendocrine regulation, and contain prolactin receptors, which would thereby be therapeutically affected, e.g., in neuroendocrine related disorders, by elevations in circulating prolactin caused by a compound of the instant invention.
- A variety of assays may be employed to test whether the compounds of the invention exhibit high affinity and selectivity for the kappa opioid receptor, long duration of in vivo bioactivity, lack of CNS side effects, and prolactin elevating activity. Receptor assays are known in the art and kappa opioid receptors from several species have been cloned, as have'mu and delta opioid receptors. Kappa opioid receptors as well as mu and delta opioid receptors are classical, seven transmembrane spanning, G-protein coupled receptors. Although these cloned receptors readily allow a particular candidate compound, e.g., a peptide, to be screened, natural sources of mammalian opioid receptors are also useful for screening, as is well known in the art (Dooley C T et al. Selective ligands for the mu, delta, and kappa opioid receptors identified from a single mixture based tetrapeptide positional scanning combinatorial library. J. Biol. Chem. 273:18848-56, 1998). Thus, screening against both kappa and mu opioid receptors, whether of recombinant or natural origin, may be carried out in order to determine the selectivity of the compound(s) for the kappa over the mu opioid receptor. In general, a mammalian form of the opioid receptor is used for screening; typically, the species source of the receptors is the same as the species for which the compound of the invention is being assessed, e.g., human placental tissue as a source of kappa opioid receptors (Porthe G et al. Kappa opiate binding sites in human placenta. Biochem. Biophys. Res. Commun. 101:1-6, 1981) for screening if the contemplated use of the screened compounds is for treatment of a human subject.
- Binding affinity refers to the strength of interaction between ligand and receptor. To demonstrate binding affinity for opioid receptors, the compounds of the invention can be evaluated using competition binding studies. These studies can be performed using cloned kappa and mu opioid receptors expressed in stable transfected cell lines or naturally occurring opioid receptors from a receptor-enriched tissue source, as noted above. In these studies, the test compounds (unlabeled or cold ligand) are used at increasing concentrations to displace the specific binding of a radiolabeled ligand that has high affinity and selectivity for the receptor studied. Tritiated U-69,593 and DAMGO can be used as ligands in kappa and mu opioid receptor studies, respectively. Both ligands are commercially available (NEN-Dupont). DAMGO is an acronym for [D-Ala2, MePhe4, Gly-ol5]-enkephalin. The affinity of the radioligands is defined by the concentration of radioligand that results in half-maximal specific binding (KD) in saturation studies. The affinity of the test compound (unlabeled or cold ligand) is determined in competition binding studies by calculating the inhibitory constant (KO according to the following formula:
-
K i =IC 50/[1+(F/K D)] - where IC50=Concentration of the cold ligand that inhibits 50% of the specific binding of the radioligand
F=free radioligand concentration
KD=affinity of the radioligand determined in saturation studies. - When performing these assays under specific conditions with relatively low concentrations of receptor, the calculated Ki for the test compound is a good approximation of its dissociation constant KD, which represents the concentration of ligand necessary to occupy one-half (50%) of the binding sites. A low Ki value in the nanomolar and subnanomolar range is considered to identify a high affinity ligand in the opioid field. Exemplary analogs have a Ki for kappa opioid receptor of about 10 nanomolar (nM) or less, and typical analogs have a Ki of about 1 nM or less. High affinity compounds: (1) enable the use of relatively low doses of drug, which minimizes the likelihood of side effects due to low affinity interactions, and (2) potentially reduce the cost of manufacturing a dose since a correspondingly smaller amount of a higher affinity compound would be required to produce the desired therapeutic effect, assuming equal absorption, distribution, metabolism, and excretion.
- These binding assays employing kappa opioid receptors and mu opioid receptors are straightforward to perform and can be readily carried out with large numbers of compounds to determine whether such compounds are kappa opioid receptor selective and have high affinity. Such binding assays can be carried out in a variety of ways as well known to one of skill in the art, and one detailed example of an assay of this general type is set forth in Young E A et al. [3H]Dynorphin A binding and kappa selectivity of prodynorphin peptides in rat, guinea pig and monkey brain. Eur. J. Pharmacol. 121:355-65, 1986.
- Various abbreviations used herein are as follows:
- By D-Nle is meant D-norleucine, and D-Hle represents D-homoleucine. D-Har represents D-homoarginine, and D-nArg represents D-norarginine which is one carbon shorter than D-Arg.
- By D-NaI is meant the D-isomer of alanine which is substituted by naphthyl on the n-carbon. Typically, D-2Nal is employed, i.e. the attachment to naphthalene is at the 2-position on the ring structure; however, D-1Nal may also be used. The abbreviations D-Cpa and D-Fpa are used to represent, respectively, chloro-D-Phe and fluoro-D-Phe, with D-4 Cpa, D-2Fpa, D-3Fpa and D-4Fpa being typical. D-Npa means nitro-D-Phe, and D-Mpa is used to represent methyl D-Phe. D-3,4 Cpa means 3,4-dichloro-D-Phe. D-Acp represents D-Ala(cyclopentyl). D-Orn represents D-ornithine, and D-Dbu represents alpha, gamma-diamino butyric acid. CML represents Calphamethyl Leu, and CMP and CMO represent Calpha Me Phe and Callpha Me Orn. By D-4Amf is meant D-4(NH2CH2)Phe, and by D-Gmf is meant Amf(amidino) which represents D-Phe where the 4-position is substituted with CH2NHC(NH)NH2. Amd represents amidino, and the symbol D-Amf(Amd) is also used. By D-Tic is meant D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid. In Ala(Thi), Thi represents the thienyl group, which is typically linked at its 2-position to alanine, although 3-thienyl is an equivalent. By Ily and Ior are respectively meant isopropyl Lys and isopropyl Orn where the side chain amino group is alkylated with isopropyl.
- By lower alkyl is meant C1 to C6, for example, C1-C4 but including cyclopropyl and cyclobutyl. Me, Et, Pr, Tpr, Bu, Pn and Bzl are used to represent methyl, ethyl, propyl, isopropyl, butyl, pentyl and benzyl. By Cyp is meant cyclopropyl, and by Cyb is meant cyclobutyl. Although the linkage is typically to one end of an alkyl chain, the linkage may be elsewhere in the chain, e.g. 3-pentyl which may also be referred to as ethylpropyl. 4Nbz and 4Abz represent 4-nitrobenzyl and 4-aminobenzyl. By 2-, 3- and 4-picolyl (Pic) are meant methylpyridine groups with the attachment being via a methylene in the 2-, 3- or 4-position.
- By Mor is meant morpholinyl,
- and by Tmo is meant thiomorpholinyl,
- Ahx is used to represent 4-aminocyclohexyl, and hEt is used to represent hydroxyethyl, i.e. —CH2CH2 OH. Aeb is used to represent 4-(2-amino-2-carboxyethyl)benzyl, i.e.
- By Pip is meant piperidinyl, and by 4-HyP and OxP are meant 4-hydroxypiperidinyl and 4-oxo-piperidinyl. By Ppz is meant piperazinyl. Ecp represents 4-ethylcarbamoylpiperazinyl; quaternary ammonium moieties, such as 4-dimethyl piperazinyl (Dmp) or other di-lower alkyl substitutions, may also be used. Substituted benzyl is typically 4-aminobenzyl, i.e.
- and by 2-Tzl is meant 2-thiazolyl, i.e.
- By Dor is meant δ-omithinyl where the side chain amino group of L-ornithine is connected by an amide bond to the C-terminus.
- D-Phe or substituted D-Phe is an example at the 1-position. The phenyl ring may be substituted at the 2-, 3- and/or 4-positions, and commonly substitutions by chlorine or fluorine at the 2 or 4-position are particular examples. The alpha-carbon atom may also be methylated. Other equivalent residues which resemble D-Phe may also be used, and these include D-Ala(cyclopentyl), D-Ala(thienyl), D-Tyr and D-Tic. The 2-position residue can also be D-Phe or substituted D-Phe with such substitutions including a substituent on the 4-position carbon of the phenyl ring or the 3- and 4-positions. Alternatively, D-alanine substituted by naphthyl can be used, as well as D-Trp and D-Tyr. The 3-position can be occupied by a residue such as D-Nle, D-Leu, D-CML, D-Hle, D-Met or D-Val; however, D-Ala(cyclopentyl) or D-Phe may also be used. D-Arg and D-Har, which may be substituted with diethyl, are examples for the 4-position; however, D-nArg and other equivalent residues may be used, such as D-Lys or D-Orn (either of which can have its omega-amino group alkylated as by isopropyl or have its α-carbon group methylated). Moreover, D-Dbu, D-4Amf (which is typically substituted with amidino), and D-His may also be used.
-
CHART OF ADDITIONAL FORMULA ABBREVIATIONS Abbreviation Definition D-Phe D-phenylalanine D-Tyr D-tyrosine D-Tic D-1,2,3,4-tetrahydroisoquinoline-3carboxylic acid D-Ala D-alanine D-1Na1 D-Alanine substituted by naphthyl on the beta carbon with the point of attachment at the 1-position on the naphthyl ring structure D-2Na1 D-Alanine substituted by naphthyl on the beta carbon with the point of attachment at the 2-position on the naphthyl ring structure D-Trp D-tryptophan D-Nle D-norleucine D-Leu D-leucine D-Hle D-homoleucine D-Met D-methionine D-Val D-valine D-Arg D-arginine D-Har D-homoarginine D-nArg D-norarginine D-Lys D-lysine D-Ily Isopropyl-D-lysine D-Arg(Et2) diethyl-D-arginine D-Har(Et2) diethyl-D-homoarginine D-Amf D-(NH2CH2)-Phenylalanine D-Gmf D-(CH2NHC(NH)NH2)-Phenylalanine D-Dbu Alpha, gamma-diamino butyric acid D-Orn D-ornithine D-Ior Isopropyl-D-ornithine Aeb 4-(2-amino-2-carboxyethyl)benzyl Ppz piperazinyl Pcp 4-phenyl carbamoyl piperazin-1-yl Aao 8-(acetylamino)-3,6-dioxaoct-1-yl Aoo 8-amino-3,6-dioxaoct-1-yl Hoh 6-(L-hydroorotylamino)-hex-1-yl; L-hydroorotic acid is C4N2H5(O)2—COOH Ghx 6-(D-gluconylamino)-hexyl Gao 6-(D-gluconylamino)-3,6-dioxaoct-1-yl D-4Fpa 4-fluoro-D-phenylalanine D-4Cpa 4-chloro-D-phenylalanine D-3,4Cpa 3,4-dichloro-D-phenylalanine D-CML Cαmethyl-D-Leucine D-Acp D-Ala(cyclopentyl) Mor Morpholinyl Tmo thiomorpholinyl Pip Piperidinyl 4-HyP 4-hydroxy piperidin-1-yl OxP 4-oxo-piperidin-1-yl Me Methyl Et Ethyl Pr Propyl Bu Butyl HEt Hydroxyethyl (i.e., —CH2CH2OH) Cyp Cyclopropyl Bzl Benzyl D-2Fpa 2-fluoro-D-phenylalanine D-Ala(2Thi) 2-thienyl-D-alanine 4Pic 4-picolyl Cαmethyl Methyl attached to the alpha carbon of an amino acid - In one embodiment, the invention provides a method of treating a mammal exhibiting insufficient or inadequate milk production or at risk of insufficient or inadequate milk production; wherein the method includes administering to the mammal an amount of a peripherally selective kappa opioid receptor agonist or salt thereof or prodrug thereof effective to treat the mammal, the peripherally selective kappa opioid receptor agonist or salt thereof or prodrug thereof being a peptide, or ionizes or is metabolized to form a peptide having the formula:
-
H-Xaa1-Xaa2-Xaa3-Xaa4-Q; and - wherein Xaa1 is (A)D-Phe, (Calpha Me)D-Phe, D-Tyr, D-Tic or D-Ala(cyclopentyl or thienyl), with A being H, NO2, F, Cl or CH3; Xaa2 is (A′)D-Phe, D-1Nal, D-2Nal, D-Tyr or D-Trp, with A′ being A or 3,4Cl2; Xaa3 is D-Nle, (B)D-Leu, D-Hle, D-Met, D-Val, D-Phe or D-Ala(cyclopentyl) with B being H or Calpha Me; Xaa4 is D-Arg, D-Har, D-nArg, D-Lys, D-Lys(Ipr), D-Arg(Et2), D-Har(Et2), D-Amf(G), D-Dbu, (B)D-Orn or D-Orn(Ipr), with G being H or amidino; and Q is NR1, R2, morpholinyl, thiomorpholinyl, (C)piperidinyl, piperazinyl, 4-mono- or 4,4-di-substituted piperazinyl or delta-ornithinyl, with R1 being lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, aminocyclohexyl, 2-thiazolyl, 2-picolyl, 3-picolyl or 4-picolyl, R2 being H or lower alkyl; and C being H, 4-hydroxy or 4-oxo. In a particular embodiment Xaa2 is D-Phe, Xaa3 is D-Nle and Xaa4 is D-Arg. In another embodiment Q is NHR1 and R1 is ethyl, propyl, butyl, cyclopropyl or cyclobutyl. In an alternative embodiment, Q is morpholinyl or thiomorpholinyl; or Q is NHR1 and R1 is 4-picolyl. In another embodiment, Xaal is D-Ala(2-thienyl); alternatively, Xaa1 is D-4FPhe and Xaa2 is D-4ClPhe. In still another embodiment, Xaa3 is D-Nle or D-Leu and Xaa4 is D-Orn or D-Amf(Amd). In another embodiment, Xaa2 is D-Phe, Xaa3 is D-Leu or D-CML and Xaa4 is D-Orn.
- The invention further provides a method of treating a mammal exhibiting insufficient or inadequate milk production or at risk of insufficient or inadequate milk production; wherein the method includes administering to the mammal an amount of a peripherally selective kappa opioid receptor agonist or salt thereof or prodrug thereof effective to treat the mammal, the peripherally selective kappa opioid receptor agonist or salt thereof or prodrug thereof being a peptide, or ionizes or is metabolized to form a peptide having the formula:
-
H-Xaa1-Xaa2-Xaa3-Xaa4-Q; and - wherein Xaa1 is D-Phe (unsubstituted or substituted by Calpha, Me, 2F, 4F or 4Cl) or D-Ala(cyclopentyl or thienyl); Xaa2 is (A′)D-Phe, D-1Nal, D-2Nal or D-Trp, with A′ being H, 4F, 4Cl, 4NO2 or 3,4Cl2; Xaa3 is D-Nle, D-Leu, D-CML, D-Met or D-Acp; Xaa4 is D-Arg, D-Arg(Et2), D-Lys, D-Ily, D-Har, D-Har(Et2), D-nArg, D-Orn, D-Ior, D-Dbu, D-Amf, and D-Amf(Amd); and Q is NR1R2, Mor, Tmo, Pip, 4-Hyp, OxP or Ppz, with R1 being Me, Et, Pr, Bu, hEt, Cyp, Bzl or 4-picolyl, and R2 being H or Et. In one embodiment, Xaa2 is D-Phe, Xaa3 is D-Nle and Xaa4 is D-Arg. In another embodiment, Q is NHR1 and R1 is ethyl, propyl, butyl, cyclopropyl or cyclobutyl. Alternatively, Q can be morpholinyl or thiomorpholinyl. In a further embodiment, Q is NHR1 and R1 is 4-picolyl. Alternatively, Q is NR1, R2 and R1 is ethyl and R2 is ethyl. In yet another embodiment, Xaa1 is D-Phe or D-Ala(2-thienyl) and Xaa2 is D-4ClPhe. In another embodiment, Xaa3 is D-Nle or D-Leu and Q is morpholinyl.
- In a particular embodiment, Xaa1 is D-Phe, D-4Fpa, D-2Fpa, D-Acp or D-Ala(2Thi); Xaa2 is (A)D-Phe, D-1Nal, D-2Nal or D-Trp, with A being 4F or 4Cl; Xaa3 is D-Nle, D-Met or D-Leu; Xaa4 is D-Arg, D-Har, D-nArg, D-Lys, D-Orn or D-Amf(Amd); and Q NHR1, Mor, Tmo, Pip or Ppz, with R1 being Et, Pr or 4Pic.
- In another particular embodiment, the peptide has the formula: H-D-Phe-D-Phe-D-Nle-D-Arg-NHEt, H-D-Phe-D-Phe-D-Nle-D-Arg-morpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NH-4-picolyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NHPr, H-D-Phe-D-Phe-D-Nle-D-Arg-thiomorpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-Net2, H-D-Phe-D-Phe-D-Nle-D-Arg-NHMe, H-D-Phe-D-Phe-D-Leu-D-Orn-morpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NHhEt, H-D-Phe-D-Phe-D-Nle-D-Arg-NH-cyclopropyl, H-D-Ala(2Thi)-D-4 Cpa-D-Leu-D-Arg-morpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-piperidinyl, H-D-Phe-D-Phe-D-Leu-D-Orn-NHEt, H-D-Phe-D-Phe-D-Leu-D-Lys-morpholinyl, or H-D-Phe-D-Phe-D-Nle-D-Arg-piperazinyl.
- Mammals exhibiting insufficient or inadequate milk production or at risk of insufficient or inadequate milk production can be treated by a method according to the present invention; the method includes administering to the mammal an amount of a peripherally selective kappa opioid receptor agonist or salt thereof or prodrug thereof effective to treat the mammal, wherein the administration includes intravenous, subcutaneous, intramuscular, intranasal, oral, or transdermal administration, such as for instance by an electrotransport device. In one embodiment of the method the electrotransport device delivers the peripherally selective kappa opioid receptor agonist through a body surface.
- In one particular aspect, the method includes: (a) providing a first electrode; (b) providing a second electrode; (c) providing a power source electrically connected to said first and said second electrodes; (d) providing at least one donor reservoir having the peripherally selective kappa opioid receptor agonist, wherein said donor reservoir is associated with said first or second electrode; and (e) delivering a therapeutically effective amount of said peripherally selective kappa opioid receptor agonist through said body surface.
- The peripherally selective kappa opioid receptor agonist can administered by any of these methods between about 1 microgram/kg of body weight to about 100 milligrams/kg of body weight of said mammal per hour, day, week or month. These methods of the invention delivering the peripherally selective kappa opioid receptor agonist administered can increase prolactin to levels greater than 10, 15, 20, 25, 50, 75, 100, 125, 150, 175, or 200 ng/ml serum above the baseline level of serum prolactin. These methods are particularly advantageous for the treatment of female animal subjects (particularly a mammal, such as for instance a primate, ungulate, canine or feline) or human patients, especially pregnant females or females that have given birth to an offspring within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 12-24, 24-26, 36-48 hours, days, weeks, or months. Suitable primates include an ape, gorilla, monkey, macaque, chimpanzee, lemur or orangutan. Suitable ungulates include a cow, pig, sheep, goat or horse.
- The invention further provides a method of treating a mammal exhibiting an insufficient or inadequate amount of milk production or at risk of exhibiting an insufficient or inadequate amount of milk production, wherein the method includes administering to the subject prior to or after childbirth an amount of a peripherally selective kappa opioid receptor agonist in conjunction with a lactation enhancer, such as for instance, oxitocin or a stabilizer effective to treat the mammal. The oxytocin can be administered within one or more hours, days, or weeks following childbirth. In a particular embodiment, the lactation enhancer or stabilizer is administered within one or more hours, days, or weeks following childbirth.
- This invention is further illustrated by the following examples which in no way should be construed as being further limiting. The contents of all cited references (including literature references, issued patents, published patent applications, and co pending patent applications) cited throughout this application are hereby expressly incorporated by reference.
- The safety, tolerability, pharmacokinetics, and prolactin-elevating activity of ascending single intravenous (IV) doses of one of the compounds of the instant invention, D-phenylalanyl-D-phenylalanyl-D-norleucyl-N-(4-pyridinylmethyl)-D-argininamide, acetate salt, herein designated as CR665, was assessed in healthy male and surgically sterile female human subjects following 1-hour or 5-minute infusions. CR665, also referenced in the literature as FE 200665, is a peripherally selective kappa opioid receptor agonist; see U.S. Pat. No. 5,965,701; also Riviere P. J.-M. et al. Novel D-amino acid tetrapeptides demonstrate unprecedented k-opioid receptor selectivity and antinociception. 30th Int. Narcotics Res. Conf. (INRC) 1999, Saratoga Springs, N.Y., Jul. 10-12, 1999; Wisniewski K et al. Long acting, selective, peripheral kappa agonists. 26th European Peptide Symposium, Montpilier, France, Sep. 11-15, 2000; Binder W et al. Analgesic and antiinflammatory effects of two novel kappa-opioid peptides. Anesthesiology. 94:1034-44, 2001; Riviere PJ. Peripheral kappa-opioid receptor agonists for visceral pain. Br J Pharmacol. 141:1331-4, 2004).
- This clinical study was conducted as a double blind, placebo controlled, ascending single intravenous (IV) dose, sequential group study. The results reported herein were obtained with 54 male and female human subjects in fifteen groups as shown in Table X below. This study was double blind and placebo controlled in order to avoid bias in the collection and evaluation of data during its conduct. Placebo was chosen as the control treatment to assess whether any observed effects were treatment related or simply reflected the study conditions. In each group, subjects received CR665 or placebo. Doses were administered as a single constant rate IV infusion over 1 hour (part A) or 5 minutes (part B) on the morning of
Day 1. Doses were administered in an escalating manner following satisfactory review of the safety data and pharmacokinetic data from the lower dose levels. There was a minimum of 6 days between dose escalations to allow sufficient time for an adequate safety review. - Dose levels were as shown in Table 1:
-
TABLE 1 Treatments Infusion Part Group Population Treatment duration A A1 Males 0.015 mg/kg/ placebo 1 hour A2 Males 0.03 mg/kg/ placebo 1 hour A3 Males 0.06 mg/kg/ placebo 1 hour A4 Males 0.12 mg/kg/ placebo 1 hour A5 Males 0.24 mg/kg/ placebo 1 hour A6 Males 0.48 mg/kg/ placebo 1 hour A7 Males 0.36 mg/kg/ placebo 1 hour A8 Males 0.48 mg/kg/ placebo 1 hour A9 Females 0.24 mg/kg/ placebo 1 hour A10 Females 0.42 mg/kg/ placebo 1 hour A12 Males 0.42 mg/kg/ placebo 1 hour B B1 Males 0.03 mg/kg/placebo 5 minutes B2 Females 0.06 mg/kg/placebo 5 minutes B3 Males 0.06 mg/kg/placebo 5 minutes B4 Males 0.09 mg/kg/placebo 5 minutes - CR665 was prepared according to Good Manufacturing Practice (GMP) standards and provided as bulk supply in 2 mL glass vials, each containing CR665 solution (1.1 mL at a concentration of 10 mg/mL [free base] in isotonic 0.04 M acetate buffer, pH 4.5). Placebo solution (isotonic 0.04°M acetate buffer, pH 4.5) for IV administration, of identical appearance, i.e., a clear, colorless, solution, was also prepared. The TV dose solutions were stored at 2° C. to 8° C.
- The individual intravenous dose for each subject was prepared from bulk supplies (2 mL vials containing 1.1 mL of CR665 or placebo solution). For each dose preparation, an appropriate volume of CR665 solution (10 mg/mL) or placebo solution was withdrawn from one or more vials using a syringe, and injected into a 60 mL Plastipak polypropylene syringe (Beckton Dickinson S.A., Spain) containing an appropriate volume of sterile NaCl buffer.
- For the 1 hour infusions, the final volume prepared was 40 mL, of which 30 mL was infused. The dose calculation was as follows:
-
- Table 2 provides some example dilutions, based on a 70 kg body weight.
-
TABLE 2 CR665 CR665 dose dose to be infused to be Concentration CR665 NaCl Dose for a 70 kg prepared of dose solutiona buffer level person (mg/ solution volume volume (mg/kg) (mg/30 mL) 40 mL) (mg/mL) (mL) (mL) 0.015 1.05 1.40 0.04 0.14 39.86 0.03 2.10 2.80 0.07 0.28 39.72 0.06 4.20 5.60 0.14 0.56 39.44 0.12 8.40 11.20 0.28 1.12 38.88 0.24 16.80 22.40 0.56 2.24 37.76 a Concentration 10 mg/mL - The dose was administered via a cannula inserted into a suitable vein of the forearm in the non dominant arm of the subject. The dose was infused over a 1 hour period in the morning between 07:00 and 10:30, using an IMED Gemini PC I infusion pump operating at a constant rate of 0.5 ml/min (30 mL/h). A total of 30 mL of dosing solution (from 40 mL in the syringe) was administered, and the subjects remained supine throughout the infusion.
- From 24 hours after the start of the infusion, meals were provided at appropriate times on each day. Other than the fluid restrictions on
Day 1, water was freely available at all times. The volume of fluid consumed up to 24 hours after the start of the infusion was recorded as part of the fluid balance assessment. Subjects fasted from food and beverages (other than water) from 22:00 onDay 1, until the clinical laboratory samples had been taken on the following day, and for at least 6 hours prior to the follow up visit. - On arrival at the clinical study center on Day −1, pre dose assessments were performed, including testing a urine sample for the presence of illicit drugs, administering an alcohol breath test, and the recording of body weight (in underclothes). Subjects then commenced a 24 hour urine collection for assessment of creatinine clearance and fluid balance. Vitals signs and 12 lead ECG were also assessed, and all subjects received a physical examination.
- The condition of each subject was monitored throughout the study. In addition, any signs or symptoms were observed and elicited by open questioning, such as “How have you been feeling since you were last asked?” at the following times for each part of the study: Pre dose, 0.5, 1, 3, 12, 24, 36 and 48 hours after the start of the infusion (up to 24 hours only for Groups A1 to A4), and at Follow up assessment.
- Subjects were also encouraged to spontaneously report adverse events occurring at any other time during the study. Any adverse events and remedial action required were to be recorded for each subject. The nature, time of onset, duration and severity were documented, together with the Project Physician's opinion of the relationship to drug administration.
- The condition of the dosing cannula site for each subject was monitored for erythema, pruritus and swelling at the following times: Pre dose, 0.5, 1, 2 and 24 hours after the start of the infusion. Subjects were also encouraged to spontaneously report adverse events relating to the infusion site at any other time during the study. Any adverse events and observations relating to the infusion site and remedial action required were to be recorded for each subject. The nature, time of onset, duration, and severity were to be documented, together with the Project Physician's opinion of the relationship to drug administration.
- Supine and standing blood pressure, supine pulse rate and oral body temperature were measured in duplicate at the following times:
Day 1; Pre dose, 15 minutes (Part B only), 30 minutes, 55 minutes, 1.5, 2, 2.5, 3, 4, 8, 12, 24 and 48 hours after the start of the infusion (up to 24 hours only for Groups A1 to A4); and at Follow up visit. Supine vital signs only were measured during the infusion period. Pre dose blood pressure and pulse rate were measured in triplicate at approximately 2 minute intervals. The median value was used as the baseline value in the data analysis. All subsequent measurements were performed singly, but repeated in duplicate if outside the relevant clinical reference ranges. If repeated, the median of the three values were used in the data analysis. Blood pressure and pulse rate were measured using automated Critikon Dinamap™ PRO400 monitors. Subjects were required to be supine for at least 5 minutes before blood pressure and pulse rate measurements. Standing blood pressure and pulse rate were then measured singly after the subject had been sitting for approximately 1 minute and then standing for approximately 2 minutes. Oral body temperature was measured singly using an Omron digital thermometer. To assess drug effects on cardiovascular function, a 12 lead resting ECG with a 10 second rhythm strip was recorded on a Marquette MAC5000 ECG machine at the following times, after the subject has been supine for at least 5 minutes:Day 1; Pre dose, 50 minutes, 2, 4, 8, 24 and 48 hours after the start of the infusion (up to 24 hours only for Groups A1 to A4); and at the follow up visit. The ECG machine computed the PR, QT and QTc intervals, QRS duration, and heart rate. The QT interval was corrected for heart rate (QTc) using Bazett's formula. For continuous ECG measurements, continuous cardiac Holter monitoring of each subject, using Reynolds Tracker II Bolter monitors, was performed from 1 hour prior to until 4 hours after the start of the infusion. Blood and urine samples were collected, after at least a 6 hour fast, for clinical laboratory evaluations at the following times during the study: Pre dose and 24 hours after the start of the infusion; and at the follow up visit. - The following evaluations were performed, as shown in Table 3.
-
TABLE 3 Units Serum biochemistry: Aspartate aminotransferase (AST) IU/L Alanine aminotransferase (ALT) IU/L Alkaline phosphatase IU/L Gamma-glutamyl transferase (GGT) IU/L Sodium mmol/L Potassium mmol/L Chloride mmol/L Calcium mmol/L Inorganic phosphate mmol/L Glucose mmol/L Urea mmol/L Bilirubin (totala) μmol/L Creatinine μmol/L Total protein g/L Albumin g/L Urinalysis: Microscopic examination + Specific gravity NA pH NA Protein + Glucose + Ketones + Blood + Urobilinogen + Hematology: White blood cell count (WBC) 109/L Red blood cell count (RBC) 1012/L Haemoglobin g/dL Haematocrit (PCV) % Mean cell volume (MCV) fL Mean cell haemoglobin (MCH) pg MCH concentration (MCHC) g/dL Platelet count 109/L Differential WBC 109/L & % Serology: Hepatitis B surface antigen (HBsAg)b neg/pos Hepatitis C antibodyb neg/pos HIV antibodiesb neg/pos aDirect bilirubin analyzed only if total bilirubin is elevated bAnalyzed at screening only Neg = Negative Pos = Positive - Blood samples (2.5 mL) were collected for evaluation of serum prolactin at the following times: Pre dose (in triplicate, with at least a 15 minute interval between each of the triplicate pre dose samples), 15 minutes, 30 minutes, 45 minutes, 1 hour (immediately prior to the end of infusion), 1 hour 5 minutes, 1
hour 10 minutes, 1 hour 15 minutes, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 hours after the start of the infusion (18 samples). - Plasma and urine samples for the analysis of CR665 and N oxide metabolite were prepared by solid phase extraction. The centrifuged eluates were quantified by liquid chromatography with tandem mass spectrometric detection (LC MS/MS). The lower limit of quantification was 1 ng/mL.
- After collection of urine samples, following removal of the aliquots for drug assay and/or urinalysis, urine was pooled over the following time intervals: 24 to 0 hours and 0 to 24 hours after the start of the infusion. A 10 mL aliquot was removed from the each pooled collection for determination of urinary creatinine.
- An assessment of fluid balance (made by comparison of volume of fluid consumed and volume of fluid excreted) was made over the following periods: 24 to 0 hours and 0 to 24 hours after the start of the infusion. During these periods, the volume of fluid consumed and the volume of urine excreted was recorded.
- A full physical examination, including a neurological examination, was performed at the following times: Discharge (
Day 2 or 3) and at Follow up visit. - For pharmacokinetic assessments, blood samples (1×3 mL) were taken from the contralateral forearm vein(s) at the following times: Pre-dose, 15 minutes, 30 minutes, 45 minutes, 1 hour (immediately prior to the end of infusion), 1 hour 5 minutes, 1
hour 10 minutes, 1 hour 15 minutes, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours after the start of the infusion). An indwelling cannula (Venflon®; BOC Ohmeda AB, Sweden) was used for all blood collection pre-dose and up to at least 12 hours after the start of the infusion. Otherwise, samples were collected using venipuncture. Blood samples were collected into pre-chilled 3 mL K3EDTA Vacutainer™ tubes (Becton Dickinson UK, Ltd., Oxford) and, after mixing, were placed in a cool box containing crushed ice/water. The samples were centrifuged, within 30 minutes of collection, at 1500 g for 10 minutes at approximately 4° C. For each sample, the separated plasma was transferred into two 5 mL suitably labeled polypropylene, tubes, and stored immediately at approximately −20° C. Plasma samples were analyzed for CR665 using liquid chromatography with tandem mass spectrometric detection. - Urine was collected into standard weight polyethylene containers over the following time intervals: Pre dose (−24 to 0), 0 to 4, 4 to 8, 8 to 12, 12 to 24 and 24 to 48 hours after the start of the infusion. During each collection period, the containers were stored in a refrigerator at 2 to 8° C. The weight (g) of each collection was recorded prior to removal of two sub samples (each approximately 4 mL) into suitably labeled polypropylene containers, which were stored within 2 hours of collection, at approximately −20° C. Additional aliquots (1×100 mL per collection period) were stored for possible future analyses. Any remaining urine from post close collection intervals was pooled with the rest of the urine collected during the 0 to 24 hour collection period, for analysis of creatinine clearance. A nominal value for specific gravity of 1.018 was used to calculate urine volume.
- The pharmacokinetic analysis was conducted using WinNonlin Enterprise Version 4.0.1.
- Pharmacokinetic parameters were determined from the plasma and urine concentrations of CR665 and the N-oxide metabolite using non compartmental procedures. The pharmacokinetic parameters determined are presented in Table 4 below.
-
TABLE 4 Pharmacokinetic Parameters Determined for CR665 and the N-Oxide Metabolite Parameter Definition AUC0-t Area under the plasma concentration-time curve from time zero up to the last quantifiable concentration AUC0-∞ Area under the plasma concentration-time curve from time zero to infinity % AUCex Percentage of AUC that is due to extrapolation from tz to infinity Cmax Maximum observed plasma concentration Cinf Plasma concentration at end of the IV infusion tmax Time of maximum observed plasma concentration tz Time of last quantifiable plasma concentration λz Apparent plasma terminal elimination rate constant t1/2 Apparent plasma terminal elimination half-life MRTint Intrinsic mean residence time CL Total plasma clearance (CR665 only) Vz Apparent volume of distribution during the terminal phase (CR665 only) Vss Apparent volume of distribution at steady-state (CR665 only) MRAUC Metabolic ratio based on AUC (N-oxide metabolite only) MRCmax Metabolic ratio based on Cmax (N-oxide metabolite only) Ae Amount of drug excreted in urine fe Percentage of dose excreted in urine CLR Renal clearance - Dose and body weight normalized values (norm) were determined for AUC0-t, AUC0-∞, Cinf and Cmax. Body weight normalized values [norm] were determined for Va, Vss, CL and CLR.
- The pharmacokinetic analysis was conducted using model independent methods as implemented in WinNonlin software, based on plasma concentrations of CR665 from those subjects who have received CR665 and have evaluable plasma concentration-time profiles.
- The following plasma pharmacokinetic parameters were determined for CR665:
-
- Cmax Maximum plasma concentration
- tmax Time of maximum plasma concentration
- t1/2z Terminal half-life=ln(2)/λz
- AUC0-t Area under the plasma concentration-time curve from time zero to time t (time of last quantifiable plasma concentration)
- AUCinf Area under the plasma concentration-time curve from time zero to infinity calculated as [AUC0-t+(Clast/λz)] where Clast is the estimated concentration at the last quantifiable concentration curve.
- λz Terminal-phase rate constant, also known as Kel
- CL Total body clearance=Dose/AUCinf
- Vz Volume of distribution based on terminal phase calculated as
-
Vz/F=Dose/λz *AUC iff - Individual elapsed sampling times were used in the pharmacokinetic analysis. Cmax and tmax were obtained directly from the experimental observations. For the purpose of calculating AUC0-t, when two consecutive plasma concentrations below the lower limit of quantification (LLOQ) were encountered after tmax, all subsequent values were excluded from the analysis. The exponential rate constant of the terminal-phase, λz, was estimated by linear regression of the log concentration-time data associated with the terminal phase of the plasma concentration-time profile. The number of data points included in the regression was determined by visual inspection. A minimum of 3 data points in the terminal phase, excluding Cmax, was required to estimate λz.
- An assessment of dose-proportionality of the pharmacokinetics of CR665 was also performed. Log-transformed AUG0-t, AUCinf and Cmax were derived and a model of the form:
-
Log(parameter)=Intercept+β*Log(Dose)+Error - where dose is a fixed term was fitted to assess a between-subject estimate of the slope in order to assess dose-proportionality. A point estimate of the slope β, with 90% confidence intervals, provides a plausible range for which the true slope occurs. The interpretation of the slope is such that a conclusion of dose-proportionality for AUG0-t, AUCinf and Cmax of CR665 will be made if the 90% CI for the slope contains the
value 1. - The pharmacodynamic analysis was conducted using WinNonlin Enterprise Version 4.0.1 (Pharsight Corporation, Mountain View, Calif., USA). The following pharmacodynamic parameters were calculated from the serum concentrations of prolactin:
-
- Change from baseline (mean of triplicate pre-dose values) at each sampling time
- Maximum observed change from baseline (Cmax)
- Area under the change from baseline time curve from 0 to 12 hours (AUC0-12 h)
- This study was conducted under a MHRA Clinical Trials Authorization (CTA) in accordance with: (1) the relevant articles of the Declaration of Helsinki as adopted by the 18th World Medical Assembly in 1964 and as revised in Tokyo (1975), Venice (1983), Hong Kong (1989), South Africa (1996) and Scotland (2000); and (2) the ICH Good Clinical Practices (GCP) consolidated guidelines adopted in the EU by CPMP, July 1996, issued as CPMP/ICH/135/95.
- All 54 subjects completed the treatment period with no severe or serious adverse events. In particular, even at the highest dose levels, there were no signs of the more typical CNS symptoms (hallucinations or dysphoria) associated with intolerable dose levels of previously tested kappa opioid receptor agonists. For the 12-lead ECG evaluations, there were no treatment related trends, significant clinical changes, or abnormalities in the morphology of the 12 lead ECG. Similarly, for the clinical laboratory evaluations, there were no treatment related trends or significant clinical findings in serum biochemistry, hematology, or urinalysis parameters. Physical examination of the subjects also revealed no treatment related findings.
- In Parts A and B of the study, there were no treatment or dose related trends in mean supine and standing systolic and diastolic blood pressure, supine and standing pulse rate or oral body temperature. No apparent treatment or dose related trends in the 12 lead ECG parameters were noted in Parts A and B. In addition, there were no clinically important findings in the morphology of the 12 lead ECGs for individual subjects at each dose level of CR665. There was no evidence of prolongation of QTc interval (Bazett's and Friedericia's corrected) at each dose level of CR665 in male and female subjects.
- For Parts A and B, there were no clinically important changes in creatinine clearance, estimated from serum creatinine, for any subject during the study. The mean creatinine clearance was generally similar prior to dosing and at 24 hours after dosing for each dose level of CR665 and placebo. There were no apparent treatment or dose related trends in fluid balance (urine excreted−fluid consumed) over the 0 to 24 hour period after the start of the infusion. However, an increase in the volume of urine excreted over the first 4 hours after the start of the infusion was observed at each dose level of CR655 compared to placebo in male and female subjects for Parts A and B of the study.
- The administration of single IV doses of CR665 caused a rapid and marked increase in serum concentrations of prolactin across all dose levels in male and female subjects. Changes from baseline (pre dose) in serum concentrations of prolactin following 1-hour and 5-minute infusions of placebo and CR665 in male and female subjects are shown in
FIGS. 1 to 3 : - The derived pharmacodynamic parameters for serum prolactin following 1-hour and 5-minute infusions of placebo and CR665 in male and female subjects are summarized in Tables 5 to 7:
-
TABLE 5 Summary of the Pharmacodynamic Parameters of Serum Prolactin (Changes from Baseline) Following a 1 hour IV Infusion in Male Subjects (Part A) Dose of (mg/kg) Placebo 0.015 0.03 0.06 0.12 0.24 0.36 0.42 0.48 [males] [males] [males] [males] [males] [males] [males] [males] [males] Parameter (N = 17) (N = 4) (N = 4) (N = 4) (N = 4) (N = 4) (N = 4) (N = 4) (N = 8) AUC0-12 h 0.760 30.8 57.4 43.6 89.5 119 140 132 131 (ng · h/mL) (27.5) (87.6) (30.3) (32.2) (38.6) (22.3) (40.0) (51.5) (74.5) Cmax 4.61 22.2 18.8 25.3 39.3 36.3 45.5 44.2 47.2 (ng/mL) (3.44) (6.44) (1.47) (6.41) (13.9) (17.3) (16.9) (10.8) (27.4) Arithmetic mean (SD) data are presented N = Number of subjects studied -
TABLE 6 Summary of the Pharmacodynamic Parameters of Serum Prolactin (Changes from Baseline) Following a 1 hour IV Infusion in Female Subjects (Part A) Dose of (mg/kg) Placebo 0.24 [females] [females] Parameter (N = 3) (N = 3) AUC0-12 h 19.7 209 (ng · h/mL) (23.5) (21.1) Cmax 3.67 68.2 (ng/mL) (2.27) (14.3) Arithmetic mean (SD) data are presented N = Number of subjects studied -
TABLE 7 Summary of the Pharmacodynamic Parameters of Serum Prolactin (Changes from Baseline) Following a 5 minute IV Infusion in Male and Female Subjects (Part B) Dose of (mg/kg) Placebo 0.03 0.06 0.09 0.06 [males] [males] [males] [males] [females] Parameter (N = 5) (N = 4) (N = 4) (N = 4) (N = 4) AUC0-12 h −0.876 24.3 74.3 68.5 96.8 (ng · h/mL) (34.1) (35.4) (44.2) (13.5) (32.9) Cmax 4.08 33.6 42.0 37.1 32.3 (ng/mL) (3.63) (14.3) (22.8) (13.3) (14.8) Arithmetic mean (SD) data are presented N = Number of subjects studied - In Part A, following 1-hour infusions of 0.015 to 0.48 mg/kg CR665 in male subjects, there was a rapid and marked increase in serum prolactin concentrations. At each dose level, maximum serum prolactin concentrations generally occurred at 1 hour after the start of the infusion, i.e. at the end of the infusion. There was an apparent dose-related increase in mean values for Cmax (maximum changes from baseline in serum prolactin) up to the 0.36 mg/kg dose level. Mean Cmax values were generally similar at the 0.36, 0.42 and 0.48 mg/kg dose levels, with maximum serum prolactin levels being approximately 5- to 6-fold higher than baseline (pre-dose) across these dose levels. Mean values for AUC0-12 h (changes from baseline) increased up to 0.36 mg/kg, and thereafter were generally similar over the 0.36 to 0.48 mg/kg dose range. Following maximum concentrations of prolactin, there was a dose-related decrease to baseline levels. Mean values had fallen to close to baseline values by 8 hours at the 0.36, 0.42 and 0.48 mg/kg dose levels.
- In Part A, following 1 hour infusions of 0.24 mg/kg CR665 in female subjects, maximum serum prolactin concentrations occurred at 1 hour after the start of the infusion. The mean Cmax values (change from baseline) in females were higher than in male subjects, with maximum serum prolactin levels being approximately 12-fold greater than baseline (pre dose) in females.
- In Part B, following 5-minute infusions of 0.03 to 0.09 mg/kg CR665 in male subjects, maximum serum prolactin concentrations occurred at 30 minutes after the start of the infusion, i.e., 25 minutes after the end of the infusion. Mean Cmax values were generally similar at the 0.03, 0.06 and 0.09 mg/kg dose levels, with maximum serum prolactin levels being approximately 4- to 6-fold higher than baseline (pre dose) across these dose levels. In female subjects, maximum serum prolactin concentrations occurred at 0.5 to 1 hour after the start of the 5-minute infusion of 0.06 mg/kg CR665. The mean Cmax value in females was similar to male subjects, with maximum serum prolactin levels being approximately 4-fold greater than baseline (pre dose) in females.
- The plasma concentrations of CR665 following a 1 hour infusion in male subjects are shown in
FIGS. 4 and 5 . - The pharmacokinetic parameters of CR665 following a 1-hour infusion in male subjects are summarized in Table 8.
-
TABLE 8 Summary of the Pharmacokinetic Parameters for CR665 Following a 1 hour IV Infusion in Male Subjects (Part A) Dose of (mg/kg) [males] 0.015 0.03 0.06 0.12 0.24 0.36 0.42 0.48 Parameter (N = 4) (N = 4) (N = 4) (N = 4) (N = 4) (N = 4) (N = 4) (N = 8) AUC0-t 30.0 70.0 129 267 474 808 1080 1120 (ng · h/mL) (20.3) (14.2) (30.2) (7.17) (10.4) (8.39) (17.4) (20.5) AUC0-∞ 31.4 72.5 132 270 478 812 1084 1125 (ng · h/mL) (21.7) (15.5) (29.8) (7.11) (10.5) (8.37) (17.5) (20.4) Cmax 27.8 65.3 119 231 431 779 943 982 (ng/mL) (15.2) (13.7) (24.8) (5.87) (8.30) (10.1) (13.7) (15.7) tmax a 1.00 1.00 0.875 0.750 1.00 1.00 1.00 0.875 (h) (0.750-1.02) (1.00-1.00) (0.733-1.35) (0.750-1.00) (1.00-1.00) (0.767-1.00) (0.750-1.00) (0.750-1.00) AUC0-t 1979 2349 2161 2232 1979 2252 2573 2333 (norm) (20.5) (14.6) (30.1) (7.06) (10.2) (8.40) (17.0) (20.5) AUC0-∞ 2072 2430 2201 2257 1994 2263 2582 2344 (norm) (22.0) (16.0) (29.7) (7.00) (10.3) (8.38) (17.1) (20.5) Cmax 1837 2189 1991 1932 1797 2170 2248 2046 (norm) (15.1) (13.8) (24.7) (5.86) (8.12) (10.1) (13.2) (15.9) t1/2 0.691 0.732 0.728 1.65 1.37 1.64 1.78 1.87 (h) (73.2) (50.0) (14.4) (24.0) (17.6) (21.0) (41.8) (36.4) MRTint 0.512 0.510 0.563 0.723 0.614 0.623 0.618 0.649 (h) (43.5) (35.8) (25.7) (23.1) (15.6) (19.8) (17.5) (20.8) CL 560 538 564 533 629 569 504 576 (mL/min) (15.2) (16.0) (17.8) (8.71) (6.47) (11.5) (21.3) (18.6) Vz 33.5 34.1 35.5 75.9 74.6 80.6 77.9 93.3 (L) (60.2) (42.2) (7.44) (20.9) (15.7) (13.3) (22.3) (39.1) Vss 17.2 16.5 19.0 23.1 23.2 21.2 18.7 22.4 (L) (35.4) (31.3) (32.1) (22.3) (18.0) (16.0) (8.42) (20.3) Geometric mean (CV %) data are presented aMedian (min − max) N = Number of subjects studied (norm) = Normalized for dose and body weight (mg/kg) - During the TV infusion of CR665 at dose levels of 0.015 to 0.48 mg/kg in male subjects, plasma concentrations increased rapidly, with maximum concentrations generally occurring at the end of the 1 hour infusion. Plasma concentrations of CR665 were generally similar at 45 minutes and 1 hour after the start of the infusion for individual subjects at each dose level.
- Following the end of the IV infusion, plasma concentrations of CR665 appeared to decline in an essentially biphasic manner with the start of the elimination phase occurring between 1.25 and 6.0 hours after the start of the infusion.
- The mean apparent elimination half life was relatively constant in the 0.015 to 0.06: mg/kg dose range, at about 0.7 hours, but became longer across the 0.12 to 0.48 mg/kg dose range, varying from 1.4 to 1.9 hours, with a trend toward longer half life values at higher doses. For individual subjects across the 0.12 to 0.48 mg/kg dose range, the apparent elimination half life ranged from 1.2 to 3.0 hours. This apparent increase in half life at higher dose levels is consistent with plasma concentrations of CR665 being quantifiable for a longer period of time at the higher dose levels, revealing more of true terminal elimination phase. As a result, statistical analysis showed that the elimination half life for CR665 was dose dependent over the entire dose range.
- AUC0-∞ and Cmax generally appeared to increase in a dose-proportional manner over the dose range of 0.015 to 0.48 mg/kg. This observation was confirmed by statistical analysis, with the estimates of the slopes (95% CI) from the regression analysis for AUC0-∞ and Cmax being 1.02 (0.978 to 1.06) and 1.02 (0.984 to 1.05).
FIG. 6 illustrates the dose-proportional increase in AUC0-∞ for CR665 over the dose range of 0.015 to 0.48 mg/kg. - The dose proportionality of the increase in AUC was found to be almost perfectly linear, as shown in
FIG. 6 , with an R2 value of 0.98, meaning that, for this data set, 98% of the variation in systemic exposure to CR665 is due to variation in the administered dose of CR665. The importance of this observation is that it enables the practitioner to predict, with a high degree of accuracy, what drug exposures will occur with a given dose of drug. In fact, one skilled in the art can use this information, together with the calculated pharmacokinetic parameters of the drug (see Table 6), to accurately estimate the plasma levels of drug that would result from intravenous infusions of different doses, at what time a steady state concentration of drug would be achieved, and how to design individualized dosage regimens to achieve steady state drug concentrations for a particular patient (Bauer, L. A. Applied Clinical Pharmacokinetics, Chap. 2, “Clinical pharmacokinetic equations and calculations”, pp. 26 49, 2001). Since controlled release formulations (e.g., microspheres) and devices (e.g., for electrotransport) are intended to provide prolonged steady state drug concentrations, the skilled practitioner utilizes this pharmacokinetic information to define the useful operating characteristics of modes of drug delivery. - Statistical analysis showed that total plasma clearance of CR665 (CL) was dose-independent; however MRTint and the volume of distribution (Vz and Vss) were found to be dose-dependent. This was due to the observed change in the elimination rate constant (λz), which was probably due to the fact that the CR665 was quantifiable for a longer period of time, post-injection, at the higher dose levels, rather than true dose-dependency in the kinetics of CR665.
- Geometric mean plasma concentrations of CR665 following a 1-hour infusion of 0.24 mg CR665 in female subjects are summarized in
FIGS. 7 and 8 . - Arithmetic mean plasma concentrations of CR665 following a 1-hour infusion of 0.24 mg/kg CR665 in male and female subjects are summarized in
FIG. 9 . - The pharmacokinetic parameters of CR665 following a 1-hour infusion of 0.24 mg/kg CR665 in male and female subjects are summarized in Table 9.
-
TABLE 9 Summary of the Pharmacokinetic Parameters for CR665 Following a 1-hour IV Infusion of 0.24 mg/kg CR665 in Male and Female Subjects (Part A) 0.24 mg/kg Males Females Parameter (N = 4) (N = 3) AUC0-t 474 440 (ng · h/mL) (10.4) (10.2) AUC0-∞ 478 442 (ng · h/mL) (10.5) (10.1) Cmax 431 384 (ng/mL) (8.30) (3.03) tmax a 1.00 0.750 (h) (1.00-1.00) (0.750-1.00) AUC0-t 1979 1846 (norm) (10.2) (9.71) AUC0-∞ 1994 1855 (norm) (10.3) (9.65) Cmax 1797 1612 (norm) (8.12) (2.33) t1/2 1.37 1.16 (h) (17.6) (15.9) MRTint 0.614 0.515 (h) (15.6) (12.9) CL 629 557 (mL/min) (6.47) (9.21) Vz 74.6 55.7 (L) (15.7) (12.4) Vss 23.2 17.2 (L) (18.0) (13.1) Geometric mean (CV %) data are presented aMedian (min-max) N = Number of subjects studied (norm) = Normalized for dose and body weight (mg/kg) - Following administration of 0.24 mg/kg CR665 in female subjects, maximum plasma concentrations were obtained at a similar time to those observed in males, i.e., close to the end of the IV infusion. Thereafter, the disposition kinetics of CR655 were similar in male and female subjects, with a mean terminal elimination half-life of approximately 1.2 to 1.4 hours. At the 0.24 mg/kg dose level, mean values for AUC0-∞, AUC0-∞ (norm), Cmax and Cmax (norm) were generally similar in male and female subjects. The between-subject variability for AUC0-∞ and Cmax was low and similar in male and female subjects at the 0.24 mg/kg dose level. These findings are important because they confirm the predictability of the pharmacokinetics of CR665, which assists the skilled practitioner in the design of alternative dosing regimens that are intended to achieve particular plasma levels of drug over time.
- The urinary excretion of CR665 following a 1-hour infusion of 0.24 mg/kg CR665 in male and female subjects is summarized in Table 10.
-
TABLE 10 Summary of the Urinary Excretion of CR665 Following a 1 hour IV Infusion of 0.24 mg/kg CR665 in Male and Female Subjects (Part A) 0.24 mg/kg Males Females Parameter (N = 4) (N = 3) Ae0-24 h 631 446 (μg) (39.1) (30.0) fe0-24 h 3.50 3.02 (%) (26.2) (23.2) CLR 0-24 h 22.0 16.8 (mL/min) (27.9) (22.7) Geometric mean (CV %) data are presented N = Number of subjects studied - The fraction of the dose excreted in the urine as unchanged drug was low in female subjects, and similar to that seen for male subjects.
- For the Part B studies, five minute infusion dosing protocols were designed using conventional pharmacokinetic calculations (e.g., Bauer, L. A. Applied Clinical Pharmacokinetics, Chap. 2, “Clinical pharmacokinetic equations and calculations”, pp. 26 49, 2001), based on the results obtained in the one hour infusion study (Part A). Doses were calculated to produce systemic exposures to CR665 similar to those seen in the one hour infusion study
- Plasma concentrations of CR665 following a 5-minute infusion in male and female subjects are shown in
FIGS. 10 and 11 . - The pharmacokinetic parameters of CR665 following a 5-minute infusion in male and female subjects are summarized in Table 11.
-
TABLE 11 Summary of the Pharmacokinetic Parameters for CR665 Following a 5-minute IV Infusion in Male and Female Subjects (Part B) Dose of (mg/kg) 0.03 0.06 0.09 0.06 [males] [males] [males] [females] Parameter (N = 3) (N = 4) (N = 4) (N = 3) AUC0-t 65.9 139 209 120 (ng · h/mL) (12.6) (15.8) (16.2) (9.29) AUC0-∞ 68.4 142 213 122 (ng · h/mL) (11.8) (16.3) (16.4) (8.79) Cmax 233 624 783 520 (ng/mL) (14.5) (32.2) (19.6) (18.8) tmax a 0.0833 0.0833 0.0833 0.0833 (h) (0.0833-0.100) (0.0833-0.0833) (0.0833-0.0833) (0.0833-0.0833) AUC0-t 2192 2327 2318 2013 (norm) (12.3) (16.0) (16.1) (8.92) AUC0-∞ 2273 2372 2369 2044 (norm) (11.6) (16.5) (16.2) (8.43) Cmax 7751 10418 8701 8716 (norm) (14.4) (32.5) (19.8) (18.4) t1/2 1.31 1.00 1.14 0.833 (h) (18.3) (13.0) (23.9) (22.4) MRTint 0.615 0.502 0.537 0.419 (h) (4.48) (26.3) (21.0) (24.2) CL 473 553 575 544 (mL/min) (7.06) (15.5) (14.3) (9.47) Vz 53.6 48.0 56.7 39.2 (L) (14.0) (13.4) (33.5) (21.5) Vss 17.4 16.6 18.5 13.7 (L) (3.13) (24.2) (24.3) (18.8) Geometric mean (CV %) data are presented aMedian (min-max) N = Number of subjects studied (norm) = Normalized for dose and body weight (mg/kg) - Following the IV infusion of CR665 at dose levels of 0.03 to 0.09 mg/kg in male subjects, plasma concentrations increased rapidly with maximum concentrations generally occurring at the end of the 5-minute infusion. Similarly, maximum concentrations of CR665 following administration of 0.06 mg/kg CR665 in female subjects were also attained at the end of the 5 minute infusion. Following the end of the IV infusion, plasma concentrations of CR665 appeared to decline in an essentially biphasic manner, with the start of the elimination phase occurring between 1.0 to 2.0 hours after the start of the infusion in both male and female subjects.
- In male subjects, the mean apparent elimination half life, about 1.0 to 1.3 hours, was similar across the 0.03 to 0.09 mg/kg dose range. Statistical analysis confirmed that the elimination half life for CR665 was independent of dose. The disposition kinetics of CR655 were similar in male and female subjects, with the mean terminal elimination half life of CR665 being approximately 0.8 hours in females at the 0.06 mg/kg dose level.
- In male subjects, AUC0-∞ and Cmax generally appeared to increase in a dose-proportional manner over the dose range 0.03 to 0.09 mg/kg. This was confirmed by statistical analysis, with the estimates of the slopes (95% CI) from the regression analysis for AUC0-∞ and Cmax being 1.04 (0.853 to 1.22) and 1.12 (0.800 to 1.44).
FIG. 12 illustrates the dose-proportional increase in AUC0-∞ for CR665 over the dose range of 0.03 to 0.09 mg/kg in male subjects. - At the 0.06 mg/kg dose level, mean values for AUC0-∞, AUC0-∞ (norm), Cmax and Cmax (norm) were generally similar in male and female subjects following a 5-minute infusion.
- Mean values for MRTint, CL, Vz and Vss were similar across the 0.03 to 0.09 mg/kg dose range in male subjects, which was confirmed by statistical analysis. Mean values for each parameter were also similar for male and female subjects at the 0.06 mg/kg dose level.
- In general, low between-subject variability was noted for AUC0-∞ and Cmax in male subjects, with CV % values ranging from 11.8 to 16.4% and 19.6% to 32.2%, respectively. Across all doses in male subjects, the pooled between-subject variability for AUC0-∞ and Cmax was 15.3% and 24.1%, respectively. The between-subject variability for AUC0-∞ and Cmax was also low in female subjects at the 0.24 mg/kg dose level, with CV % values of 8.8% and 18.8%, respectively.
- The urinary excretion of CR665 following a 5-minute infusion in male and female subjects is summarized in Table 12:
-
TABLE 12 Summary of the Urinary Excretion of CR665 Following a 5-minute IV Infusion in Male and Female Subjects (Part B) Dose of (mg/kg) 0.03 0.06 0.09 0.06 [males] [males] [males] [females] Parameter (N = 3) (N = 4) (N = 4) (N = 3) Ae0-24 h 70.0 157 262 153 (μg) (27.3) (25.8) (13.5) (16.9) fe0-24 h 3.60 3.33 3.56 3.83 (%) (29.6) (27.6) (7.29) (24.0) CLR 0-24 h 17.1 18.4 20.5 20.9 (mL/min) (22.7) (24.6) (12.0) (17.7) Geometric mean (CV %) data are presented N = Number of subjects studied - In male subjects, the fraction of the dose excreted in the urine as unchanged drug was low for all dose levels, with approximately 3.5% being eliminated up to 24 hours post-dose. The fraction of unchanged drug excreted in the urine was also low in female subjects (3.8%), and similar to male subjects.
- The amount of CR665 excreted in the urine increased in a dose proportional manner over the dose range studied in male subjects. This was confirmed by statistical analysis, with the slopes of the regression not being significantly different from unity. Renal clearance was generally low and similar across all dose levels, with dose independence being confirmed by statistical analysis.
- The results of the statistical analyses to assess the effect of infusion time on the pharmacokinetic parameters of CR665 in male subjects are presented in Table 13.
-
TABLE 13 Statistical Analysis of the Effect of Infusion Time on the Pharmacokinetic Parameters for CR665 in Male Subjects (Parts A & B) Geometric least Ratio of squares means geometric least 5-minute 1-hour squares means 90% CI for the 95% CI for the Parameter infusion infusion 5-minute:1-hour ratio ratio AUC0-t 2286 2238 1.02 0.957 to 1.09 0.944 to 1.11 (norm) AUC0-∞ 2343 2260 1.04 0.971 to 1.11 0.957 to 1.12 (norm) Cmax 9002 2003 4.49 3.98 to 5.08 3.87 to 5.22 (norm) t1/2 1.28 1.25 1.02 0.804 to 1.29 0.762 to 1.37 (h) MRTint 0.558 0.605 0.923 0.817 to 1.04 0.794 to 1.07 (h) CL 538 557 0.964 0.903 to 1.03 0.889 to 1.05 (mL/min) Vz 61.0 59.1 1.03 0.825 to 1.29 0.784 to 1.36 (L) Vss 18.1 20.1 0.900 0.804 to 1.01 0.783 to 1.03 (L) fe0-24 h 3.48 3.46 1.01 0.908 to 1.12 0.887 to 1.15 (%) (norm) = Normalized for dose and body weight (mg/kg) - In male subjects, the following pharmacokinetic parameters for CR665 were similar following an IV infusion time of 1-hour versus 5-minutes: AUC0-∞, AUC0-t, t1/2, CL, Vz, Vss, and fe0-24 h, suggesting that the overall systemic exposure to CR665, based upon AUC and disposition kinetics, were not affected by the different infusion times. The only parameter, however, for which the statistical analysis confirmed a significant difference was Cmax, which was, as expected, approximately 4.5-fold higher for the 5-minute compared to the 1-hour infusion.
- The statistical analyses of the effect of infusion time on the pharmacokinetic parameters of CR665 in female subjects are presented in Table 14.
-
TABLE 14 Statistical Analysis of the Effect of Infusion Time on the Pharmacokinetic Parameters for CR665 in Female Subjects Geometric least Ratio of squares means geometric least 5-minute 1-hour squares means 90% CI for the 95% CI for the Parameter infusion infusion 5-minute:1-hour ratio ratio AUC0-t 2013 1936 1.04 0.918 to 1.18 0.893 to 1.21 (norm) AUC0-∞ 2044 1943 1.05 0.928 to 1.19 0.903 to 1.23 (norm) Cmax 8716 1655 5.27 4.17 to 6.66 3.96 to 7.01 (norm) t1/2 0.946 1.05 0.901 0.606 to 1.34 0.554 to 1.47 (h) MRTint 0.430 0.498 0.864 0.708 to 1.06 0.677 to 1.10 (h) CL 544 573 0.950 0.837 to 1.08 0.813 to 1.11 (mL/min) Vz 45.7 50.2 0.911 0.628 to 1.32 0.577 to 1.44 (L) Vss 14.1 17.0 0.832 0.692 to 1.00 0.664 to 1.04 (L) fe0-24 h 3.83 2.70 1.42 1.16 to 1.73 1.11 to 1.81 (%) (norm) = Normalized for dose and body weight (mg/kg) - In female subjects, the following pharmacokinetic parameters for CR665 were similar following an IV infusion time of 1-hour versus 5-minutes: AUC0-∞, AUC0-t, t1/2, CL, Vz, Vss, and fe0-24 h suggesting that the overall systemic exposure to CR665, based upon AUC and disposition kinetics, were not affected by the different infusion times. However, as would be expected, Cmax was significantly higher (5.3-fold) for the 5-minute compared to the 1-hour infusion. These findings reinforce the predictability of the pharmacokinetics of CR665, which aids the skilled practitioner in the design of drug administration protocols that are designed to achieve a particular level of systemic exposure to drug without undue experimentation.
- The relationship between pharmacodynamic parameters of serum prolactin (changes from baseline) and pharmacokinetic parameters of CR665 following IV infusions of 0.015 to 0.36 mg/kg in male subjects is presented in
FIGS. 13 and 14 . - In Part A, there was a direct linear correlation between serum concentrations of prolactin (based on AUC0-12h and Cmax) and the plasma concentration of CR665 (based on AUC0-∞ and Cmax) over the 0.015 to 0.36 mg/kg dose range following a 1-hour infusion in male subjects, with correlation coefficients of 0.667 and 0.565 for AUC and Cmax values, respectively. The AUC0-12 h and Cmax values for serum prolactin appeared to plateau at higher AUC0-∞ and Cmax values for CR665 associated with dose levels of 0.36 to 0.48 mg/kg, indicating that the maximum increase in serum prolactin had been achieved by 0.36 mg/kg CR665 administered as a 1-hour infusion.
- In Part B, there was no apparent correlation between serum prolactin concentrations and plasma CR665 concentrations in male subjects following a 5-minute infusion. A likely cause of the absence of a correlation is the temporal dissociation of pharmacokinetics and pharmacodynamics in these subjects: while plasma CR665 concentrations peaked at the end of the 5-minute infusion and declined thereafter, serum prolactin concentrations only began to significantly rise at 10 minutes (5 minutes after the end of the infusion), and continued to rise at 30 minutes, with substantial but declining levels measured at 60 minutes. Under these conditions, a correlation between plasma CR665 concentrations and serum prolactin concentrations would not be expected. However, with longer (e.g., 1 hour) infusions of CR665, the plasma concentration of CR665 may better reflect the concentration of CR665 in the pharmacodynamically relevant compartment (i.e., high affinity kappa opioid receptors), and thereby yield the significant linear relationship shown in
FIGS. 13 and 14 . - Following administration of 0.015 to 0.48 mg/kg CR665 as a 1-hour infusion in male subjects, AUC0-∞ and Cmax increased in a dose-proportional manner over the entire dose range. The between-subject variability in the pharmacokinetics of CR665 was low in male subjects.
- In female subjects, maximum plasma concentrations of CR665 occurred at the end of the 1-hour infusion period following a 0.24 mg/kg dose, which was similar to male subjects. The systemic exposure of CR665, based on AUC0-∞ and Cmax, was similar in male and female subjects. The disposition of CR665 was also similar between genders, with a mean terminal elimination half-life of 1.2 hours in female subjects. Furthermore, similar between-subject variability was observed in male and female subjects.
- The duration of infusion had no effect on the overall systemic exposure to CR665, with AUC0-∞ being similar following the 1-hour and 5-minute infusions in both male and female subjects. However, maximum plasma concentrations of CR665 were notably higher following the 5-minute infusion compared to the 1-hour infusion, being approximately 4.5-fold higher in male subjects and 5.3-fold higher in female subjects. The difference in Cmax was expected because of the higher rate of infusion used for the 5-minute infusion (360 mL/hour) compared to the 1-hour infusion (30 mL/hour). The disposition kinetics of CR665 was similar for the 1-hour and 5-minute infusion, and low between-subject variability was observed for both infusion times.
- The apparent volume of distribution at steady state (Vss) of CR665 in male subjects ranged from 19 to 23 L over the 0.12 to 0.48 mg/kg dose range, which is similar to the volume of extracellular fluid, and is consistent for a peptide with limited ability to penetrate lipid-containing membranes. This observation reflects another aspect of the present invention: a relatively low volume of distribution. The volume of distribution is a quantitative measure of the extent of distribution of drug outside the vasculature; it is the apparent volume which would contain the entire amount of drug in the body at the same concentration it is present in the blood. In general, a compound with a low volume of distribution will have physical characteristics that impede transport across biological membranes. Thus, a polar compound with a low apparent volume of distribution, such as CR665, would not be expected to cross the blood-brain barrier as well as lipid-soluble compounds that typically have a higher apparent volume of distribution, and a greater propensity to cross the blood-brain barrier.
- All patents and other references cited herein are hereby incorporated by reference.
- Other embodiments are within the following claims.
Claims (22)
1. A method of elevating levels of serum prolactin in a mammal in need of elevated or stabilized levels of serum prolactin, comprising administering to said mammal an amount of a peripherally selective kappa opioid receptor agonist, a salt thereof or a pro-drug thereof effective to elevate or stabilize levels of serum prolactin in the mammal.
2. The method of claim 1 , wherein said peripherally, selective kappa opioid receptor agonist, a salt thereof or a pro-drug thereof comprises a peptide.
3. The method of claim 2 , wherein said peptide has a binding affinity for the kappa opioid receptor that is 10 times greater, 100 times greater, 1,000 times greater, or more than its binding affinity for non-kappa opioid receptors.
4. The method of claim 2 , wherein said peptide has the formula:
H-Xaa1-Xaa2-Xaa3-Xaa4-Q; and
H-Xaa1-Xaa2-Xaa3-Xaa4-Q; and
wherein Xaa1 is (A)D-Phe, (Calpha Me)D-Phe, D-Tyr, D-Tic or D-Ala(cyclopentyl or thienyl), with A being H, NO2, F, C1 or CH3; Xaa2 is (A′)D-Phe, D-1Nal, D-2Nal, D-Tyr or D-Trp, with A′ being A or 3,4Cl2; Xaa3 is D-Nle, (B)D-Leu, D-Hle, D-Met, D-Val, D-Phe or D-Ala(cyclopentyl) with B being H or Calpha Me; Xaa4 is D-Arg, D-Har, D-nArg, D-Lys, D-Lys(Ipr), D-Arg(Et2), D-Har(Et2), D-Amf(G), D-Dbu, (B)D-Orn or D-Orn(Ipr), with G being H or amidino; and Q is NR1R2, morpholinyl, thiomorpholinyl, (C)piperidinyl, piperazinyl, 4-mono- or 4,4-di-substituted piperazinyl or delta-ornithinyl, with R1 being lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, aminocyclohexyl, 2-thiazolyl, 2-picolyl, 3-picolyl or 4-picolyl, R2 being H or lower alkyl; and C being H, 4-hydroxy or 4-oxo.
5. The method of claim 4 , wherein Q is morpholinyl or thiomorpholinyl.
6. The method of claim 4 , wherein Q is NHR1 and R1 is 4-picolyl.
7. The method of claim 2 , wherein said peptide has the formula:
H-Xaa1-Xaa2-Xaa3-Xaa4-Q; and
H-Xaa1-Xaa2-Xaa3-Xaa4-Q; and
wherein Xaa1 is D-Phe (unsubstituted or substituted by Calpha, Me, 2F, 4F or 4Cl) or D-Ala(cyclopentyl or thienyl); Xaa2 is (A′)D-Phe, D-1Nal, D-2Nal or D-Trp, with A′ being H, 4F, 4Cl, 4NO2 or 3,4Cl2; Xaa3 is D-Nle, D-Leu, D-CML, D-Met or D-Acp; Xaa4 is D-Arg, D-Arg(Et2), D-Lys, D-Ily, D-Har, D-Har(Et2), D-nArg, D-Orn, D-Ior, D-Dbu, D-Amf, and D-Amf(Amd); and Q is NR1R2, Mor, Tmo, Pip, 4-Hyp, OxP or Ppz, with R1 being Me, Et, Pr, Bu, hEt, Cyp, Bzl or 4-picolyl, and R2 being H or Et.
8. The method of claim 7 , wherein Xaa2 is D-Phe, Xaa3 is D-Nle and Xaa4 is D-Arg.
9. The method of claim 7 , wherein Q is morpholinyl or thiomorpholinyl.
10. The method of claim 7 , wherein Q is NHR1 and R1 is 4-picolyl.
11. The method of claim 7 , wherein Xaa3 is D-Nle or D-Leu and Q is morpholinyl.
12. The method of claim 7 , wherein Xaa1 is D-Phe, D-4Fpa, D-2Fpa, D-Acp or D-Ala(2Thi); Xaa2 is (A)D-Phe, D-1Nal, D-2Nal or D-Trp, with A being 4F or 4Cl; Xaa3 is D-Nle, D-Met or D-Leu; Xaa4 is D-Arg, D-Har, D-nArg, D-Lys, D-Orn or D-Amf(Amd); and Q is NHR1, Mor, Tmo, Pip or Ppz, with R1 being Et, Pr or 4Pic.
13. The method of claim 2 , wherein said peptide has the formula: H-D-Phe-D-Phe-D-Nle-D-Arg-NHEt, H-D-Phe-D-Phe-D-Nle-D-Arg-morpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NH-4-picolyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NHPr, H-D-Phe-D-Phe-D-Nle-D-Arg-thiomorpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-Net2, H-D-Phe-D-Phe-D-Nle-D-Arg-NHMe, H-D-Phe-D-Phe-D-Leu-D-Orn-morpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NHhEt, H-D-Phe-D-Phe-D-Nle-D-Arg-NH-cyclopropyl, H-D-Ala(2Thi)-D-4 Cpa-D-Leu7D-Arg-morpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-piperidinyl, H-D-Phe-D-Phe-D-Leu-D-Orn-NHEt, H-D-Phe-D-Phe-D-Leu-D-Lys-morpholinyl, or H-D-Phe-D-Phe-D-Nle-D-Arg-piperazinyl.
14. The method of claim 1 , wherein said peripherally selective kappa opioid receptor agonist, when administered peripherally, does not substantially cross the blood-brain barrier.
15. The method of claim 1 , wherein said administration comprises intravenous, subcutaneous, intramuscular, intranasal, oral, or transdermal administration.
16. The method of claim 15 , wherein said transdermal administration is provided by an electrotransport device.
17. The method of claim 16 , wherein said administration comprises:
(a) providing a first electrode;
(b) providing a second electrode;
(c) providing a power source electrically connected to said first and said second electrodes;
(d) providing at least one donor reservoir having the peripherally selective kappa opioid receptor agonist, wherein said donor reservoir is associated with said first or second electrode; and
(e) delivering a therapeutically effective amount of said peripherally selective kappa opioid receptor agonist through said body surface.
18. A method of treating a mammal in need of elevated or stabilized prolactin levels, said method comprising administering to said mammal an amount of a peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof, and administering, either separately or in combination with said peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof, an amount of an, additional prolactin elevating compound, effective to treat the mammal.
19. The method of claim 18 , wherein the prolactin-elevating agent is a D2 dopamine receptor antagonist or a mu opioid receptor agonist.
20. A method for treating reduced sperm motility, an age-related disorder, type 1 diabetes, insomnia, or inadequate REM sleep, insufficient or inadequate lactation, or for preventing insufficient or inadequate lactation, in a mammal, comprising administering an amount of a peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof, effective to treat or prevent insufficient or inadequate lactation, or to treat reduced sperm motility, age-related disorder, type 1 diabetes, insomnia, or inadequate REM sleep in the mammal.
21. The method of claim 20 , wherein such amount of a peripherally selective kappa opioid receptor agonist or a salt thereof or a pro-drug thereof is administered to said mammal prior to or after childbirth in conjunction with a lactation enhancer or stabilizer effective to treat said mammal.
22. The method of claim 21 , wherein the lactation enhancer comprises oxytocin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/087,142 US20140221277A1 (en) | 2006-05-26 | 2013-11-22 | Method For Elevating Prolactin In Mammals |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80867706P | 2006-05-26 | 2006-05-26 | |
PCT/US2007/012285 WO2007139826A2 (en) | 2006-05-26 | 2007-05-22 | Method for elevating prolactin in mammals |
US30059509A | 2009-04-22 | 2009-04-22 | |
US13/543,128 US20130012431A1 (en) | 2006-05-26 | 2012-07-06 | Method For Elevating Prolactin In Mammals |
US14/087,142 US20140221277A1 (en) | 2006-05-26 | 2013-11-22 | Method For Elevating Prolactin In Mammals |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/543,128 Continuation US20130012431A1 (en) | 2006-05-26 | 2012-07-06 | Method For Elevating Prolactin In Mammals |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140221277A1 true US20140221277A1 (en) | 2014-08-07 |
Family
ID=38654611
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/300,595 Active 2028-11-12 US8217000B2 (en) | 2006-05-26 | 2007-05-22 | Method for elevating prolactin in mammals |
US13/543,128 Abandoned US20130012431A1 (en) | 2006-05-26 | 2012-07-06 | Method For Elevating Prolactin In Mammals |
US14/087,142 Abandoned US20140221277A1 (en) | 2006-05-26 | 2013-11-22 | Method For Elevating Prolactin In Mammals |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/300,595 Active 2028-11-12 US8217000B2 (en) | 2006-05-26 | 2007-05-22 | Method for elevating prolactin in mammals |
US13/543,128 Abandoned US20130012431A1 (en) | 2006-05-26 | 2012-07-06 | Method For Elevating Prolactin In Mammals |
Country Status (6)
Country | Link |
---|---|
US (3) | US8217000B2 (en) |
EP (1) | EP2040733A2 (en) |
JP (1) | JP2009538310A (en) |
CN (1) | CN101454017A (en) |
CA (1) | CA2653072A1 (en) |
WO (1) | WO2007139826A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007139826A2 (en) * | 2006-05-26 | 2007-12-06 | Cara Therapeutics, Inc. | Method for elevating prolactin in mammals |
US7842662B2 (en) * | 2006-11-10 | 2010-11-30 | Cara Therapeutics, Inc. | Synthetic peptide amide dimers |
WO2010118880A1 (en) * | 2009-04-17 | 2010-10-21 | Lipotec S.A. | Peptides used in the treatment and/or care of the skin and/or hair and their use in cosmetic or pharmaceutical compositions |
US9056114B2 (en) * | 2009-08-28 | 2015-06-16 | Jeffrey P. Erickson | Chemical induction of lactation |
WO2016181408A2 (en) * | 2015-05-11 | 2016-11-17 | Cadila Healthcare Limited | NOVEL SHORT-CHAIN PEPTIDES AS KAPPA (κ) OPIOID RECEPTORS (KOR) AGONIST |
CN107098876B (en) * | 2016-02-23 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | Phenyl propionamide derivative, preparation method and medical application thereof |
WO2017210668A1 (en) * | 2016-06-03 | 2017-12-07 | Jt Pharmaceuticals, Inc. | Sustained release compositions of kappa-opioid receptor agonist |
WO2019054485A1 (en) * | 2017-09-14 | 2019-03-21 | めぐみ 田中 | Anti-aging agent and anti-aging method |
AU2019271812A1 (en) | 2018-05-16 | 2021-01-07 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition of KOR receptor agonist |
JPWO2020054795A1 (en) * | 2018-09-14 | 2021-08-30 | めぐみ 田中 | Anti-aging agents and anti-aging methods |
CN114401982A (en) * | 2019-04-23 | 2022-04-26 | 加利福尼亚大学董事会 | Compositions and methods useful for enhancing milk production |
JP2023536221A (en) | 2020-06-25 | 2023-08-24 | ヒューマンウェル ファーマシューティカル ユーエス | Peptides for the treatment of medical disorders |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965701A (en) * | 1997-12-23 | 1999-10-12 | Ferring Bv | Kappa receptor opioid peptides |
WO2007139826A2 (en) * | 2006-05-26 | 2007-12-06 | Cara Therapeutics, Inc. | Method for elevating prolactin in mammals |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4481191A (en) * | 1983-03-30 | 1984-11-06 | The Regents Of The University Of California | Method for controlling blood pressure |
US5189064A (en) * | 1985-07-22 | 1993-02-23 | Matrix Technologies, Inc. | Treatment of cocaine addiction |
US5861439A (en) * | 1994-11-14 | 1999-01-19 | Alza Corporation | Method for enhanced electrotransport agent delivery |
AUPN603895A0 (en) * | 1995-10-19 | 1995-11-09 | University Of Queensland, The | Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids |
US6718201B1 (en) * | 1996-06-07 | 2004-04-06 | Alza Corporation | Electrotransport agent delivery method and apparatus |
GB0221712D0 (en) * | 2002-09-19 | 2002-10-30 | Ardana Bioscience Ltd | Methods of treatment |
US20080132445A1 (en) * | 2002-09-25 | 2008-06-05 | Garvan Institute Of Medical Reserach | Method for Inducing Mammary Epithelial Cell Differentiation |
US7842662B2 (en) * | 2006-11-10 | 2010-11-30 | Cara Therapeutics, Inc. | Synthetic peptide amide dimers |
-
2007
- 2007-05-22 WO PCT/US2007/012285 patent/WO2007139826A2/en active Application Filing
- 2007-05-22 EP EP07795228A patent/EP2040733A2/en not_active Withdrawn
- 2007-05-22 JP JP2009512124A patent/JP2009538310A/en not_active Withdrawn
- 2007-05-22 US US12/300,595 patent/US8217000B2/en active Active
- 2007-05-22 CA CA002653072A patent/CA2653072A1/en not_active Abandoned
- 2007-05-22 CN CNA2007800192315A patent/CN101454017A/en active Pending
-
2012
- 2012-07-06 US US13/543,128 patent/US20130012431A1/en not_active Abandoned
-
2013
- 2013-11-22 US US14/087,142 patent/US20140221277A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965701A (en) * | 1997-12-23 | 1999-10-12 | Ferring Bv | Kappa receptor opioid peptides |
WO2007139826A2 (en) * | 2006-05-26 | 2007-12-06 | Cara Therapeutics, Inc. | Method for elevating prolactin in mammals |
US8217000B2 (en) * | 2006-05-26 | 2012-07-10 | Cara Therapeutics, Inc. | Method for elevating prolactin in mammals |
Non-Patent Citations (3)
Title |
---|
Butelman et al. Comparison of the discriminative and neuroendocrine effects of centrally penetrating kappa-opioid agonist in rhesus monkeys. Psychopharmacology. 2002, Volume 164, pages 115-120. * |
Butelman et al. Peripheral Selectivity And Apparent Efficacy of Dynorphins... Drug and Alcohol Dependence. 2002, Volume 66, page S24, Abstract No. 85. * |
Krulich et al. Opioid Kappa Receptors and the Secretion of Prolactin... Neuroendocrinology. 1986, Volume 42, pages 75-81. * |
Also Published As
Publication number | Publication date |
---|---|
JP2009538310A (en) | 2009-11-05 |
EP2040733A2 (en) | 2009-04-01 |
CN101454017A (en) | 2009-06-10 |
US8217000B2 (en) | 2012-07-10 |
US20090312271A1 (en) | 2009-12-17 |
US20130012431A1 (en) | 2013-01-10 |
WO2007139826A2 (en) | 2007-12-06 |
CA2653072A1 (en) | 2007-12-06 |
WO2007139826A3 (en) | 2008-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8217000B2 (en) | Method for elevating prolactin in mammals | |
US6548501B2 (en) | Composition and methods for stimulating gastrointestinal motility | |
US7732398B2 (en) | Medicinal uses of mu-opioid receptor agonists | |
EP2389941A1 (en) | Growth-hormone secretagogues | |
US20100029575A1 (en) | N-Oxides of Kappa Receptor Peptides | |
US20020013320A1 (en) | Use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease | |
JP2009538824A (en) | Amylin and amylin agonists for the treatment of psychiatric disorders and disorders | |
US20040122062A1 (en) | Use of growth hormone secretagogues for treatment of physical performance decline | |
US20020103221A1 (en) | Use of growth hormone secretagogues for improvement of functional health status | |
Prommer | The role of fentanyl in cancer-related pain | |
JP2002145801A (en) | Method for using growth hormone secernent in combination with physical exercise | |
US20220362328A1 (en) | Uses of bremelanotide in therapy for female sexual dysfunction | |
US20030199514A1 (en) | Methods for improving efficacy of treatment with growth hormone secretagogues | |
JPH01501708A (en) | Nasal administration of amino acids | |
Hung | The Role of Endogenous Opioids in Pregnancy and Anesthesia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CARA THERAPEUTICS, INC., CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MENZAGHI, FREDERIQUE;LEWIS, MICHAEL E.;CHALMERS, DEREK T.;SIGNING DATES FROM 20130620 TO 20130709;REEL/FRAME:031989/0674 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: CARA THERAPEUTICS, INC., CONNECTICUT Free format text: CHANGE OF ADDRESS;ASSIGNOR:CARA THERAPEUTICS, INC.;REEL/FRAME:067070/0643 Effective date: 20240409 |